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ABSTRACT 
 
The metabolism of androgenic anabolic steroids has been studied in the racing 
greyhound. Various drug preparations have been investigated utilising different 
derivatisation techniques, coupled with gas chromatographic analysis, to enable the 
identification of key metabolites in canine post administration samples. This has led to 
an increased understanding of some of the generic routes of steroid metabolism that 
take place in the greyhound. This valuable information can help to support metabolism 
studies in the future. The identification of specific metabolites for each compound 
investigated, has provided a means for controlling the misuse of these compounds, and 
contributed valuable enhancements to screening protocols utilised in the canine sports 
drug testing industry. 
Utilisation of the techniques described, resulted in the identification of specific major 
metabolites of the anabolic steroid methyltestosterone, namely 17α-methyl-5β-
androstan-3α-17β-diol and 17α-methyl-5β-androstan-3α,16α,17β-triol. 16α- 
hydroxylation was shown to be a major phase I metabolic pathway in the canine along 
with phase II conjugation with glucuronic acid. Similar results were obtained during the 
metabolism study of the progestatgenic steroid norethisterone. Several di- and tri-
hydroxy metabolites were detected in the glucuronic acid fraction of the post 
administration urines from this study. The norethisterone metabolism study also 
provided some insight, into the area of trace contaminants of pharmaceutical 
preparations. Low levels of nandrolone metabolites were also detected in the 
norethisterone post administration urine samples, leading to the discovery that the 
administered pharmaceutical tablets contained small quantities of nandrolone and 19-
norandrostenedione, albeit below FDA approved contaminant levels. Modern methods 
of drug screening employ such highly sensitive techniques, that they allow for the 
detection of metabolites of such trace contaminants, following administration of the 
drug preparation to the greyhound. It is therefore important to have a broad 
understanding of the metabolism of various drug preparations, both banned and 
permitted substances alike; as detection of a trace amount of a banned substance 
metabolite, arising from the administration of a permitted medication, whose 
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metabolite profile is unknown, and therefore potentially not detected, could present an 
interesting case. 
In conjunction with research into controlling the use of banned substances for the 
purposes of suppressing oestrus in the greyhound bitch, an investigation into 
normal/reference levels of endogenous hormones has been carried out. The endogenous 
steroid levels in a population of 212 greyhound bitches have been studied with a view 
to establishing a method for the detection of the exogenous administration of the 
endogenous anabolic steroid testosterone. The major urinary metabolites investigated 
were epiandrosterone, 5β-androstane-3α,17β-diol and 5α-androstane-3β,17β-diol. 
Statistical evaluations have been carried out to support the implementation of a suitable 
threshold for the key testosterone metabolites, namely 5β-androstane-3α,17β-diol and 
epiandrosterone. The detection of 5β-androstane-3α,17β-diol was found to be a very 
good indicator of the exogenous administration of testosterone to the greyhound bitch, 
when compared with the reference population data for this metabolite. However, 
further statistical/analytical data evaluation was deemed necessary before an absolute 
threshold could be implemented for this analyte, for the purposes of controlling the 
misuse of testosterone in the racing greyhound bitch. 
To support the understanding of endogenous steroid levels in the female greyhound, yet 
further, the endogenous reproductive steroid profiles were measured throughout the 
entire oestrus cycle of a cohort of 33 racing bitches. The results of the study clearly 
indicate a surge in androgen metabolites during the first 7-10 days of the oestrus cycle, 
in particular epiandrosterone and 5α-androstane-3β,17β-diol. This unique set of data 
has provided detailed information regarding the fluctuating concentrations of androgen 
and progesterone metabolites (following ovulation), at key stages of the canine oestrus 
cycle. The information obtained from this research can be used to support regulatory 
decisions regarding the misuse of testosterone in the racing greyhound bitch. 
 
Keywords: Greyhound, oestrus cycle, testosterone, anabolic steroid metabolism, gas 
chromatography, mass spectrometry, methyltestosterone, norethisterone, nandrolone. 
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1.  INTRODUCTION 
1.1 GREYHOUNDS: HISTORY, RACING AND REGULATION 
1.1.1  The Greyhound 
Greyhounds are one of a number of breeds of dog that hunt using a combination of 
sight and speed as opposed to scent and endurance. They are therefore categorised and 
commonly referred to as sighthounds. They originate from ancient Europe and are 
believed to be early relatives of herding dogs. The modern day racing greyhound can be 
traced back to 18th and 19th century studbooks which were ultimately registered with 
coursing and racing authorities in the United Kingdom. Regular competitions were held 
in Great Britain to see which breeder owned the most agile dog in the country; such 
competitions and indeed animal stock, being the predecessors of historical hare 
coursing and the modern, track based greyhound racing industry we know today.  
The greyhound has been revered for centuries both for its aesthetic looks (the first ever 
Best in Show at Crufts was given to a greyhound), but moreover for its athletic ability 
and speed. The greyhound is the second fastest land mammal from a standing start (the 
Cheetah being the fastest) and can reach up to 45 mph in a race, just a few strides after 
leaving the starting traps. The physique of the greyhound makes it perfectly suited for 
sprint racing, as it has a high proportion of fast twitch muscle surrounding a relatively 
light frame. Male dogs stand shoulder height at about 28-30in and are 4.5 - 6 stone in 
weight. The female ‘bitch’ is usually smaller; 27-28in at the shoulder and 3.5 - 5 stone 
in weight. Despite this difference in stature, greyhound racing is one of very few sports 
and possibly the only unaccompanied, individual athletic sport, where females compete 
against males on a ‘level playing field’, with no concession allocated to the female. 
 
1.1.2 Greyhound Racing 
Greyhound racing was first introduced in Great Britain in the 1920s and soon increased 
in popularity becoming the second highest spectator sport after football. Unlike the 
historical hare coursing, greyhounds now follow a mechanical hare or lure that circuits 
the perimeter of the track and provides them with the stimulus to chase ‘potential prey’ 
at top speed for a short period of time. Various venues have come and gone over time 
resulting in 26 present day tracks currently operating in Great Britain. During the early 
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years of greyhound racing it soon became apparent that a governing body was required 
to oversee proceedings, due to the increase in race prize funds and money changing 
hands, including ‘wagers’ between owners, and the ever increasing threat of foul play. 
In 1928 the National Greyhound Racing Club (NGRC) was set up to control the 
industry and enforce a new set of rules to ensure fair practice by all interested parties. 
Bookmaking, previously confined to the racetrack by law since the mid 1800s, became 
legal on British high streets in 1961, although various betting outlets had already been 
operating illegally for many years prior to this. The temptation to cheat for monetary 
gain has been apparent across numerous sporting disciplines for many years (animal 
and human) and with an increase in the outlets and opportunity for wagering on the 
outcome of greyhound races, drug testing was a required part of the developing 
infrastructure of the sport.  
The Greyhound Board of Great Britain (GBGB) was set up in 2009 to oversee all 
aspects of greyhound racing. This involves track promotion and regulatory affairs, as 
well as the stewardship at the tracks along with integrity and welfare measures, 
including drug testing, much of which was previously controlled by the NGRC. 
 
1.1.3 Drug testing 
In 1963 the Horseracing Forensic Laboratory (HFL) was established in Newmarket to 
provide drug testing services to the British horseracing industry. In 1991 the laboratory 
took on the role of providing drug testing to the greyhound racing industry as well, and 
continues to provide this service today. The work of the laboratory involves the 
detection of veterinary medications (subject to the rules of greyhound racing[1]) as well 
as such substances that would be considered doping agents used in an attempt to alter 
the performance of a racing greyhound, either positively (e.g. anabolic steroids) or 
negatively (e.g. sedatives).  
The rules of racing include strict controls on the use of medications in racing 
greyhounds and one area of significant debate for many years has been the use of 
steroidal preparations for the purposes of suppressing the oestrus cycle in racing 
greyhound bitches. To suppress or not to suppress?....that is the question. For every 
trainer that believes it is necessary to suppress the season of a bitch in order to stabilize 
her form and enable her to be trained uniformly all year round, there is another who is 
happy to allow the bitch to come into season and use the potential fluctuations in her 
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form to their possible advantage (although this is by no means guaranteed). Whilst both 
of these approaches to training bitches are equally acceptable to the GBGB (racecards 
are required to provide information regarding suppression and season dates) it is the 
nature of some of the compounds that have been used for suppression of oestrus, in 
particular testosterone, that have caused the industry the greatest concern. Regular and 
continued use of testosterone to suppress oestrus in greyhound bitches could be 
performance enhancing and also potentially have a negative impact on fertility in those 
animals destined for breeding after racing (although this has not been proved). Hence, 
the use of testosterone as an oestrus suppressant is no longer permitted by the GBGB. 
Testosterone has been one of the most widely abused anabolic steroids in a variety of 
sports for many decades but is also a naturally occurring endogenous steroid and 
therefore its qualitative detection in a racing animal does not necessarily constitute a 
breach of the rules of racing. Therefore, controlling the abuse of testosterone in 
greyhound racing requires a quantitative approach. 
 
1.1.4 Steroids and Doping in sport 
The term ‘doping’ dates back to the 1800s in England, apparently defining a mixture of 
opium and narcotics given to horses. Prior to that, it originated as a Dutch word used in 
South Africa to define the taking of strong alcoholic drink at religious worship and was 
also used to define sedating or ‘nobbling’ of either animals or indeed individuals[2]. 
Nowadays, the term “doping offence” would probably be interpreted by most people as 
the use of ‘drugs in sport’, animal or human, whatever the pharmacological effects. 
Anabolic steroids are clearly used in an attempt to enhance performance, as opposed to 
‘nobbling’ and the history of their use in humans dates back to the ancient Greek 
Olympics where athletes of the time are thought to have explored different means of 
improving their strength, involving the consumption of various organs of animals, 
including the testicles, which were thought to impart strength. 
Historical studies within the last hundred years have indeed shown that testosterone can 
be extracted from such tissues in milligram quantities[3]; work which ultimately 
provided the building blocks for the early pharmaceutical industry in the 1930s to 
develop synthetic testosterone and eventually other synthetic mimics with structurally 
specific alkyl substituent groups, designed to inhibit first pass metabolism and hence 
make them orally active. 
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Current knowledge of in vivo first pass metabolism indicates that testosterone is 
predominantly metabolised when taken orally and its beneficial activity therefore 
reduced[4]. Interestingly, the androstenedione (a precursor of testosterone) content of 
testicular tissue may have been of more benefit to the ancient Greek athlete than 
testosterone itself. Androstenedione is one of the many precursor ‘pro-hormones’ 
available through the Internet for the past decade or more, that are marketed with a 
knowledge of first pass metabolic mechanisms, to try and introduce as much of the 
related parent steroid (in this case testosterone) into the circulation as possible, despite 
the compound being taken orally. Many of these compounds have some anabolic 
activity in their own right, but large quantities need to be regularly ingested in order for 
them to be really effective; the relative androgenicity of androstenedione being about 
15% of that of testosterone[5] and increases in serum free testosterone levels (i.e. 
biologically active), following androstenedione administration, although elevated, have 
been shown to be relatively modest[6]. 
So for many years, human athletes have chosen to take a variety of compounds to try 
and enhance their sporting performance. The establishment of international routine 
dope testing involving sophisticated analytical techniques has introduced an almost 
‘secondary competition’ for some athletes, who try and beat the ever evolving system. 
Doping control programmes are therefore vital in supporting the integrity of sport and 
to an extent the health education of athletes, as regular abuse of anabolic steroids can 
cause harmful side effects such as liver damage and endocrine system disruption. They 
can also cause high blood pressure and actual anatomical changes, including, amongst 
others, alteration of the physical structure of the heart that can lead to severe cardiac 
complications[7,8]. 
 
1.1.5 Drug testing and the rules of Greyhound Racing 
It is by and large the choice of a human athlete whether they take performance 
enhancing substances that could also cause them significant health risks; in some cases 
life-threatening; although the German Democratic Republic government controlled 
athlete doping programme, in the 1980s, is a well-documented exception to this 
premise[9]. Nevertheless, despite understanding the risks, many athletes have expressed 
a much greater desire for victory and short term prestige over health and longevity of 
life[10]. However, for an animal athlete the choice still lies with humans and, as such, 
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routine dope testing in this sphere is not only vital to the integrity of the sport but also 
to the welfare of the racing animals as well.   
The rules of the Greyhound Board of Great Britain (GBGB) regarding the use of drugs 
and medications in greyhound racing are as follows:-  
Rule 217: A greyhound when taking part in a Race or Trial must at that time be free 
of medicines, tonics or substances that could affect its performance or well-being, the 
origin of which could not be traced to normal and ordinary feeding. The only permitted 
exceptions to this rule are:- 
 
i) Medicinal products which have been authorised by the Veterinary 
Medicines directorate for the suppression of a bitch’s season, prescribed by 
a Veterinary surgeon. 
ii) Medicinal products which have been authorised by the Veterinary 
Medicines Directorate as anti-parasitic drugs (for internal/external) 
parasites or as vaccines. 
 
The drugs permitted for use for the suppression of oestrus, under the current exceptions 
of Rule 217(i) are four progestins, megestrol acetate, proligestone, 
medroxyprogesterone acetate and more recently norethisterone. The use of any other 
steroid hormone for oestrus suppression is currently prohibited.  
Therefore, the use of anabolic steroids for performance enhancement in either male or 
female greyhounds is strictly prohibited and methods for detecting the administration of 
such compounds to greyhounds are necessary for an effective doping control 
programme. Knowledge of the metabolism of steroids in the greyhound is therefore 
vital to support such a programme. 
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1.2 STEROID STRUCTURE AND NOMENCLATURE 
 
1.2.1 Steroids 
Steroids are naturally occurring lipid compounds involved in a wide range of 
homeostatic and physiological mechanisms in living organisms and their biochemical 
activity has been extensively studied in a variety of mammalian species. They are 
synthesised in various tissues of the body, e.g. adrenal gland, liver, testis and ovary. 
The structures of all steroids are based on a 4-ring perhydrocyclopentanophenanthrene 
nucleus (Figure 1.1).  
 
 
 
Figure 1.1: Perhydrocyclopentanophenanthrene nucleus (gonane) 
 
Each hydrocarbon ring is assigned a letter (A-D) which is often referred to when 
discussing Phase I metabolism of steroids. Each carbon atom is sequentially numbered 
to assist with the chemical naming of steroid compounds that belong to the various 
different classes. The parent compound from which all the steroid hormones are 
biosynthetically derived is cholesterol (Figure 1.2), which is believed to have been first 
identified in the 18th century when it was isolated from gallstones (Greek names 
chole=bile and stereos=solid). 
 
Figure 1.2: Structure and nomenclature of cholesterol 
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Important groups of physiological steroids are formed in vivo initially by the action of 
various lyase enzymes on the cholesterol structure. This results in a range of different 
subclasses (see Figure 1.3) being produced within or near to the tissue locations in 
which they are required to elicit their activity. Conversely, as is also the case for a lot of 
endogenous steroids, they originate in tissues that act as a site for production and are 
then distributed around the body to remote target organs where they then exert their 
effect.   
Enzymatic cleavage of cholesterol between C24 and C25 produces the C24 
hydrocarbon cholane, to which the bile acids are related (e.g. cholic acid). Cleavage 
between C20 and C22 results in the formation of the C21 series, the pregnanes (e.g. 
progesterone). Cleavage between C17 and C20 results in the formation of the C19 
series, the androstanes (e.g. testosterone) and subsequent removal of the C-19 methyl 
group from C10 (a process of aromatisation) produces the C18 series, the estranes. 
 
 
Cholane (C24)            Pregnane (C21) 
 
                         
   Androstane (C19)    Estrane (C18) 
 
 
Fig 1.3: Hydrocarbon nuclei used in steroid nomenclature 
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Officially, steroids are probably most appropriately named using the International 
Union of Pure and Applied Chemistry (IUPAC) nomenclature[11] (e.g. pregn-4-ene-
3,20-dione; Figure 1.4).  In brief summary, this naming process involves choosing the 
category of steroid depending upon its hydrocarbon nucleus (Figure 1.3), adding in any 
sites of unsaturation within the 4-ring nucleus; listing as prefixes the key functional 
groups attached to the chosen base structure nucleus, followed by adding a final single 
suffix for the functional group which holds the highest rank according to the IUPAC 
recommendations, which for a large number of -keto steroids in the pregnane, 
androstane and estrane class, invariably results in the suffix -one or -dione, for di-keto 
compounds. For ease of interpretation in scientific texts, steroids are also often referred 
to by their trivial names as well (e.g. progesterone, Figure 1.4). Either is considered 
appropriate depending upon the required level of detail and/or context. 
 
 
 
Figure 1.4: Structure of progesterone; pregn-4-ene-3,20-dione (note double bond at 
C4=C5) 
 
1.2.2  Steroid conformation 
The cyclohexane rings of the steroid nucleus can adopt one of two conformations; 
either the ‘chair’ or ‘boat’ form (Figure 1.5), although the boat form is not sterically 
favoured. When the A, B and C rings are all in the chair form the molecule is 
effectively planar in structure. The valencies of the carbon atoms of the ring structure 
are of two types, those at right angles to the ring structure are the ‘axial’ bonds and 
those in the general plane of the ring are the ‘equatorial’ bonds (Figure 1.5). By 
convention it is agreed that the methyl groups at C18 and C19 project upwards from the 
upper face of the molecule (with their free chemical rotation, they are effectively 
analogous to two helicopter propellers, albeit tetrahedral in conformation). 
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The upper side of the molecule is known as the beta-side; the underside being the 
alpha. Any substituent functional groups projecting upwards are therefore assigned the 
β-configuration and those projecting downwards the α-configuration. When structures 
are drawn in scientific texts β-bonds are usually represented by a solid black notation 
and α-bonds by a dotted line notation. Bonds where the stereochemistry is unknown are 
represented by a wavy line. 
 
     
 
 Chair form       Boat form  
 
       Beta-side 
 
       alpha-side 
 
Figure 1.5: Steroid configuration 
 
Reduction of the double bond at C4=C5 (see Figure 1.4) i.e. 4-pregnene to 5-pregnane 
can occur from either the alpha- or beta- side of the molecule depending on the enzyme 
involved (e.g. 5α or 5β reductase). 5α reduction results in the incorporation of hydrogen 
in the α-configuration (below the plane of the molecule) at C5, which keeps the chair 
conformation of the A-ring intact and therefore the molecule remains planar in 
structure. 5β reduction incorporates hydrogen in the β-configuration (albeit virtually 
equatorial in orientation) which produces a significant change in the confirmation of 
the A-ring in relation to the rest of the molecule, the A-ring being effectively positioned 
at right angles to the planar structure of the B-ring (see Figure 1.6).  
In 5α-androstane the angular methyl group (C19) and the hydrogen atom at C5 are on 
opposite sides of the plane of the steroid molecule forming an AB-ring ‘trans’ union. In 
5β-androstane, the angular methyl group and the hydrogen atom project from the B-
side of the steroid molecule producing a ‘cis’ AB-ring union. Both -cis and -trans AB-
Equatorial bond 
Axial bond 
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ring unions are prevalent in steroid hormone structures, but the BC and CD ring unions 
are always in the trans configuration. 
This confirmation difference is quite significant when considering steroid receptor 
binding in vivo, as the 5β-reduced androgenic steroids for example, are often markedly 
reduced in activity and effect due to a poor ‘fit’ with receptors, compared with their 5α-
reduced counterparts[12]. The difference in confirmation is also of significance for a 
number of compounds when considering their separation on an analytical column 
during gas chromatographic steroid analysis. 
 
 
   
     
             Figure 1.6: Steroid conformation 
 
The different steroid classes and structures define the biochemical and pharmacological 
action of individual steroids within the body. Substituent groups attached at the 
different numbered carbon locations, provide the structural variation necessary for the 
cellular activities and receptor interactions required for each steroid to exert its effect in 
vivo.  
Synthetic steroids are chemical analogues of natural steroids. In the case of synthetic 
androgens these are manufactured and produced by making modifications or adding 
substituent groups to the structure of testosterone, in order to alter the ratio of 
androgenic to anabolic activity of the molecule, depending upon the desired 
pharmacological action. Synthetic progestagens tend to be based on the structure of 
progesterone, with structural alterations enhancing the mode of action and reducing 
potential side effects. 
5β-reduction 
5α-reduction 
 
H 
H 
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1.3 STEROID BIOCHEMISTRY AND BIOSYNTHESIS 
 
The majority of cholesterol used for steroid biosynthesis comes from the blood, 
originating from hepatic synthesis. A relatively small contribution comes from 
intestinally absorbed cholesterol from the diet[12]. Any cholesterol that is surplus to the 
requirements of the body is stored, lipid bound, to low density lipoprotein (LDL), on 
the inside wall of blood vessels (hence the need to control excessive dietary intake to 
avoid exacerbating certain cardiovascular diseases). Cholesterol is transported into 
steroid producing cells bound to lipoprotein. Once in the cell it is disassociated from 
the lipid and initially converted into pregnenolone. At this stage, endogenous steroid 
synthesis is under control from the hypothalamic-pituitary axis (HP axis).  
The hypothalamus produces hormone ‘releasing factors’ that act on the pituitary gland 
causing it in turn to secrete protein hormones that act on target organs such as the 
adrenal gland, testis and ovary. These tissues are the primary producers of the array of 
endogenous steroids required for the maintenance of normal mammalian homeostasis. 
The activities of these tissues are discussed below, with greater emphasis on the 
reproductive tissues and their associated steroids, as they form the basis of the research 
in this thesis. 
 
1.3.1 Adrenal gland 
Adrenocorticotrophic hormone (ACTH) is secreted by the pituitary to act on the 
adrenal gland, which in turn, produces a range of corticosteroids (C21 steroids) , these 
being divided into the subclasses of glucocorticoids and mineralocorticoids.  Cortisol is 
the primary glucocorticoid secreted from the adrenal gland in mammals, usually in 
response to stress and is responsible for mobilising glucose into the bloodstream from 
muscle stores, regulating the immune system and controlling inflammation in certain 
tissues. Its production increases markedly during the classical fear, fight or flight 
response in mammalian species. Mineralocorticoids, e.g. aldosterone help to maintain 
blood pressure via control of kidney function and the reabsorption of salt and water.  
Under ACTH control the adrenal gland also produces the weak androgens 
dehydroepiandrosterone (DHEA) and androstenedione, the latter of which is the 
precursor to the production of relatively small quantities of testosterone and oestrogens 
(oestrone / oestradiol). In female dogs and humans this is the major source of 
 13 
 
physiological testosterone production, whereas in the male, much greater quantities are 
produced directly by the testis.  
 
1.3.2  Testis 
Testosterone is one of the C19 steroids which make up the androgen class of 
compounds. Testosterone and other androgenic compounds are synthesised primarily in 
the testis in the male (and to a much lesser extent in the ovaries in the female), where 
they are responsible for maintenance of sexual characteristics and the hormonal control 
of reproduction. The anabolic effect of endogenous testosterone is most noticeable 
during male puberty where increases in bone density and overall muscle mass are 
observed. 
The production of testosterone in the testis is under the control of follicle stimulating 
hormone (FSH) and luteinising hormone (LH), both of which are released by the 
pituitary gland. In humans, testosterone is released into the circulation and bound to 
two major transport proteins, albumin and sex hormone binding globulin (SHBG). Only 
approximately 2% of circulating testosterone is present in the unbound/free form in 
human males and 1% in females[12]. The free form testosterone is the biologically 
active form which can be transported into the relevant cells for androgen receptor 
binding, or further conversion to 5a-dihydrotestosterone (DHT) which is the active and 
indeed more potent androgen in various target tissues[5]. Under normal homeostatic 
conditions the level of unbound testosterone is in dynamic equilibrium with the protein 
bound form, ensuring that biologically active levels are maintained. The levels of total 
testosterone in the bloodstream are controlled by a negative feedback mechanism 
through the HP axis whereby increased testosterone levels exert a direct negative effect 
on the production of LH, which in turn reduces the production of testosterone.  
Negative feedback mechanisms are prevalent in nature particularly in relation to the 
regulation of hormones via the HP axis. When testosterone is abused and administered 
at high doses for prolonged periods in males, the activity of the HP axis can be 
disturbed to the point where little to no LH is secreted, leading to testicular atrophy, 
although this is considered to be reversible some weeks/months after cessation of use. 
In the female, regular abuse of a high level of testosterone would interfere with normal 
hormonal balance and cause potentially irreversible side effects due to masculinisation 
(i.e. virilisation.) 
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Figure 1.7 shows some of the key biosynthetic pathways of steroidogenesis that take 
place in the adrenal gland, testis and ovary. The cellular enzymes involved in these 
processes are also highlighted. The abundance and activity of these enzymes varies 
from each tissue location depending upon the required terminal products[13]. 
 
 
  
 Cholesterol 
   
Pregnenolone   progesterone 
   
17OH pregnenolone  17-OH progesterone 
     
DHEA    androstenedione   testosterone  
        
     Oestrone   oestradiol 
 
 
Figure 1.7: Biosynthesis of reproductive steroids: Enzymes involved: 1. C20-22 
desmolase and 20- and 22-hydroxylases; 2. 17-hydroxylase; 3. 3β-hydroxysteroid 
oxidoreductase and ∆5→4-3-oxosteroid isomerase; 4. C20-17-desmolase; 5. 17B-
hydroxysteroid oxidoreductase. 6. Aromatase cascade: 19-hydroxylase; 
19hydroxysteroidoxidoreductase; C10-19-desmolase. 
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1.3.3 Ovary 
Steroidogenesis in the ovary is also under the control of FSH and LH[14]. 
Demethylation of androgens at C-19 and aromatisation of the A-ring results in the 
formation of oestrogens (C18 steroids), which are produced in large quantities in the 
female and are responsible, in conjunction with progesterone and related compounds 
(C21 steroids), for the normal control of the oestrus cycle in the female. At certain 
stages of the oestrus cycle and during pregnancy there are marked alterations in the 
levels of hormones produced by the ovary. Progesterone (and pregnenolone) is a 
precursor to the production of androgens and subsequently oestrogens, and as such is 
not secreted into the bloodstream in significant quantities until key stages of the oestrus 
cycle. This is also true of the androgens up to the point of ovulation. The production of 
steroids in the ovary is therefore carefully compartmentalised and controlled by various 
interactions of the pituitary hormones and the ovarian steroid products alike. It is a 
finely balanced mechanism, which to this day is not completely understood in detail at 
the cellular level. The complex balance of oestrogen and progesterone in the normal 
oestrus cycle can, however, be disrupted and indeed controlled, by exogenous 
administration of androgenic, oestrogenic or progestagenic hormones. 
1.4 THE OESTRUS CYCLE 
 
The greyhound bitch, unlike the human, is essentially a seasonally mono-oestrus 
animal. Before highlighting the key events in the canine oestrus cycle, a brief summary 
of events in the human ovarian cycle is given to provide a comparison with that of the 
bitch as well as outlining features that are common to both. 
1.4.1 Human ovarian/menstrual cycle 
The human ovarian cycle occurs on average once a month and begins on day one with 
about 4 days of menstrual bleeding[14]. As oestrogen levels begin to rise the follicular 
phase begins with a number of follicles being prepared for potential ovulation. Under 
control by FSH and LH the follicles develop and increase in size with the proliferation 
of various cell types (these will be discussed in more detail for the greyhound in 
chapter 5). As ovulation approaches one of the more dominant follicles is chosen and 
continues to develop while the other follicles atrophy. Around 2 weeks into the cycle, 
oestrogen levels, having reached a maximum, suddenly drop away. This maximum 
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level is achieved via one of nature’s few and rather interesting positive feedback 
mechanisms; where once a critical oestrogen level is reached, rather than negative 
regulation of production taking place as before, a dramatic further increase occurs. This 
is followed by a surge in LH. This stimulates ovulation via rupture of the dominant 
follicle, releasing the egg into the fallopian tube for potential fertilization, which 
usually needs to occur with 24 hours of ovulation (the egg can remain viable for up to a 
week in the canine[15]). In the ovary, the residual ruptured follicle, or corpus luteum 
(Latin for ‘yellow body’ – due to the high lipid content of the cells) starts to secrete 
progesterone in preparation of the maintenance of the uterus lining for a possible 
implantation and ultimately pregnancy. If no fertilization takes place the corpus luteum 
degenerates through a process called luteolysis (luteal phase of the cycle). Luteolysis 
occurs when there is no luteotrophic hormonal support for the developing corpus 
luteum and can last up to 2 weeks resulting in the shedding of the uterine lining and the 
egg (menstruation). The cycle then begins again. In summary the cycle has three main 
phases; the follicular phase, ovulation and the luteal phase. 
 
1.4.2 The oestrus cycle of the greyhound bitch 
The oestrus cycle of the bitch has been characterised by as many as six phases but for 
simplicity there are four clearly defined phases of significant duration that will be 
discussed here. These comprise Pro-oestrus, Oestrus, Di-oestrus and Anoestrus[16]. 
  
Pro-oestrus: lasts approximately 9 days, during which time the bitch will exhibit both 
anatomical and behavioural changes including the commencement of bleeding, 
increased urination and attractiveness to male dogs (but generally unreceptive). 
Oestrus: which again lasts on average for 9 days, at the outset of which the bitch will 
normally ovulate and be receptive to males; this being a major reason for not allowing 
bitches to race during this time. 
Di-oestrus: (80-90 days) during which post-ovulatory levels of progesterone rise 
(produced from the developing corpus luteum) and ultimately fall back to basal after 
around 3 months. 
Anoestrus: the final stage, following luteal regression, which will last for around 4 
months in the average bitch. The bitch will remain sexually inactive during this time 
until the commencement of pro-oestrus returns.  
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Therefore the average oestrus cycle in the greyhound bitch lasts for 8 or 9 months[17]. 
One notable significant difference in the greyhound cycle compared with the human is 
the maintenance of the corpus luteum in the absence of fertilization and pregnancy. The 
levels of progesterone produced in pregnancy are on average higher than those 
produced in the normal oestrus cycle, but levels will be variable from one animal to 
another, as will be the lifespans of the corpora lutea. In fact, the only reliable hormonal 
indicator of pregnancy in the greyhound is the protein relaxin[18,19], which is produced 
in part to prepare the pelvic ligaments for parturition. It appears in plasma at about 25 
days after ovulation with levels peaking at around day 50. The prolonged luteal phase 
in di-oestrus means that the bitch is under the influence of progesterone for a prolonged 
period and in the latter luteal stages, prolactin as well, which continues to maintain the 
corpus luteum. The basis of regression of the corpus luteum in the greyhound bitch is 
poorly understood as it does not involve secretion of prostglandin F2a (a luteolytic fatty 
acid produced by the ovary or uterus in other animals, including the mare[20]) or the 
withdrawal of luteotrophic support as in the human. 
The hormonal and pheromonal changes in the canine resulting in ‘oestrus’ receptivity 
are believed to have evolved out of the human, hence the terminology ‘ovarian’ or 
‘menstrual’ cycle.  However, there is a body of research that might suggest evidence to 
the contrary[21]. The canine oestrus cycle is discussed in further detail in chapter 5. 
1.5 CONTROL OF THE OESTRUS CYCLE 
1.5.1 Synthetic steroids used to control the oestrus cycle in the greyhound 
The prolonged luteal phase is the reason given by many trainers for poor performance 
in the bitch for several weeks towards the end of di-oestrus and the beginning of 
anoestrus. Such trainers prefer to suppress or postpone the oestrus cycle in the bitch to 
maintain a consistent level of form for racing.  
The following compounds are examples of the types of steroid preparations used and 
their proposed mode of action to prevent the racing bitch coming into season. The 
compound used and the dosing regimen will vary depending upon the stage of the cycle 
that the bitch is currently at before treatment.  
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1.5.1.1 Synthetic progestagens 
Megestrol acetate (see Figure 1.8) is a progestagen that is structurally related to and 
mimics the action of progesterone, putting the bitch in a ‘luteal’ state. This drug is 
considered effective when given as a short course in pro-oestrus and for a longer 
duration in anoestrus[21,23]. Its actions involve the suppression of follicle development 
and ovulation via modulation of the secretion of FSH and LH. 
Another progestagen, norethisterone (see Figure 1.8) is a human contraceptive that acts 
by thickening the uterine wall to prevent implantation of the egg following ovulation. It 
can prevent ovulation as well, but not consistently. It is not known whether these 
modes of action are similar in the greyhound bitch, but nevertheless from recent 
anecdotal evidence as well as previous research[24,25] it does appear to be an effective 
oestrus suppressant, although it may need to be administered on a daily basis (as in 
humans) to be fully effective. One study has shown no ill effect of the long term usage 
of norethisterone in the greyhound bitch[26]. Due to their substituent groups present at 
C-17 both megestrol acetate and norethisterone are orally active and therefore available 
as tablet preparations. 
 
   
 Megestrol acetate     Norethisterone 
 
Figure 1.8: Structures of synthetic progestagens: the functional groups shown in red 
represent the synthetic additions to the structure of progesterone (in the case of 
megestrol acetate) and to the structure of nandrolone (in the case of norethisterone) 
 
1.5.1.2 Synthetic androgens 
The main reproductive effect of exogenous androgen administration is to cause 
suppression of ovarian activity via negative feedback on the pituitary which decreases 
gonadotrophin secretion. The ovaries still contain primary and secondary follicles but 
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these are unable to mature to ovulatory size. Androgens are not as effective as 
progestagens when given in short timespan doses at key stages of the oestrus 
cycle[16,27]. They therefore tend to be used on a semi-regular basis. For example 
methyltestosterone is known to have been given in tablet form on an almost daily basis 
to suppress oestrus in racing greyhounds (based on intelligence from international drug 
testing authorities). Nandrolone and testosterone are usually given in the form of 
injectable esters, providing a slow release of the drug into the circulation over a period 
of many weeks. Dosing is therefore only required once or twice a month. Structures of 
some of these compounds (including the ester form) are shown in Figure 1.9.  
  
Methyltestosterone    Testosterone decanoate ester 
 
Figure 1.9: Structures of synthetic androgens: the functional groups shown in red 
represent the synthetic additions to the structure of testosterone. 
 
1.5.2 Structure /Activity relationship of synthetic steroids 
It is interesting to note the structure/receptor binding activity relationship for various 
compounds depending upon the functional groups that are present in the C-17α 
position. In general terms, fully saturated alkyl groups are present at this position in the 
structure of androgenic-anabolic steroids whereas unsaturated groups are present in 
progestagens. There is some crossover of androgen and progesterone receptor binding 
activity for various compounds in vivo, i.e. neither group is 100% selective for its 
intended pharmacological receptor activity[12,28]. The 3-keto-4-ene moiety of the A-ring 
is extremely important for efficient androgenic activity in vivo[5], but clearly this is also 
in conjunction with a suitable associated structure at C-17 in the D-ring. In fact 
epimerisation of the 17β-hydroxy function of testosterone to 17α-hydroxy testosterone 
or ‘epitestosterone’ results in this compound having virtually no androgenic/anabolic 
activity at all[5].  
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Some examples of related steroid structures and their pharmacological action are shown 
in Figure 1.10. All of these compounds have been produced in their time by the 
pharmaceutical industry for human or veterinary use with the exception of 
tetrahydrogestrinone (THG). THG was one of the first ‘designer’ steroids to be 
discovered in 2003[29]. Based on its structure and knowledge of steroid biochemistry it 
was clearly predicted by its makers to have androgenic activity and be effective when 
taken orally. It has been shown to be a potent androgenic compound some 10x stronger 
than trenbolone[30,31]. It was also expected to be potentially difficult to detect (see 
derivatisation techniques).  
 
Trenbolone (1,2)  Gestrinone (1,2,3)  THG (1,2) 
(1) Binds androgen receptors 
(2) Binds progesterone receptors 
(3) Binds oestrogen receptors 
   
Nandrolone (anabolic)       Norethisterone (progestagen)      Norethandrolone (anabolic) 
Figure 1.10: Structurally related anabolic and progestagenic steroids 
 
Gestrinone, THG, norethandrolone and norethisterone are orally active compounds. 
Nandrolone and trenbolone are normally given as ester linked preparations to avoid 
first pass metabolism of the unprotected hydroxyl group at C-17 by liver enzymes.   
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1.6 STEROID METABOLISM 
 
The metabolism of anabolic steroids has been studied and reviewed in various 
mammalian species, including the cow[32], the horse[33], human[34], and the dog[35], 
although to date studies have not been extensive in the latter. Knowledge of 
metabolism is clearly important in the sports testing industry in order to be able to 
identify key marker analytes for the detection of drugs of abuse. 
 
1.6.1 Phase I metabolism 
Structural alterations to the steroid, as well as activating it for receptor activity, can also 
result in rendering the molecule relatively inactive and thus prepare it for excretion 
from the body. Such structural alterations are termed Phase I metabolic conversions, 
the majority of which are performed by liver enzymes. Steroids enter the liver via the 
circulating blood vessels. Endogenous steroids that enter the circulation are therefore 
constantly being metabolised. Exogenous drug administrations via injection routes (e.g. 
intramuscular or intra-articular) introduce the proprietary preparation into the 
bloodstream, and in the case of steroid esters (following de-esterification by hydrolase 
enzymes present in the blood), the parent compound is able to exert its effect before 
reaching the liver and being metabolised. Oral steroid administration results in the drug 
being absorbed from the intestine and transported directly through the liver via the 
hepatic portal vein. This results in what is termed extensive first pass metabolism of the 
drug, meaning that a much smaller percentage of the active parent compound reaches 
the bloodstream. However, as previously highlighted, many of the orally active steroids 
have 17a-alkyl substituent groups that block enzyme activity on the D-ring and allow 
more of the intact drug to reach the circulation, thereby increasing its bioavailability. 
The primary role of Phase I metabolism is to reduce the pharmacological activity of 
drug a molecule and increase its polarity to aid excretion from the body, (e.g. addition 
of hydroxyl functional groups). Various enzymes perform a range of Phase I 
transformations including oxidation of 17-hydroxy functions to -keto groups (this 
significantly reduces the pharmacological activity of anabolic steroids[5]); reduction of 
the 4-ene double bond (5α/β reductases); reduction of the 3-keto function to 3α or 3β 
hydroxy groups and various hydroxylases that incorporate hydroxy functions at 
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different carbon locations of the steroid ring structure. Some common sites of steroid 
metabolism are shown in Figure 1.11. 
 
 
    
 
 
Figure 1.11: Common sites of metabolism for anabolic steroids 
 
1.6.2 Phase II metabolism 
Liver enzymes are also responsible for Phase II metabolism which increases the 
polarity of a steroid molecule still further by conjugating it with various water soluble 
molecules such as sulphate groups or glucuronic acid. This aids the urinary excretion 
process for steroidal compounds. In fact for some compounds, whose structures are 
unable to be altered by Phase I enzymes, conjugation may be the only means by which 
the body can increase their polarity to aid excretion. Such compounds tend to be quite 
toxic to the liver and include the 17α-alkyl steroids and compounds whose structures 
have a high degree of A,B,C ring unsaturation, (e.g. trenbolone related), making them a 
poor ‘fit’ in the active site for many of the Phase I liver enzymes[34]. Some examples of 
steroid conjugate structures are shown in Fig 1.12. 
 
   
OO OH
OH
OH
COOH
O  
 DHEA sulphate     Testosterone glucuronide 
Figure 1.12: Structures of Phase II conjugates 
Oxidation of 17B-hydroxy to keto 
group; but inhibited if 17a alkyl 
function is present. 
Epimerisation at C-17 
Hydroxylation at C16, C15 
Hydroxylation at C-6 
Reduction of keto at C3 
Reduction at C5 
Hydroxylation at C11 
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1.7 METHODS OF STEROID DETECTION 
 
Steroids can be analysed in a variety of biological matrices including blood, saliva, 
urine, bile, hair and tissue. Various methods have been described over many years and 
reviewed for various mammalian species including the cow[32], and in particular in 
relation to sports drug testing in the horse[33],[36] and human[37],[38]. 
The analytical approaches to steroid detection have developed and adapted over time to 
improve selectivity and sensitivity. Radioimmunoassay (RIA) was a popular analytical 
technique in the 1970s and developments for application to the analysis of anabolic 
steroids were implemented for use at the Olympic games around that time[39]. This 
technique was accompanied by enzyme linked immunosorbent assays (ELISA) in the 
1980s. Unwanted cross reactivity in immunoassays can be an issue with complex 
matrices (providing ‘false’ positives) and analyte identification is not necessarily 
possible, (requiring confirmation by an alternative technique, e.g. gas chromatography-
mass spectrometry [GC-MS]) although rapid throughput is advantageous and some of 
these assays are still used for certain applications today, particularly if they are analyte 
specific or limited to a minimum number of analytes (i.e. drug group specific). 
However, alongside these techniques gas chromatography (GC) and liquid 
chromatography (LC) were developing fast, ultimately to be combined with mass 
spectrometry to provide highly selective methods for detection of whole drug groups 
such as anabolic steroids as well as stimulants, beta blockers and non-steroidal anti-
inflammatory drugs (NSAIDS), all of which are of interest in the anti-doping sector. In 
the 2000s, particularly with the introduction of atmospheric pressure chemical 
ionization (APCI), liquid chromatography-mass spectrometry (LC-MS) became the 
analytical approach of choice for most drug groups in various sectors of the drug 
testing industry and is suited to the analysis of plasma as a matrix. This technique can 
provide relatively comprehensive drug testing coverage for anabolic steroids[40] since 
the parent drug is detectable in plasma for a lot of compounds following intramuscular 
administration. The presence of a 4-ene moiety adjacent to the the 3-keto function, 
which is present in a large number of anabolic agents, allows these compounds to be 
ionised effectively for analysis by LC-MS.  
However, as previously described earlier in this chapter, the oral route of drug 
administration results in extensive first pass metabolism of certain anabolic steroids, 
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with little or no parent drug being excreted in some cases, and reduction of structural 
double bonds produces relatively poorly-ionisable, fully saturated steroid metabolites, 
which are unsuitable for effective LC-MS analysis[33,36]. Therefore, GC-MS and now 
the recently revitalised GC-MS/MS market still plays a significant role in sports drug 
testing labs for the analysis of androgenic-anabolic steroid metabolites,  particularly if 
more informative mass spectra are required.  
The choice of analytical method will largely depend upon the matrix being analysed, 
the chemical nature of the analytes of interest in that matrix and the required context for 
the results obtained. In recent years blood analysis has made its way into mainstream 
animal sports testing, providing the sports regulator with a means to take a large 
number of samples from numerous animals in a relatively short space of time. This can 
be a useful approach depending upon the requirements of such testing and the actual 
timing of the sampling. The British Horseracing Authority (BHA) currently operates a 
system of testing horses in their training stables to detect potential steroid abuse that 
may be occurring during the lead up to the actual race day.  
However, at present (analogous to GC-MS vs LC-MS), urine still represents the main 
matrix of choice over blood for regular routine drug testing in sport (both animal and 
human) and therefore the vast majority of research over the years has focussed on 
developing methods to provide routine detection drug capability in this matrix. Urine 
samples will usually contain a greater concentration of analytes available for analysis 
and will also provide a greater retrospective window of detection for compounds that 
may have been administered many days or even weeks prior to the test sample 
collection date.  
The process of successful steroid analysis and data interpretation can involve various 
stages, including sample preparation, extraction, derivatisation and instrumental 
analysis. Focussing on analysis of urine by GC-MS the various stages are summarised 
as follows:- 
 
1.7.1 Sample preparation 
The conjugated status of the analytes needs to be taken into consideration when 
developing methods for the analysis and detection of anabolic steroids in biological 
matrices. 
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Removal of phase II conjugate groups is necessary for analysis prior to GC-MS. Intact 
conjugates can be analysed by LC-MS/MS for certain compounds, but this is still a 
complex analysis for a multi residue screening approach, with reduced detection 
capability for some analytes, although progress is being made in this area[41]. 
Hydrolysis of steroid glucuronides usually involves the use of β-glucuronidase from 
E.coli, which is relatively pure and provides a clean glucuronide fraction analysis. The 
process usually involves incubation at a suitable pH and temperature for a number of 
hours. An enzyme preparation from Helix Pomatia (HP) also cleaves glucuronides but 
contains aryl sulphatase activity as well, allowing it to cleave primarily aryl sulphates 
and to a much lesser extent, some alkyl sulphates (but this is stereochemistry 
dependant), which could lead to miss-assignment of a metabolite to the wrong Phase II 
fraction. HP has also been shown to produce steroid analyte artefacts under certain 
conditions[42]. However, with knowledge of its enzyme activity HP has been used 
successfully for specific applications[43].  
Hydrolysis of sulphates can be achieved by mild acid hydrolysis or solvolysis. Strong 
acid hydrolysis or methanolysis techniques can remove both glucuronide and sulphate 
conjugates in one step, which can be advantageous to speed up analysis under certain 
circumstances. However, this process can result in artefact formation and degradation 
of certain steroids[44,45] so is not recommended for initial research purposes. 
Hydrolysis of conjugates can take place as the first step in an analytical procedure 
(known as direct hydrolysis) but this can have implications if samples have any 
potential bacterial contamination/activity associated with them. If so, some bacterial 
degradation may already have occurred following sample collection, although this will 
be significantly exacerbated by incubating the sample at 37oC for 12-16 hours (a 
standard process for hydrolysis with β-glucuronidase from E.Coli.). Therefore it is 
recommended to pre-extract samples prior to hydrolysis to remove any potential 
bacteria and their enzymes. Solid phase extraction is the best way to achieve this. 
1.7.2 Extraction methods 
Liquid liquid solvent extraction methods are simple approaches to the preparation of 
unconjugated steroid extracts from urine samples that have been utilised for many years 
and simply involve maximising the partition co-efficient between the chosen organic 
extracting solvent phase and the aqueous sample phase. Diethyl ether is a good 
example of an extraction solvent for this purpose.  
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Solid phase extraction involves the use of solid material (sorbent) appropriately 
supported, to which the sample is applied to allow interaction of the drug molecules 
with the solid material. The residual matrix (urine) is rinsed away before choosing an 
appropriate solvent to use for elution of the analytes from the surface of the sorbent. 
Early studies of solid phase extraction involved the use of resins such as amberlite 
XAD2[46] and sephadex LH20[47], but perhaps the most important and influential 
breakthrough came with the introduction of solid phase in cartridge form, most notably 
the C18 Sep-pak This phase was extensively studied for use in steroid extraction, 
including a thorough evaluation of analyte recoveries which were shown to be equal to 
or better than other methods of extraction[48]. In the 1980s there was a marked increase 
in the development of solid phase extraction (SPE) cartridges that provided a more 
selective and cleaner extract prior to derivatisation and analysis by mass spectrometry. 
C18 cartridges are essentially a silica backbone coated with silanol residues, which can 
then be substituted with functional groups such as C18 chains providing a hydrophobic 
structure with which the 4-ring steroid structures readily associate through Van der 
Waals interactions. SPE generally produces cleaner sample extracts than liquid–liquid, 
allowing for lower limits of detection and improved longevity of response from the 
analytical instrumentation before routine maintenance is required, which maintains 
instrument efficiency for longer.  
More modern SPE phases have been developed in the last decade using polymer 
technology including various substituted styrene-divinyl benzenes (SDVB)[49]. These 
cartridges give a wide range of flexibility of analytical approach and some novel 
methods have been developed for steroid analysis using these cartridges to separate 
different conjugates[35]. 
Pure neutral extracts can also be obtained by utilising a sequential combination of SPE 
approaches in one procedure using mixed mode anion exchange cartridges. This can 
produce very clean extracts allowing for sub-nanogram steroid detection capability 
when coupled with a selected ion monitoring (SIM) GC-MS procedure[50]. Modern 
polymer phases have become invaluable in the routine screening environment due to 
their chemical robustness compared with silica based sorbents[49]. Silica based 
cartridges usually require activation of the sorbent/conditioning prior to use, and the 
extraction should be a continuous process to avoid any possibility of the sorbent drying 
out, resulting in loss of phase viability. This is in contrast with polymer phases that are 
not prone to phase collapse during the extraction process. 
 27 
 
Unsubstituted silica phase cartridges are also of significant value to clean up extracts of 
steroids further still. Such methods can remove very polar steroids and can help with 
removal of a number of adrenal corticosteroid metabolites to improve the 
chromatographic quality and analyte co-elution issues. Nevertheless a final steroid 
extract that has been through a number of different sample preparation stages will still 
contain a complex mixture of endogenous steroids and their metabolites. Therefore, 
suitable chromatographic methods are still required to assist with the detection of, and 
if required, accurate quantitation of anabolic steroid metabolites.  
Despite essentially being a group of neutral non-polar analytes the steroids have quite a 
variety of extraction behaviours even within that group and therefore the choice of 
extraction is vital, particularly when exploring all potential analytes available in a 
metabolism study. Many of the steroid recoveries originally established for C18 
cartridges (80-90% for most analytes) are applicable today and this classical approach 
is a cornerstone for steroid extraction, despite the development of more novel 
approaches.  
Solvent choice is also important in these methods to ensure that analytes are not 
wrongly assigned to different conjugate fractions. For C18 cartridges this can be 
overcome by eluting the entire fraction with methanol, splitting the eluent in half and 
only performing enzyme hydrolysis on one portion of eluent, then comparing the 
results and yields of the very polar metabolites obtained after analysis of the two 
separate extracts. Identical yields for a particular metabolite would indicate that it is 
excreted in the unconjugated form. Due to their complexity such analytical approaches 
are unlikely to be used in routine screening environments when being applied to large 
numbers of samples on a daily basis. However, this knowledge could be important if 
the highly polar metabolite in question appears to be the most abundant in the overall 
profile and potentially the most useful for detecting abuse of the parent drug.  
To assist with monitoring extraction processes, deuterated steroid standards have 
become available for inclusion into extraction processes, and in more recent years 
certain conjugates of deuterated standards as well. These can be quite expensive but 
will no doubt increase in availability and reduce in price over time. 
1.7.3 Derivatisation techniques 
Steroids will normally require derivatisation prior to GC-MS analysis as they exhibit 
poor gas chromatographic properties. Steroid metabolites containing keto and hydroxyl 
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functions are poorly resolved on GC columns and can also undergo degradation in the 
injection port when underivatised. The most common approach to the derivatisation of 
steroids is the formation of trimethylsilyl (TMS) derivatives using N-methyl-N-
trimethylsilyltrifluoracetamide (MSTFA) and this approach was first introduced in 
1969[51] Hydroxy groups react quantitatively with MSTFA to produce stable TMS 
ethers. Sample extracts can be dissolved in MSTFA and injected directly onto the 
column. This will result in spontaneous formation of the TMS ether. However for more 
sterically hindered hydroxyl functions a catalyst is also required to force the 
derivatisation such as trimethylsilylimidazole (TMSI) [52,53]. Steroids containing keto 
functions require a different approach. One such method is condensation with amines 
such as hydroxyl amine or methoxyamine to form oximes[54]. The hydroxyl functions 
are then derivatised with MSTFA as a second reaction step. For most compounds this 
results in the formation of two derivative isomers and often two chromatographic peaks 
in a 75:25% ratio. This can be very useful as a diagnostic aid, particularly as the oxime 
group is stable during the second TMS ether derivatisation step, resultimg in an MO-
TMS derivative.  
 A one step derivatisation process for both keto and hydroxyl functions has been 
developed[53] that produces TMS ether TMS enol ether derivatives. More than one 
product can be formed but in practice the shift is often 95-99% in favour of the most 
stable form. These derivatives are stable under GC-MS conditions. Due to handling 
issues with TMSI reagent, derivatisations are often performed with a reaction mixture 
comprising MSTFA/NH4I/ethanethiol (2000:1:3)(v/w/v), from which the reactive 
TMSI is formed in situ. Like MSTFA this mixture can be injected directly onto the GC-
MS system. Example structures of the derivatised products are shown in Figure 1.13. 
 
    
 
Enol-tms product 1 (99%)     Enol-tms product 2 (1%)  
 
Figure 1.13: Derivatised structures of testosterone enol-bis-tms[53]. 
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The enol-tms derivatisation results in products with a greater degree of unsaturation 
within the steroid ring structure. As such compounds whose molecular structures 
already have a significantly high degree of unsaturation throughout the ring A,B,C 
rings (e.g trenbolone and THG) generally will not form stable enol-tms for analysis. 
These compounds are therefore best detected by LC-MS techniques. 
A similar derivative to the TMS derivative that can also be used for steroid analysis is 
the tertiarybutyldimethylsilyl (TBDMS) derivative[55]. This is a more bulky derivative 
and requires a catalyst to assist with its formation. Enol-TBDMS derivatives can also 
be formed using a similar procedure to enol-tms derivatives, but the reaction mixture is 
not volatile enough to allow it to be directly injected on to the GC-MS system like the 
enol-tms mixture. Therefore a back extraction to remove excess reagent is required, 
which although is a more time consuming analytical process, results in a final extract 
that can be cleaner than the enol-tms final extract and also more stable for a longer 
period of time if subsequent injections of the extract are required. Unlike TMS 
derivatives the more bulky TBDMS derivatives are stable to hydrolysis increasing the 
practicality of their use in the laboratory. The spectra obtained with TBDMS 
derivatives exhibit intense, relatively stable, M+ - 57 ions[55] (loss of the tertiary butyl 
group) and this can be particularly useful when analysing fully saturated –diol and -triol 
compounds whose mass spectra are often dominated by lower mass ions, making them 
less suitable for GC-MS/MS analysis if sensitive detection methods are required. 
Other derivatives of interest are those that can assist with structural elucidation, e.g. in 
relation to stereochemistry of particular functional groups. Examples include acetonide 
derivatives[56] and cyclic boronates which will form across adjacent hydroxyl functions 
(1-2 diols) and in the case of the boronates across non-adjacent hydroxyl functions (1-3 
diols) as well[57]. 
1.7.4 Gas Chromatography 
Gas chromatography consists of the introduction of a small volume of volatile solvent, 
which contains a proportion of the derivatised sample extract, into a heated glass liner 
where the analytes are vaporised and swept by carrier gas (usually helium) onto a 
microbore capillary column. The column is coated on the inside surface with a 
liquid/stationary phase. The analytes in the extraction mixture are then separated based 
on their volatility and differing interactions with the column phase. Elution in gas 
chromatography is based upon the effective vapour pressure of the analyte, which is a 
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function of its latent vapour pressure, reduced by its solubility in the stationary phase 
and by the number of interactions the analyte undergoes with the stationary phase. All 
of these are affected by temperature and, combined, they determine the equilibrium 
distribution of the analyte between the two phases.  
The open tubular column was invented by Golay in 1957 and since that time important 
advances have been made in the development of GC columns. The most significant 
advancement in analysis of steroids by GC has been the development of fused silica 
capillary columns, particularly those with deactivated surfaces and cross linked 
liquid/stationary phases. Common examples in use today are dimethyl polysiloxane 
(100% phase) or various substitutions of this phase with more polar embedded groups 
to alter column selectivity and the potential separation / elution order of a group of 
analytes (e.g. 5% phenyl, 50% phenyl). Non-polar phases tend to exhibit greater 
thermal stability than polar phases. 
However, novel column chemistries and the incorporation of silphenylene into the 
column backbone has increased thermal stability of columns such as the cross linked 
BPX5 (5% phenyl polysilphenylene-siloxane), allowing for increased operating 
temperatures whilst reducing column bleed. All of these modifications serve to enhance 
detection sensitivity by reducing the bleed and background noise detected by the mass 
spectrometer compared with the signal from the eluting analytes. 
With complex mixtures of steroids in the urinary extract it is important to ensure that 
all the analytes have eluted from the column before the end of the analytical run. Any 
compounds not eluted may end up being eluted during subsequent runs at much earlier 
retention times than is appropriate for their derivatised structure, molecular weight, 
boiling point etc. causing confusion in interpretation of data and, in the case of SIM 
data, co-elution with a key target analyte could cause quantitative interpretation errors. 
In practice (unpublished) some of the latest eluting urinary analytes are those from the 
adrenal gland such as allo-tetrahydrocortisol, the retention time and elution of which 
has been used as a reasonable marker for determining the appropriate end to a GC oven 
cycle for many of the methods used for analysis of steroid extracts in this thesis. 
Subsequent to this work, backflushing techniques have become relatively mainstream, 
meaning once the last analyte of interest has entered the mass spectrometer, the carrier 
gas flow can be reversed to allow rapid backflushing of the residual analytes off the 
column via an oulet through a switching valve. This results in shorter run times and a 
cleaner mass spectrometer which can be advantageous for large batches of samples. 
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1.7.5 Mass Spectrometry 
A mass spectrometer is a sensitive analytical instrument that provides information 
about a chemical sample. The sample is converted into ions by interaction with high 
energy electrons (usually 70eV). High energy electron ionisation (EI) results in 
fragmentation of the molecular ion (M+.). Fragment ions are then separated according 
to their mass-to-charge ratios. The ions formed and their relative abundance under a 
specific set of conditions serves as a ‘fingerprint’ for analyte identification. There are 
various types of mass spectrometer and each includes a device to introduce the sample; 
an ionization source in which the sample is ionized; a mass analyser in which the 
charged particles are separated according to their mass ratios; ion collection, 
amplification and detection devices; and finally a data system for data interpretation[58]. 
Different instruments are capable of different degrees of discrimination between two 
components of similar mass or resolving power. Magnetic sector instruments have high 
resolution capability >10,000 (e.g. the ability to distinguish between two components 
of mass 100.000 and 100.010). Steroid analysis is generally carried out on quadrupole 
analysers or ion traps, both of which have unit resolution capability (i.e. the ability to 
distinguish mass 100.0 from 101.0). 
1.7.5.1 Quadrupole Mass filters 
A quadrupole is a mass analyser comprising four rods (coll. ‘quads’) arranged 
equidistantly in a parallel rectangle (see Figure 1.14). The ion beam from the ion source 
travels through the quadrupole in the z-axis. A high DC voltage in combination with a 
 
    
   
Figure 1.14 – Cross section of a quadrupole mass analyser 
(reproduced from Finnigan corporation manual 1990) 
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radio frequency (RF) applied to the rods creates a 3D time variable field within the 
quadrupole. Ions travel through this field following an oscillating path. By controlling 
the RF and DC voltages it is possible to select only ions of interest to be transferred to 
the detector. This can be in the form a large mass range for full scan analysis, or for 
greater sensitivity, only a handful of ions of certain mass to charge ratio can be selected 
(selected ion mode or SIM). The mass analyser is therefore operating as a mass filter. 
In a single quadrupole there is only one analyser, but a triple quadrupole has three sets 
effectively comprising two mass analysers with a collision cell between them (see 
Figure 1.15). Ions from Q1, selected for entry into the collision cell (Q2) on the basis of 
their m/z can be further fragmented (usually using collision with a high energy inert gas 
e.g. argon) and the resulting fragments can be separated in the third quadrupole (Q3) 
and detected. As with single quad analysis, Q3 can scan over a large range to produce a 
product-scan mass spectrum or for just a handful of product ions of selected mass to 
charge ratios (known as selected reaction monitoring [SRM] transitions). 
 
  
 
Figure 1.15: Schematic of a triple quadrupole mass analyser 
(reproduced from Finnigan corporation manual 1990) 
 
1.7.5.2  Ion Trap mass spectrometer 
Mass spectrometers based on ion trap technology are different in design from other MS 
systems. Ion traps combine the functions of an ion source and mass analyser in one 
location. This is achieved in a cylindrical ion trap by a simple three electrode assembly, 
consisting of a ring electrode and two end caps (see Figure 1.16). Electrons from a 
heated filament are pulsed into the central cavity by a gate electrode, where they ionize 
the molecules. The ion trap is then scanned from low to high mass by increasing the RF 
potential on the ring electrode. The unique feature of ion trap mass spectrometers is that 
they trap and store ions generated over time within the trap cavity. Applying RF 
voltage to the central ring electrode causes ions of interest to be trapped and 
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accumulated in the ion source. The trapped ions are sorted by changing the electric 
field inside the trap by manipulating the RF field and then sequentially ejecting the ions 
from the trap according to their mass-to-charge ratio (from low to high mass) into the 
electron multiplier where they are detected. The effective ‘trapping’ and accumulation 
of ions results in the concentration of the ions of interest and consequently in the very 
high sensitivities obtainable with the ion trap detector in full-scan mode. A high mass 
adjust facility for the tuning parameters also allows for accumulation of much greater 
quantities of molecular ions, even for some compounds that are normally significantly 
fragmented in quadrupole analysers. This provides molecular ion information in full 
scan mode and a suitable precursor ion for MS/MS analyses.  
    
  Figure 1.16: Schematic of the ion trap mass spectrometer 
(reproduced from Finnigan corporation manual 1990) 
 
1.7.6 Technical challenges and alternative techniques 
Despite the major advances in technology over the years there are still technical 
challenges that arise during routine analysis of anabolic steroids. These include the 
continued use of endogenous steroids such as testosterone. In the human testing field 
testosterone is detected by comparing the ratio of testosterone to epitestosterone (T:E 
ratio). If this exceeds 4:1 it is deemed suspicious. Significantly elevated levels of 
testosterone are also suspicious (e.g. >200 ng/ml urine) even if the T:E ratio is less than 
4:1 and in particular, if in conjunction, the epitetosterone level is also greater than 200 
ng/ml. Such a scenario indicates the possible administration of both testosterone and 
epitestosterone, the latter being used to ‘mask’ the former. However, the technique of 
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isotope ratio mass spectrometry (IRMS) is now employed in the human testing area 
allowing an assessment of the δ13C to δ12C ratio of certain key metabolites to indicate 
whether the origin of the testosterone is from an exogenous source, as synthetic drug 
preparations contain a slightly higher proportion of the 13C isotope[13,59,60]. The 
technique is relatively complex and certainly not mainstream in all laboratories but has 
been used to successfully confirm the use of endogenous steroids of a synthetic origin. 
However, this is not without its challenges though, as it has been recently suggested 
that underground labs are now using different plant based materials for their synthetic 
production, such that the isotopic signature of the resulting compounds is more closely 
aligned to the endogenous ratio, which reduces the ability of the test to discriminate a 
difference. To date the technique has only been applied with minimal use for anabolic 
steroid detection in the animal sport testing industry[61] but it may have further 
applications in the future. 
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1.8 PROJECT OVERVIEW 
 
The aim of this project is to apply extraction, derivatisation and GC-MS techniques to 
the structure elucidation and quantitation of metabolites of anabolic and progestagenic 
steroids in the greyhound. The outcomes of these studies will support drug testing 
programmes in the greyhound racing industry. Knowledge of steroid metabolism is 
essential for the identification of key analytes to underpin a successful drug screening 
programme for both synthetic and endogenous compounds in animal sports. To date 
there is relatively little published information on the metabolism and detection of 
anabolic steroids in the racing greyhound and there are no established population based 
reference ranges for endogenous steroids, to support methods to control the abuse of 
testosterone; one of the major challenges of the sports drug testing industry as a whole. 
The thesis contains four experimental chapters:- 
Chapter 2 describes an investigation into the metabolism of the anabolic steroid 
methyltestosterone, using reference material synthesis coupled with derivatisation 
techniques and mass spectrometry to elucidate the major metabolites excreted in the 
greyhound. 
Chapter 3 describes an investigation into the metabolism of the progestagenic steroid 
norethisterone, using the procedures outlined for the methyltestosterone investigation, 
along with an analysis of the proprietary preparation of norethisterone to provide some 
insight into the metabolic profile observed. 
Chapter 4 describes an investigation into the metabolism of the endogenous steroid 
testosterone to identify key marker analytes for quantitation in a population of blank 
greyhound bitches: thereby establishing an understanding of the ‘normal’ levels of 
these metabolites in female greyhound urine. This data would support the 
implementation of a threshold for these metabolites to allow the administration of 
testosterone to be controlled by the greyhound racing industry. 
Chapter 5 describes the development of a quantitative extraction procedure for 
determining the levels of testosterone and progesterone metabolites in greyhound urine. 
The methodology was used to produce longitudinal urinary profiles of these key 
endogenous metabolites, throughout the oestrus cycle in a population of greyhound 
bitches. 
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2. SYNTHETIC STEROID METABOLISM:  
 METHYLTESTOSTERONE 
2.1 INTRODUCTION 
The abuse of anabolic steroids for performance enhancement in sports is well 
documented and has been discussed in chapter 1. A number of metabolism studies have 
been undertaken in various species other than the greyhound, in order to identify the 
key metabolites which enable the detection of the administration of steroids for 
regulatory drug testing procedures.[1-5]. The use of anabolic steroids for performance 
enhancement both in training and during competition is strictly prohibited by the 
Greyhound Board of Great Britain (GBGB). The use of specifically licensed steroidal 
oestrus suppressants is currently permitted for racing greyhound bitches, both in Great 
Britain[6] and internationally. Veterinary preparations of both progestagens and 
androgens are available for such use, but the androgenic compounds are currently 
banned in Great Britain under the GBGB rules of racing (see chapter 1).  Repeated use 
of certain anabolic agents to suppress the oestrus cycle may have unwanted side effects 
on the animals, which is of concern to the GBGB, whose aim is to try and eradicate the 
use of androgenic anabolic steroids from greyhound racing in Great Britain. 
Methyltestosterone is an anabolic agent that has been widely used as an effective 
oestrus suppressant for many years particularly in America, but racing greyhound 
bitches may also benefit substantially from the primary pharmacological effect of the 
drug, namely its anabolic activity[7]. As an orally active compound of the 17α-alkyl 
group of steroids it may also cause liver damage if used regularly for long periods.  
Therefore its use as an oestrus suppressant is now prohibited and so its potential abuse 
requires strict control. 
Anabolic steroids tend to be extensively metabolised in mammalian species and the 
development of effective control procedures in sport requires knowledge of the major 
urinary metabolites to target, for drug screening and confirmatory analysis. The 
metabolism of methyltestosterone has previously been investigated in detail in 
human[4,8] and horse[3,9,10] but to a lesser extent in the greyhound. An early study by 
Mosbach et al11 into the faecal metabolism in the dog indicated that a large proportion 
of an oral dose was excreted by this route; an observation also supported by Yamamoto 
et al[12]. Williams et al studied both the in vivo[13] and in vitro[14] metabolism of 
methyltestosterone in the dog using liquid chromatography-mass spectrometry (LC-
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MS) techniques. However, due to the limitations of this analytical technique for steroid 
metabolite detection, only metabolites containing a keto function were observed, since 
fully reduced metabolites tend to show a poor response under electrospray ionisation 
conditions[15,16]. As highlighted in chapter 1 the preferred technique for the analysis of 
anabolic steroids in animal sports drug surveillance is gas chromatography-mass 
spectrometry (GC-MS). This chapter represents the first GC-MS study of the 
metabolism and detection of methyltestosterone in the greyhound. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Solvents and chemicals 
C18 Sep-Pak Vac SPE cartridges (500 mg, 6 cc, end capped) were obtained from 
Waters Ltd (Hertfordshire, UK). Methanol, hexane, chloroform, acetone, toluene and 
diethylether, Analar or HPLC grade, were obtained from Rathburn Chemicals Ltd 
(Walkerburn, Scotland). Sodium hydroxide, disodium hydrogen orthophosphate 
dihydrate, sodium dihydrogen orthophosphate monohydrate (AnalaR grade) and para-
toluenesulphonic acid were supplied by BDH (Poole, UK). Sodium sulphate, anhydrous 
calcium chloride, ammonium iodide, pyridine, lipophilic sephadex, and methoxylamine 
hydrochloride, tert-butyl methyl ether (TBME), methylmagnesium bromide in ether 
and β-Glucuronidase from Escherichia.coli were supplied by Sigma Chemical Co. Ltd 
(Poole, UK). N-methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) was obtained 
from Macherey-Nagel (Düren, Germany).  Ethanethiol was supplied by Aldrich 
Chemical Co. Ltd (Poole, UK). [3H2]-16,16,17-5α-androstan-3α-17β-diol (D3-
androstanediol internal standard) was prepared at HFL Sport Science, Fordham, Camb., 
UK. 
16α-hydroxy-5α-androstane-3α-ol-17-one, 16α-hydroxy-5α-androstane-3β-ol-17-one, 
16α-hydroxy-5β-androstane-3α-ol-17-one, 16α-hydroxy-5β-androstane-3β-ol-17-one, 
17α-methyl-5α-androstan-3α-17β-diol, 17α-methyl-5α-androstan-3β-17β-diol and 
16β-hydroxytestosterone were all obtained from Steraloids Inc. (Newport, Rhode 
Island, USA)17α-methyl-5β-androstan-3β-17β-diol was obtained from Research Plus 
Inc. (Bayonne, New Jersey, USA) and 17α-methyl-5β-androstan-3α-17β-diol from 
Cerilliant  (Austin, Texas, USA.) 
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2.2.2 Drug administration to animals: sample collection 
Administration studies were carried out at Racing Chemistry, Iowa, U.S.A. (see 
Appendix II regarding ethical considerations). Pre-administration urine samples were 
collected from two greyhound bitches and the drug preparation Orandrone™ (Intervet 
UK Ltd) was administered orally to both animals at a dose of 5mg per day for 7 days. 
Naturally voided urine samples were collected at +2, 4, 8, 24, 36, 48, 72 hours and +4, 
5, 6 and 7 days after the final dose. The urines were stored at -20oC awaiting analysis. 
 
2.2.3 Sample extraction 
Aliquots of canine urine (4 mL) were spiked with D3-androstanediol (internal standard) 
at a level of 25 ng mL-1.  Extraction cartridges (C18 Sep-Pak Vac, 6 cc, 500 mg), were 
conditioned with methanol (5 mL) and water (reagent grade, 5 mL). The urine samples 
were then passed through the cartridges followed by water (5 mL).  The column was 
washed with hexane (5 mL) and then dried with air under vacuum for 5 min.  Free 
fraction extracts were then eluted with diethyl ether (4 mL).  The glucuronide fraction 
was eluted with methanol (5 mL). The ether was evaporated to dryness under oxygen 
free nitrogen (OFN) at 40ºC in GC vials. The methanolic eluates were evaporated using 
OFN at 80ºC, the residue dissolved in phosphate buffer (1 mL, pH 6.8, 0.1 M) 
containing β-glucuronidase E. coli (250 µL, 10 units µL-1) and the solution incubated 
overnight at 37ºC. 
 
After incubation, sodium hydroxide (500 µl, 2 M) was added to each sample and the 
sample mixed using a Whirlimixer. Liquid-liquid extraction was carried using tertiary 
butyl methyl ether (TBME, 4 mL). The aqueous layer was removed and the organic 
solvent washed with sodium hydroxide (2 x 500 µL, 2 M).  The TBME was dried over 
anhydrous sodium sulphate and then evaporated to dryness under OFN at 40ºC in GC 
vials. 
 
2.2.4 Derivatisation procedures 
2.2.4.1 Enol-tms derivatives 
The Enol-tms derivatisation reagent was prepared from MSTFA (1 mL), ammonium 
iodide (3 mg) and ethanethiol (6 µL); the mixture being heated at 80ºC for 20 mins to 
dissolve solid material. The derivatising reagent (30 µL) was added to standards and 
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urinary extracts and the solution heated at 80oC for 1.5 – 2 hours, and a 1 µL aliquot 
injected on to GC-MS for analysis. 
 
2.2.4.2 O-Methyloxime-TMS derivatives 
O-methyloxime-TMS derivatives (MO-TMS) were also formed with separate extracts 
of post administration urines.  Following solid phase extraction and evaporation to 
dryness under OFN, MO-TMS derivatives were formed by adding ‘MO reagent’ (8% 
methoxylamine HCl in pyridine; 100 µL) to the urinary extract and heating at 80ºC for 
30 mins.  The extracts were then evaporated to dryness under OFN.  
Trimethylsilylimidazole (50 µL) was added and the solution heated at 80ºC for 2 hours.  
The reaction mixture was then dissolved in chloroform:hexane (1:1, 1 mL) and passed 
through a 20 mm Sephadex LH20 mini-column [prepared in-house]. A further aliquot 
of chloroform:hexane (1:1, 1 mL) was used to rinse the vial and then added to the 
Sephadex column.  The extracts were then evaporated to dryness, reconstituted in 
MSTFA and analysed by GC-MS. 
 
2.2.4.3 Acetonide-tms derivatives 
Acetonide-tms derivatives were prepared using a modified version of the procedure 
described by Houghton et al[2]. 16β-hydroxy testosterone internal standard was added 
to each sample prior to derivatisation in order to demonstrate the efficiency of 
acetonide derivative formation. Dried urine extracts or synthesised reference standards 
(as applicable) were reconstituted in dried acetone (2mL) containing ρ-
toluenesulphonic acid (~2 mg). Anhydrous CaCl2 (~50 mg) was added and the solution 
was rotary mixed for 4-5 hr. Following centrifugation the supernatant was removed and 
evaporated to dryness in a clean glass tube under OFN at 60ºC. The dried residue was 
dissolved in toluene and washed with 2 M sodium hydroxide (1 mL) followed by 
reagent grade water (1 mL). The final aqueous layer was removed and the organic 
solvent dried over anhydrous sodium sulphate. The organic solvent was then 
evaporated to dryness. Trimethylsilyl derivatisation was performed using the Enol-tms 
derivatisation procedure previously described and samples analysed by Gas 
Chromatography-Mass Spectrometry (GC-MS). To check the potential formation of 
acetonide derivatives for the more polar tetrol metabolites, toluene was substituted with 
TBME during the washing stage of the procedure to ensure solubility and efficiency of 
extraction for these analytes. 
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2.2.5 Gas chromatography/Mass spectrometry analysis 
Full Scan GC-MS analysis was carried out in positive ion electron ionisation mode, 
using a Thermo Finnigan (Austin, Texas, USA) DSQII bench top mass analyser 
instrument fitted with an SGE (SGE Europe Ltd, Milton Keynes, U.K.) BPX5 column, 
(approx. 29m, 0.25 mm id, 0.25 µm film thickness). The temperature of the 
split/splitless injector was 260ºC.  Injections were made in the splitless mode which 
was maintained for 1.0 minute. The interface temperature was 260ºC. Injection volume 
was 1 µl.  The GC temperature programme was started at 180 ºC and held for 0.5 min.  
Initial ramp 180ºC to 290ºC at 3ºC min-1 and then further from 290 ºC to 330ºC at 40 
ºC min-1. The final temp was held at 330ºC for 3 min.   Data was acquired from 8 to 41 
min. 
 
2.2.6 Synthesis of 17-methyl-5-androstane-3,16α,17-triol stereoisomers 
5α-androstane-3α,16α-diol-17-one, 5α-androstane-3β,16α-diol-17-one, 5β-
androstane-3α,16α-diol-17-one and 5β-androstane-3β,16α-diol-17-one (2 mg) were 
dissolved separately in dried ether (1 mL) to which was added  
methylmagnesiumbromide in dried ether (1 mL; 3M: Grignard reagent.) The solution 
was left overnight at room temperature. Isopropyl alcohol was then carefully added to 
destroy the residual Grignard reagent. Ethyl acetate (4 mL) was added to the mixture 
followed by 1 M hydrochloric acid (4 mL) and the mixture shaken. Following brief 
centrifugation, the aqueous layer was discarded and the organic layer dried with 
anhydrous sodium sulphate for 15 min. The organic layer was then evaporated to 
dryness under OFN at 80ºC. The residue was analysed by GC-MS as the TMS and 
acetonide-TMS derivatives. 
 
2.2.7 NMR Spectroscopy of synthetic starting material 
NMR spectroscopy experiments were carried out to determine the authenticity of the 
starting material (5β-androstane-3α,16α-diol-17-one) used to synthesise the major 
metabolite identified in this study. Two experiments were performed using a Bruker 
(Coventry, UK) Advance DRX500 spectrophotometer to determine both the purity and 
verify the structure of the compound. 
Purity was ascertained by the acquisition of a C13 spectrum. A single set of signals 
demonstrated the presence of only one compound. An NOESY (Nuclear Overhauser 
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Effect) experiment showed that the 18-methyl group was on the same face of the 
molecule as the proton at C-16, thereby indicating that the hydroxyl function at C-16 
was in the alpha configuration. 
 
2.3 RESULTS AND DISCUSSION 
The GC-MS analysis of enol-tms derivatised urinary extracts of the post-administration 
urine samples, resulted in the identification of several different metabolites of 
methyltestosterone: no parent drug was observed. Phase one transformations involved 
reduction of the 4-ene group, either individually or in conjunction with the keto group 
at C-3 along with hydroxylations at C-16 and possibly at C-6. The mass spectra of the 
C16 hydroxylated di-hydroxy metabolites indicate that the second hydroxylation is not 
associated with the D-ring. The metabolites that have been identified or tentatively 
identified are listed in Table 1. The sulphate fraction was not analysed as previous 
studies by the authors (unpublished data) and other workers[12,13] have indicated that 
sulphate conjugation does not appear to be a significant phase II metabolic pathway in 
the canine. 
 
Table 2.1: GC retention time (RT) data, relative abundance and conjugated status of 
urinary methyltestosterone metabolites as TMS derivatives. 
 
*total excreted based on TIC areas of these eight metabolites in the +4hr and +8hr urines from both animals.  **F- 
represents analytes detected in the ether fraction (non-hydrolysed ). G – represents analytes detected in the methanol 
fraction (enzyme hydrolysed) MWt (tms): Derivatised molecular weight. 
 
Urinary metabolites of methyltestosterone 
 
RT 
mins 
 
 MWt 
(tms) 
 
Base 
peak 
(m/z) 
 
% of  
total* 
 
Conj.  
status 
 
17α-methyl-5α-androstan-3β,17β-diol (M1) 25.94 450 143 25% G 
17α-methyl-5β-androstan-3α,17β-diol (M2) 23.99 450 143 2% G 
17α-methyl-5β-androstan-3α,16α,17β-triol (M3) 27.95 538 218 45% G 
17α-methyl-5α-androstan-3β,16α,17β-triol (M4) 30.06 538 218 5% G 
?17α-methyl-5z-androstan-6z,17β-diol-3one (M5) 28.87 536 143 15% G 
?17α-methyl-5z-androstan-3z,6z,17β-triol (M6) 26.48 538 143 3% G 
?17α-methyl-5z-androstan-6z,16α,17β-triol-3one (M7) 31.47 624 218 2% **F:G 
?17α-methyl-5z-androstan-3z,6z,16α,17β-tetrol (M8) 30.79 626 218 3% **F:G 
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Scheme 2.1:  Structures of methyltestosterone (MT) and its canine urinary metabolites: 17α-methyl-5α-
androstan-3β,17β-diol (M1); 17α-methyl-5β-androstan-3α,17β-diol (M2); 17α-methyl-5β-androstan-
3α,16α,17β-triol (M3); 17α-methyl-5α-androstan-3β,16α,17β-triol (M4); ?17α-methyl-5z-androstan-
6z,17β-diol-3one (M5); ?17α-methyl-5z-androstan-3z,6z,17β-triol (M6); ?17α-methyl-5z-androstan-
6z,16α,17β-triol-3one(M7); ?17α-methyl-5z-androstan-3z,6z,16α,17β-tetrol(M8).  
(? = tentative assignment) 
 
2.3.1 17-methylandrostane-3,17-diols 
Two fully reduced 17α-methylandrostanediol metabolites were detected by comparison 
with authentic reference standards (Scheme 2.1); 17α-methyl-5α-androstan-3β-17β-
diol (M1) and 17α-methyl-5β-androstan-3α,17β-diol (M2). The mass spectra of these 
two compounds (see figures 2.1 and 2.2) were dominated by the well documented 
fragment m/z 143, assigned to the unaltered D-ring of a 17α-methyl steroid[3,17], (see 
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scheme 2.2a), with molecular ions of m/z 450 and fragments ions of m/z 435 [M-CH3]+, 
m/z 345 [M-CH3-TMSiOH]+ and m/z 255 [M-CH3- 2xTMSiOH]+. 
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Figure 2.1: Full scan mass spectrum of 17α-methyl-5α-androstan-3β-17β-diol (M1) -
enol-tms derivative 
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Figure 2.2: Full scan mass spectrum of 17α-methyl-5β-androstan-3α,17β-diol (M2) -
enol-tms derivative 
 
 
Both metabolites were detected exclusively in the glucuronide fraction with the 17α-
methyl-5α-androstan-3β-17β-diol isomer excreted in significant quantities and being 
one of the major metabolites observed in this study (see Table 2.1). 
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Scheme 2.2a: D ring fragmentation mechanism to produce m/z 143 (R1 and R2 = H) 
and 231 (R1= O-TMS and R2 = H) 
 
 
 
                         
 
       
 
Scheme 2.2b: D ring fragmentation mechanism of 17α-methyl 16-hydroxy metabolite 
to produce m/z 218.  
 
The presence of both m/z 218 and m/z 231 ions, indicates the presence of a 16-hydroxy 
group in the D-ring. A 15-hydroxy group would produce only the m/z 231 ion. 
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2.3.2 17-methylandrostane-3,16,17-triols. 
The most abundant (based on signal intensity in the TIC) metabolite (M3) present in 
the post administration urine was excreted in such large quantities (see Table 2.1), that 
it was desirable to try and elucidate its structure in order to understand more about the 
major phase I metabolic pathways in the greyhound.  The metabolite showed a 
molecular ion of m/z 538 with major fragment ions at m/z 218 and m/z 231. This 
indicated a bis-reduced mono-hydroxy metabolite and the major fragment ions have 
previously been identified as the characteristic D-ring fragments from 16-hydroxy 
metabolites of 17α-methyl anabolic steroids[3] (see Scheme 2.2b). The full scan mass 
spectrum of the enol-tms derivative of this compound is shown in Figure 2.3. 
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Figure 2.3: Full scan mass spectrum of M3 enol-tms derivative 
 
 
The other major fragment ions of m/z 448, m/z 358 and m/z 268 represent three 
sequential losses of 90Da (3xTMSiOH groups), indicating three hydroxy functions are 
present in the metabolite structure. This metabolite was therefore identified as an 
isomer of 17-methylandrostane-3,16,17-triol (M3).  
A second metabolite with the same mass spectrum and different GC retention time was 
also detected but was present in much smaller quantities than the major metabolite and 
was believed to be a second stereoisomer of 17-methyl-5-androstane-3,16,17-triol. An 
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initial experiment to elucidate the stereochemistry of the D-ring was performed, which 
involved the formation of an acetonide derivative. The GC-MS analysis of urine 
extracts subjected to this derivatisation procedure resulted in the same tris-tms 
derivative formation and mass spectrum (M+. 538) for this analyte, thereby indicating 
that no acetonide derivative had been produced. Acetonide derivatives will only form 
across adjacent cis hydroxy functions and are not observed for trans isomers (see 
Scheme 2.3). The internal marker, 16β-hydroxytestosterone (a cis-diol) added to all the 
extracts analysed, formed an acetonide under the conditions used. The administered 
drug, 17α-methyltestosterone has the 17β-hydroxy configuration and it was therefore 
concluded that the 16-hydroxylated metabolites had the 16α-configuration. 
 
Scheme 2.3: Acetonide derivatisation for 16,17-diol moieties: 
 
 
To establish the stereochemistry of the major metabolite (M3) at C5 and C3 a Grignard 
synthesis was performed on four stereoisomers of 16α-hydroxy-5-androstane-3-ol-17-
one. The reaction produced one major and one minor product in each case, both 
producing full scan mass spectra similar to that shown in Figure 2.3 when subjected to 
the enol-tms derivatisation procedure. The products were then derivatised using the 
acetonide-tms procedure, which resulted in the major synthetic products forming 
acetonide derivatives with M+. ions of m/z 434 and fragment ions m/z 419 [M – CH3]+, 
m/z 359 [M –(CH3)2CO2H].+ and 269 [M – CH3]+. The minor products produced tris–
tms derivatives as before. Since the Grignard reaction can only produce two products it 
was concluded that the minor product in each case was the 17α-methyl-17β-hydroxy-
stereoisomer; the major products being the 17β-methyl-17α-hydroxy-stereoisomers. 
The GC retention times for each of the reference standards produced are shown in 
Table 2.2 The chromatographic conditions used enabled separation of all eight 
stereoisomers allowing a relative retention time comparison with the metabolite peaks 
in the post administration urine extract. When compared with the retentions times of 
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the urinary metabolites (Table 2.1) the major excreted metabolite was identified as 
17α-methyl-5β-androstan-3α,16α,17β-triol (M3), with the minor metabolite being 
17α-methyl-5α-androstan-3β,16α,17β-triol (M4). The stereochemistry of these 
metabolites at C5 and C3 are the same as that for the 17-methylandrostane-3,17-diol 
metabolites identified, although the quantities excreted are reversed (Table 2.1), 
perhaps suggesting that the 5β3α A-ring configuration is more amenable to subsequent 
16-hydroxylation than the 5α3β; possibly due to steric ‘fit’ with the metabolic enzyme. 
 
Table 2.2: GC retention time data for the TMS derivatives of the 17α-
methylandrostane-3,17-diol and 17α-methylandrostane-3,16α,17-triol reference 
standards 
 
Reference standards 
Derivatised 
MWt 
(tms) 
Retention time of tms derivative 
(mins) 
17α-methyl-5α-androstan-3β,17β-diol 450 25.93 
17α-methyl-5β-androstan-3α,17β-diol 450 23.98 
17α-methyl-5α-androstan-3α,17β-diol 450 23.81 
17α-methyl-5β-androstan-3β,17β-diol 450 23.40 
17α-methyl-5β-androstan-3α,16α,17β-triol 538 27.94 
17α-methyl-5β-androstan-3β,16α,17β-triol 538 27.59 
17α-methyl-5α-androstan-3α,16α,17β-triol 538 28.04 
17α-methyl-5α-androstan-3β,16α,17β-triol 538 30.06 
17β-methyl-5β-androstan-3α,16α,17α-triol 538 24.52 
17β-methyl-5β-androstan-3β,16α,17α-triol 538 24.74 
17β-methyl-5α-androstan-3β,16α,17α-triol 538 28.38 
17β-methyl-5α-androstan-3α,16α,17α-triol 538 25.08 
 
There is the possibility that the major 16-hydroxy metabolites detected could be 16β-
hydroxy-17-epimers (17α-hydroxy-17β-methyl-), analytes which also would not form 
acetonide derivatives. However, epimerisation of 17α-methyl steroids in human and 
horse has been shown to be associated with hydrolytic removal of sulphate conjugate 
groups, resulting in analytes being present in the free urinary fraction as well as the 
glucuronide fraction[4,18,19]. Previous studies have also indicated that sulphate 
conjugation is not a major pathway in the greyhound[12,13] and the major 16-hydroxy 
metabolites observed in this study were all exclusively detected as glucuronides. The 
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presence of 17-epimeric metabolites in the glucuronide fraction has been observed to 
an extent in humans and is believed to be partly due to enterohepatic circulation of 
metabolites[18], but this process has previously been reported as relatively minor in the 
dog despite significant biliary excretion[12]. 
 
2.3.3 Additional C20O3 metabolites 
Two further metabolites with base peaks of m/z 143 were also detected in the post 
administration urine. The enol-tms derivative full scan mass spectrum of the first of 
these is shown in Figure 2.4. The spectrum shows an M+. ion of m/z 536 with fragments 
ions of m/z 521 [M - CH3]+, m/z 446 [M - TMSiOH].+, m/z 431 [M - CH3 - TMSiOH]+, 
m/z 356 [M – 2xTMSiOH].+ and m/z 341 [M - CH3 - 2xTMSiOH].+. These data 
indicated a mono-reduced, mono-hydroxy metabolite.  
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Fig 2.4: Mass spectrum of M5-enol-tms derivative (m/z 143 base peak is scaled to 
25%) 
 
The presence of the m/z 143 ion shows that the D-ring was unaltered and the site of 
oxidation is suggested as possibly C6, in keeping with other mammalian species such 
as human[2] and horse[9]. The presence of a 3-keto function was demonstrated for this 
metabolite by the formation of an O-methyloxime-trimethylsilyl ether derivative, which 
or 
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produced a full scan mono-methoxime-bis-tms mass spectrum (see Figure 2.5) showing 
a relatively weak molecular ion of m/z 493 and fragment ions at m/z 478 [M - CH3].+, 
m/z 462 [M - OCH3].+, m/z 403 [M - TMSiOH].+, m/z 388 [M - CH3 - TMSiOH]+, m/z 
313 [M - 2xTMSiOH].+ and m/z 282 [M - OCH3 - 2xTMSiOH].+. This metabolite was 
therefore postulated to be 17α-methyl-5z-androstan-6z,17β-diol-3-one (M5).  
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Figure 2.5: Full scan spectrum of M5 – O-methyloxime-tms ether derivative 
 
 
M5 was the third most abundant metabolite observed in this study and was excreted 
exclusively in the glucuronide conjugate fraction. The second of the additional C20O3 
metabolites observed showed a molecular ion of m/z 538, indicating a bis-reduced-
mono-hydroxy metabolite. The full scan TMS-derivative mass spectrum of this 
metabolite is shown in Figure 2.6. As with M5 the m/z 143 ion was still present 
indicating the most likely site of oxidation to be at C-6, along with full reduction of the 
4-ene-3 keto function. Similar to M3 and M4, the other major fragment ions of m/z 448, 
m/z 358 and m/z 268 represent three sequential losses of 90Da (3xTMSiOH groups), 
indicating three hydroxy functions are present in the metabolite structure. This 
metabolite was therefore postulated as a fully saturated 17α-methyl-5z-androstan-
3z,6z,17β-triol (M6) and was also excreted in the glucuronide fraction. A smaller 
quantity of an additional stereoisomer exhibiting the same mass spectrum as M6 but 
with different GC retention properties was also detected suggesting the presence of 
another stereoisomer of 17α-methyl-5z-androstan-3z,6z,17β-triol 
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Figure 2.6: Mass spectrum of M6–enol-tms derivative (m/z 143 base peak is scaled to 
25%) 
 
 
2.3.4 C20O4 metabolites 
Figure 2.7 shows the enol-tms derivative full scan mass spectrum of a metabolite with a 
molecular ion of m/z 624 and fragment ions at m/z 534 [M - TMSiOH]+, m/z 444 [M - 
2xTMSiOH]+. The major ions in the mass spectrum are the diagnostic D-ring fragments 
for a 16-hydroxylated metabolite (m/z 218 and m/z 231). These data indicated a mono-
reduced, bis-hydroxy metabolite. As with metabolite M5, this compound had only one 
site of reduction. This was again identified as C4/C5 by generating an O-methyloxime-
trimethylsilyl ether derivative which produced a derivatised product with a molecular 
ion of m/z 581 (Figure 2.8), indicating that the 3-keto function remained intact.  
The mass spectrum of this derivative showed fragments at m/z 550 [M - OCH3].+, m/z 
491 [M - TMSiOH]+, m/z 476 [M – CH3 - TMSiOH].+, m/z 401 [M – 2xTMSiOH)]+ and 
m/z 311 [M – 3xTMSiOH)]+. This metabolite was therefore postulated as 17α-methyl-
5z-androstan-6z,16α,17β-triol-3-one (M7). 
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Figure 2.7: Full scan spectrum of M7 enol-tms derivative 
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Figure 2.8: Full scan spectrum of M7 – O-methyloxime-tms ether derivative 
 
 
Figure 2.9 shows the tetra-tms mass spectrum of a fully A-ring reduced tetrol 
metabolite with a molecular ion at m/z 626 and fragment ions at m/z 536, m/z 446 and 
m/z 356 representing three sequential losses of 90Da (3xTMSiOH groups), indicating 
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three hydroxy functions are present in the metabolite structure. The characteristic D-
ring fragments m/z 218 and m/z 231 are also present. This metabolite was therefore 
postulated as a fully saturated 17α-methyl-5z-androstane-3z,6z,16α,17β-tetrol (M8).  
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Figure 2.9: Full scan spectrum of M8 enol-tms derivative 
 
Smaller quantities of two additional stereoisomers exhibiting the same mass spectra as 
M8, but with different GC retention properties were also detected. All of the C20O4 
metabolites detected in the post administration urine were present in approximately 
equal amounts in both the free and glucuronide conjugate fractions. The hydroxyl 
functions at C-16 and C-17 for all of these compounds were all concluded to be in the 
trans configuration as none of these metabolites formed acetonide derivatives when 
subjected to that derivatisation procedure. It was therefore concluded that all the 16-
hydroxylated metabolites detected had the 16α-configuration.  The wash stage of the 
procedure was performed using TBME, as initial use of toluene resulted in the apparent 
‘loss’ of the metabolites prior to GC-MS analysis, most probably due to the poor 
partitioning of these highly polar metabolites between the sodium hydroxide and 
toluene. 
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2.4 CONCLUSION 
 
The urinary metabolites identified in this study have provided an increased 
understanding of the in vivo phase I metabolism of 17α-methyltestosterone in the 
greyhound. The metabolic pathways include reduction of the 4-ene-3-one group of the 
A-ring, and oxidations at C16 and possibly C6. The 5α3β and 5β3α stereochemistry of 
the fully A-ring reduced metabolites is comparable to the stereochemistry of the major 
metabolites observed in the metabolism of testosterone in the greyhound[20,21] (chapter 
4). 
The structures of the urinary metabolites reported in this study are shown in Scheme 1 
and stereochemical configurations have been assigned where possible by comparison 
with suitable reference standards. 16α-hydroxylation would appear to be a major phase 
I metabolic pathway in the greyhound based upon both the prevalence and quantity of 
metabolites identified with that substituent group. The apparent lack of 16-beta 
hydroxylated metabolites is interesting in relation to other mammalian species where 
16-beta hydroxylation has been shown to be a prevalent phase one metabolic 
transformation for many anabolic steroids[4,5,13]. 
A 16β-hydroxy structural configuration could be possible for the greyhound in 
conjunction with 17-epimerisation, but this would seem less likely for metabolites 
excreted exclusively in the glucuronide fraction. Considering this in relation to the 
C20O4 metabolites that were apparently present in both the free and conjugated 
fractions in equal amounts, it is concluded that their partitioned excretion may be based 
upon their polarity as opposed to hydrolytic desulphation, which has been reported in 
both human and equine metabolism studies. However, it may also be possible that such 
highly polar, polyhydroxylated metabolites are not completely eluted from C18 with 
ether during the extraction procedure described and that a residual amount of 
unconjugated metabolite may be eluted with methanol, resulting in it being potentially, 
erroneously assigned as a glucuronide, after hydrolysis. Future work is necessary to 
clarify the conjugated status of the more polar metabolites and determine whether 17-
epimerisation exists as a systemic metabolic process in the greyhound. 
The results of this study have supported the drug surveillance control of the 
administration of methyltestosterone, having been readily included in a generic 
extraction and GC-MS steroid screen at HFL Sport Science. The data should also 
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support future metabolic studies of other anabolic steroids in the greyhound. The 
structures of the major metabolites 17α-methyl-5β-androstan-3α-17β-diol and 17α-
methyl-5β-androstan-3α,16α,17β-triol have been fully elucidated and their detection 
and identification in urinary extracts by mass spectrometric techniques will provide an 
effective approach to screening and confirmatory analysis for the control of 17α-
methyltestosterone use in the greyhound. 
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3.  SYNTHETIC STEROID METABOLISM:  
 NORETHISTERONE 
3.1 INTRODUCTION 
The greyhound industry in Great Britain has, for a number of years, been reviewing 
some of the options regarding the use of steroidal preparations for oestrus suppression 
in the greyhound bitch and seeking an effective solution in line with a policy of 
banning the use of performance enhancing agents under the rules of racing[1]. As 
outlined in chapter 1 both anabolic agents and progestagens are available for use to 
suppress oestrus, but those available for use are the subject of differing concern for 
greyhound trainers and racing regulators. 
Most of the available progestins (e.g. proligestone and medroxyprogesterone acetate) 
are considered to have a number of unwanted negative side effects related to racing 
performance in the bitch such as weight gain, lethargy and diabetes, as well as under 
certain circumstances potentiating the incidence of clinical conditions such as cyctic 
endometrial hyperplasia and pyometra. These effects can be minimised depending upon 
the duration of treatment and the point in the cycle at which treatment commences. The 
anabolic agent testosterone (licensed for oestrus suppression for many years in the 
industry) has no adverse performance related side effects but is clearly an androgenic 
anabolic agent and is therefore considered performance enhancing in the racing 
greyhound. 
In March 2011 the Greyhound Board of Great Britain (GBGB) following consultation 
with the Veterinary Medicines Directorate (VMD) permitted the use of norethisterone 
via the cascade system (allowing a licensed human drug preparation to be used in 
greyhounds under certain circumstances[2]). 
Norethisterone (a progestagen) has a wide variety of human uses, including the 
postponement of menstruation and the treatment of menstrual disorders such as 
endometriosis. One of the major uses is as an ingredient of oral contraceptives where it 
inhibits ovulation by suppressing the mid cycle surge of luteinising hormone and 
rendering the endometrium unreceptive to implantation. In the mid 1970’s, Prole 
demonstrated that norethisterone could be used as an effective oestrus suppressant in 
the greyhound bitch[3,4] with no apparent significant side effects. Its use has therefore 
become popular amongst certain greyhound trainers, who wish to suppress the season 
of a racing greyhound bitch. 
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Metabolism of norethisterone has been reported in human[5] and rat[6]. There have also 
been a number of studies in humans relating to the detection of nandrolone metabolites 
following the administration of pharmaceutical preparations of norethisterone[7-10]. This 
has had implications when considering that nandrolone use is prohibited by the World 
Anti Doping Agency (WADA). 
Metabolites of nandrolone have been shown to be endogenous in humans[11-19] and 
threshold levels are therefore in place to control its misuse in human sports. To date 
nandrolone metabolites have not been shown to be endogenous in the greyhound and as 
such there is no threshold in place for these substances. The administration of 
nandrolone is prohibited in UK greyhound racing. 
The metabolism of norethisterone has not been previously investigated in the 
greyhound and this paper represents the first such study. It has been noted in previous 
greyhound steroid metabolism studies that liquid chromatography-mass spectrometry 
(LC-MS) is not suitable for the analysis of saturated steroid metabolites[20]. Gas 
chromatography-mass spectrometry (GC-MS) and selective derivatisation techniques 
have therefore been used to identify urinary metabolites of norethisterone following 
oral administration to the greyhound. An investigation of the pharmaceutical 
preparation itself has also been carried out to try and establish the origins of some of 
the metabolites observed. The metabolites identified in this study have been used in the 
routine drug surveillance screens performed at HFL Sport Science to monitor the use of 
norethisterone in greyhound racing and provide insight into the overall urinary profile 
observed for certain animals. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Solvents and chemicals 
C18 Sep-Pak Vac SPE cartridges (500 mg, 6 cc, end capped) were obtained from 
Waters Ltd (Hertfordshire, UK). Methanol, hexane, chloroform, acetone, toluene and 
diethylether, Analar or HPLC grade, were obtained from Rathburn Chemicals Ltd 
(Walkerburn, Scotland). Sodium hydroxide, disodium hydrogen orthophosphate 
dihydrate, sodium dihydrogen orthophosphate monohydrate (AnalaR grade) and para-
toluenesulphonic acid were supplied by BDH (Poole, UK). Sodium sulphate, anhydrous 
calcium chloride, ammonium iodide, pyridine, lipophilic sephadex, and methoxylamine 
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hydrochloride, tertiary-butyl methyl ether (TBME), β-Glucuronidase from 
Escherichia.coli , nandrolone, 19-norandrost-4-ene-3,17-dione and norethisterone were 
supplied by Sigma Chemical Co. Ltd (Poole, UK). N-methyl-N-(trimethylsilyl)-
trifluoroacetamide (MSTFA) was obtained from Macherey-Nagel (Düren, Germany).  
Ethanethiol was supplied by Aldrich Chemical Co. Ltd (Poole, UK).  
 2H3-16,16,17-5α-androstan-3α,17β-diol (d3-androstanediol internal standard) was 
prepared at HFL Sport Science, Fordham, Camb., UK. 2H5-etiocholanolone (d5-
etiocholanolone internal standard) and 19-noretiocholanolone glucuronide were 
obtained from NMI, Sydney, New South Wales 2073, Australia. 17α-ethynyl-5α-
estran-3β,17β-diol, 17α-ethynyl-5β-estran-3α,17β-diol, 19-norepiandrosterone, 19-
noretiocholanolone and 16β-hydroxytestosterone were all obtained from Steraloids Inc. 
(Newport, Rhode Island, USA). 
3.2.2 Drug administration to animals: sample collection 
Administration studies were carried out at Racing Chemistry, Iowa, U.S.A. Following 
ethics approval (Appendix II) pre-administration urine samples were collected from 
two greyhound bitches and the drug preparation Utovlan® (Pharmacia, Milton Keynes, 
UK) was administered orally to both animals at a dose of 5mg per day for 8 days. Urine 
samples were collected at +2, 4, 8, 24, 36, 48, 72 hours and +4, 5, 6, 7 and 8 days after 
the final dose. The urines were stored at -20oC awaiting analysis. 
3.2.3 Sample extraction 
Aliquots of canine urine (4 mL) were spiked with internal markers d3-androstanediol 
and d5-etiocholanonlone at a level of 25 ng mL-1.  Extraction cartridges (C18 Sep-Pak 
Vac, 6 cc, 500 mg, Waters Ltd., Hertfordshire, UK) were conditioned with methanol (5 
mL) and water (reagent grade, 5 mL). The urine samples were then passed through the 
cartridges followed by water (5 mL).  The column was washed with hexane (5 mL) and 
then dried with air under vacuum for 5 min.  Free fraction extracts were then eluted 
with diethyl ether (4 mL).  The glucuronide fraction was eluted with methanol (5 mL). 
The ether was evaporated to dryness under oxygen free nitrogen (OFN) at 40ºC in GC 
vials. The methanolic eluates were evaporated using OFN at 80ºC, the residue 
dissolved in phosphate buffer (1 mL, pH 6.8, 0.1 M) containing β-glucuronidase E. coli 
(250 µl, 10 units µL-1) and the solution incubated overnight at 37ºC. 
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After incubation, sodium hydroxide (500 µL, 2 M) was added to each sample and the 
sample mixed using a Whirlimixer. Liquid-liquid extraction was carried out using 
tertiary butyl methyl ether (TBME, 4 mL). The aqueous layer was removed and the 
organic solvent washed with sodium hydroxide (2 x 500 µL, 2 M).  The TBME was 
dried over anhydrous sodium sulphate and then evaporated to dryness under OFN at 
40ºC in GC vials. 
 
3.2.4 Derivatisation procedures 
3.2.4.1 Enol-tms derivatives 
Enol-tms derivatives were prepared as described in chapter 2 section 2.2.4.1. 
3.2.4.2 Methoxylamine-tms derivatives 
Methoxylamine-tms derivatives were prepared as described in chapter 2 section 2.2.4.2 
 
3.2.4.3 Acetonide-tms derivatives 
Acetonide-tms derivatives were prepared using a previously described procedure[20] as 
outlined in chapter 2 section 2.2.4.3.  16β-hydroxy testosterone internal standard was 
added to each sample prior to derivatisation in order to demonstrate the efficiency of 
acetonide derivative formation. Dried urine extracts or synthesised reference standards 
(as applicable) were reconstituted in dried acetone (2mL) containing ρ-
toluenesulphonic acid (~2 mg). Anhydrous CaCl2 (~50 mg) was added and the solution 
was rotary mixed for 4-5 hr. Following centrifugation the supernatant was removed and 
evaporated to dryness in a clean glass tube under OFN at 60ºC. The dried residue was 
dissolved in toluene and washed with 2 M sodium hydroxide (1 mL) followed by 
reagent grade water (1 mL). The final aqueous layer was removed and the organic 
solvent dried over anhydrous sodium sulphate. The organic solvent was then 
evaporated to dryness. Trimethylsilyl derivatisation was performed using the Enol-tms 
derivatisation procedure previously described and samples analysed by GC-MS. To 
check the potential formation of acetonide derivatives for the more polar tetrol 
metabolites, toluene was substituted with TBME during the washing stage of the 
procedure to ensure solubility and efficiency of extraction for these analytes. 
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3.2.5 GC-MS analysis 
Full Scan GC-MS analysis was carried out in positive ion electron ionisation mode, 
using a Thermo Finnigan (Austin, Texas, USA) Voyager single quadrupole bench top 
instrument fitted with an SGE (SGE Europe Ltd, Milton Keynes, U.K.) BPX5 column, 
(approx. 25 m, 0.22 mm id, 0.25 µm film thickness). The temperature of the 
split/splitless injector was 260ºC.  Injections were made in the splitless mode which 
was maintained for 1.0 minute. The interface temperature was 280ºC. Injection volume 
was 1 µl.  The GC temperature programme was started at 180 ºC and held for 0.5 min, 
followed by an initial ramp 180 ºC to 290 ºC at 5ºC min-1 and then a further ramp from 
290 ºC to 330 ºC at 40 ºC min-1. The final temp was held at 330ºC for 3 min.  
 
3.2.6 GC-MS/MS analysis for confirmation of the identity of 19-
norepiandrosterone in norethisterone post administration urine. 
GC-MS/MS analysis was carried out in positive ion electron ionisation mode, using a 
Thermo Finnigan GCQ ion trap bench top instrument with an SGE BPX50 column 
(approx. 25m, 0.25mm id, 0.25um film thickness).  
The temperature of the split/splitless injector was 275 ºC.  Injections were made in the 
splitless mode which was maintained for 1.0 minute. The interface temperature was 
280 ºC. Injection volume was 1 µl.  The GC temperature programme was started at 125 
ºC and held for 1.0 min, followed by an initial ramp 125 ºC to 190 ºC at 25 ºC min-1 
and then a further ramp from 190 ºC to 240 ºC at 6 ºC min-1 and finally from 240 ºC to 
310 ºC at 35 ºC min-1. The final temp was held at 310 ºC for 1 min. GC-MS/MS 
acquisition was performed using a precursor ion of m/z 405 (representing M+ -15 [CH3] 
for 19-norandrosterone-enol-bis-tms) with a collision energy of 1.0v, notch width 
1.0amu, isolation time 8.0ms, collision time 15ms and a q factor of 0.45, scanning over 
the mass range m/z 100 to m/z 410. The source temperature was set at 220 oC. 
 
3.2.7 Analysis of norethisterone (Utovlan®) tablets 
One 5mg tablet was crushed and mixed with 2 mL of reagent grade water. The mix was 
centrifuged (3000 rpm, 5 min) and the water layer removed for extraction. A 
liquid/liquid extraction with 4mL chloroform:ethyl acetate (1:1) was performed for on a 
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rotary mixer (20 min). The mixture was centrifuged (3000 rpm, 5 mins), the organic 
layer removed, evaporated to dryness under nitrogen (60 oC) and reconstituted in 1 mL 
reagent grade water for solid phase extraction. A SPE cartridge (C18 Sep-Pak Vac, 6cc, 
500 mg) was conditioned with methanol (5 mL) and water (5 mL). The tablet extract 
was passed through the cartridge followed by water (5 mL). The column was washed 
with hexane (5 mL), dried (5 min) and then eluted with diethylether (4 mL). The ether 
was dried over anhydrous sodium sulphate and then evaporated to dryness under 
nitrogen. An enol-tms derivative of the extract was prepared for GC-MS analysis as 
previously described. GC-MS analysis was performed in full scan mode using the GC 
conditions described for the confirmation analysis of 19-norepiandrosterone in post 
administration urine. 
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3.3 RESULTS AND DISCUSSION 
 
The GC-MS analysis of enol-tms derivatised urinary extracts of the post administration 
urine samples resulted in the identification of the parent drug norethisterone and several 
metabolites of norethisterone, summarised in Scheme 3.1. Phase one transformations 
involved reduction of the 4-ene group, either alone or, more frequently, in conjunction 
with the keto group at C-3. Hydroxylations presumed to be at C-6 and C-16, although it 
was not possible to establish the precise locations of the hydroxyl functions. The 
metabolites that have been either identified or tentatively suggested are listed in Table 
3.1.  
Selective enzymatic hydrolysis procedures indicated that the major metabolites were 
predominantly excreted as glucuronic acid conjugates and detection of the 
administration of norethisterone was possible for up to 8 days post dose (based upon 
detection of metabolites M4 and M5) using the methods described in this manuscript. 
The sulphate fraction was not analysed as previous studies by the authors (unpublished 
data) and others[21,22] have indicated that sulphate conjugation does not appear to be a 
significant phase II metabolic pathway in the canine. 
 
Table 3.1: Summary of norethisterone metabolites with estimated distribution in free 
and conjugated fractions and analytical nomenclature 
Urinary metabolites of norethisterone 
(?= tentative assignment) 
Derivatised  
MWt 
(TMS) 
Base 
Peak 
(m/z) 
 
RT 
Mins 
 
Total* 
Excreted 
Conjugated  
status 
Norethisterone 442 442 18.52 5% G 
17α-ethinyl-5β-estrane-3α,17β-diol (M2) 446 431 16.03 10% G 
17α-ethinyl-5α-estrane-3β,17β-diol (M1) 446 431 16.91 10% G 
?16-hydroxynorethisterone or 6-
hydroxynorethisterone (M3) 530 515 19.43 10% G 
17α-ethinyl-5-estrane-triol (M4) 534 519 17.95 15% G 
17α-ethinyl-5-estrane-triol (M5) 534 519 18.66 15% G 
17α-ethinyl-5-estrane-triol (M6) 534 519 19.08 10% G 
?17α-ethinyl-5-estrane-3,6,16,17-tetrol (M7) 622 607 19.20 10% F**,G 
?17α-ethinyl-5-estrane-3,6,16,17-tetrol (M8) 622 607 19.77 5% F**,G 
17α-ethinyl-5-estrane-diol-3-one (M9) 532 517 19.06 10% G 
 
*based on TIC areas of these eight metabolites.  **F- represents analytes detected in the ether fraction 
(non-hydrolysed). G – represents analytes detected in the methanol fraction (enzyme hydrolysed) 
 
 71 
 
 
 
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
        
 
Scheme 3.1 – Identified and postulated metabolites of norethisterone in the greyhound 
 
 
 
 
 
 
 
 
 
Norethisterone 
MWt = 298 
17α-ethinyl-5z-estrane-3z,6z,16α,17β-tetrol 
       (M7, M8) 
 
17α-ethinyl-5z-estrane-3z,16α,17β-triol 
  (M4,M5,M6) 
 
6z-hydroxy-norethisterone               
 (M3) 
 
16α-hydroxy-norethisterone (M3) 
17α-ethinyl-5z-estrane-16α,17β-diol-3-one 
        (M9)           
 
17α-ethinyl-5z-estrane-3z,6z,17β-triol 
        (M4,M5,M6) 
 
17α-ethinyl-5β-estrane-3α,17β-diol (M2) 
17α-ethinyl-5α-estrane-3β,17β-diol (M1) 
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3.3.1 17-ethynyl-estrane-3,17-diols 
Two fully reduced 17α-ethynylestranediol metabolites were detected by comparison 
with authentic reference standards; 17α-ethynyl-5α-estran-3β,17β-diol (M1) and 17α-
ethynyl-5β-estran-3α,17β-diol (M2). The mass spectra of the TMS derivatives of these 
two compounds were dominated by the fragment ion m/z 431, [M-CH3]+ resulting from 
the loss of a methyl group from the molecular ion of m/z 446 and fragment ions of m/z 
341 [M-CH3-TMSiOH]+. The full scan mass spectrum of M2 is shown in Figure 3.1. 
The 17α-ethynyl function appears to impart a significant degree of stability to the 
structure resulting in the intense m/z 431 ion, in contrast to the fully saturated ‘-diol’ 
metabolites which normally exhibit a considerably greater degree of fragmentation than 
that observed here[20,23,24]. Both metabolites were detected exclusively in the 
glucuronide fraction. (see Table 3.1). 
 
Figure 3.1: Mass spectrum and derivatised chemical structure of 17α-ethinyl-5β-
estrane-3α,17β-diol (M2) 
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3.3.2 17-ethynyl-dihydroxy-estran-3-one 
A single metabolite with an intense molecular ion of m/z 530 was observed 
representing a mono-hydroxy norethisterone (M3, Figure 3.2). This metabolite was 
postulated as either 6z-hydroxy norethisterone or 16α-hydroxy norethisterone, C6 and 
C16 being the most likely sites of phase I metabolic hydroxylation based on studies 
performed in the greyhound to date[20,23,25]. Following acetonide derivatisation and 
subsequent TMS derivatisation of a post administration urine extract, the mass 
spectrum of this metabolite remained unchanged as an enol-tris tms deriviative. 
Therefore, if the hydroxyl function was present at C-16 it would be in the 16α 
configuration, as a -cis acetonide derivative would be formed across a 16β,17β-diol 
moiety[20]. This metabolite (M3) was excreted in the glucuronide fraction. 
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Figure 3.2: Mass spectrum and proposed derivatised chemical structures of 16-
hydroxynorethisterone or 6-hydroxynorethisterone (M3) 
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3.3.3 17-ethynyl-estranetriols   
A number of metabolites (3 major, 2minor) were observed exhibiting characteristics of 
mono-hydroxy, bis-reduced phase I metabolic transformations. These metabolites 
showed a molecular ion of m/z 534 with a major fragment ion at m/z 519 [M-CH3]+. An 
example full scan mass spectrum of the enol-tms derivative of one of these metabolites 
is shown in Figure 3.3. The other major fragment ions of m/z 429, 339 and 249 
represent three sequential losses of 90Da (3xTMSiOH groups), indicating that three 
hydroxyl functions are present in the metabolite structure. These metabolites were 
therefore postulated as either 17α-ethynyl-estrane-3,6,17-triols or 17α-ethynyl-estrane-
3,16α,17-triols, but there was insufficient fragmentation information to distinguish 6-
hydroxy- from 16-hydroxy- metabolites. The major triol metabolites are likely to have 
the same stereochemistry at C3 and C5 as the 17α-ethynyl-estranediols, namely 5α,3β 
and 5β,3α, which would also be in keeping with previously identified major 
metabolites of methyltestosterone and testosterone in the greyhound[20,23]. The triol 
metabolites were excreted almost exclusively in the glucuronide fraction. 
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Figure 3.3: Mass spectrum and proposed derivatised chemical structures of 17α-
ethinyl-5-estrane-triol (M4). 
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3.3.4 17-ethynyl-estranetetrols  
Two major metabolites were observed exhibiting characteristics of di-hydroxy, bis-
reduced phase I metabolic transformations. These metabolites showed a molecular ion 
of m/z 622 with a major fragment ion at m/z 607 [M-CH3]+. An example full scan mass 
spectrum of the enol-tms derivative of one of these metabolites is shown in Figure 3.4. 
The other major fragment ions of m/z 517, 427, 337 and 247 represent four sequential 
losses of 90Da (4xTMSiOH groups), indicating that four hydroxyl functions are present 
in the metabolite structure. These metabolites were therefore postulated as 17α-
ethynyl-estrane-3,6,16,17-tetrols. 
None of the triol or tetrol metabolites produced acetonide derivatives leading to the 
conclusion that any 16-hydroxylation would be in the alpha configuration, which is in 
keeping with previous greyhound steroid metabolism studies[20]. The tetrol metabolites 
were excreted in both the free and glucuronide fractions. 
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Figure 3.4: Mass spectrum and proposed derivatised chemical structures of 17α-
ethinyl-5-estrane-3,6,16,17-tetrol (M8) 
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OTMS
C CH
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H
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3.3.5 17-ethynyl-trihydroxy-estran-3-one 
A single metabolite with a base peak of m/z 517 was also detected in the glucuronide 
fraction of the post administration urine. The enol-tms derivative full scan mass 
spectrum of this metabolite is shown in Figure 3.5a. The spectrum shows an M+. ion of 
m/z 532 with fragment ions of m/z 517 [M - CH3]+, m/z 442 [M - TMSiOH].+, m/z 427 
[M - CH3 - TMSiOH]+, m/z 352 [M – 2xTMSiOH].+ and m/z 337 [M - CH3 - 
2xTMSiOH]+. These data indicate a mono-reduced, monohydroxy metabolite. The 
presence of a 3-keto function was demonstrated for this metabolite by the formation of 
an O-methyloxime-trimethylsilyl ether derivative, which produced a full scan mono-
methoxime-bis-tms mass spectrum (Figure 3.5b) showing a molecular ion of m/z 489 
and an intense fragment ion at m/z 474 [M - CH3]+; other fragment ions included m/z 
399 [M - TMSiOH].+, m/z 384 [M - CH3 - TMSiOH]+, m/z 368 [M- TMSiOH - 
OCH3].+,  m/z 309 [M - 2xTMSiOH].+ and m/z 278 [M - OCH3 - 2xTMSiOH]+. This 
metabolite was therefore postulated to be either 17α-ethynyl-6z,17β-dihydroxy-5z-
estran-3-one or 17α-ethynyl-16α,17β-dihydroxy-5z-estran-3-one (M9), the 16α-
configuration proposed as no acetonide derivative was formed with this metabolite.   
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Figure 3.5a: Mass spectrum and proposed derivatised chemical structures of the mono-
hydroxy, mono-reduced norethisterone metabolite (M9) 
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Figure 3.5b: Mass spectrum and proposed derivatised chemical structures of MO-TMS 
derivative of 17α-ethinyl-5-estrane-diol-3-one (M9)  
3.3.6 19-norepiandrosterone and 19-noretiocholanolone 
Nandrolone metabolites (19-norepiandrosterone and 19-noretiocholanolone) were also 
observed in the early post administration urine samples at low levels. Confirmation of 
the presence of 19-norepiandrosterone was perfomed using GC-MS/MS (Figure 3.6) 
The identification of nandrolone metabolites following the administration of 
norethisterone was considered to be relatively unusual bearing in mind they represent 
C-dealkylation as a phase I metabolic transformation; dealkylation of hetero atoms N,O 
and S would appear to be a more common metabolic process[26]. However, C-
dealkylation has been suggested as a minor metabolic pathway for other species[10,27,28]. 
The electron withdrawing nature of the ethynyl function compared to the electron 
donating nature of aliphatic alkyl C-17 substituent groups present on orally active 
anabolic steroids may, in part, facilitate this C-dealkylation. Nevertheless an analysis of 
the Utovlan® tablets was performed to investigate their composition. 
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Figure 3.6: Comparison of GC-MS/MS mass spectra (enol-tms derivatives) of 19-
norepiandrosterone from a +4hrs norethisterone post administration urine (A) and a 19-
norepiandrosterone reference standard (B)  
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Figure 3.7: GC-MS analysis of norethisterone tablet extract (TIC and derivatised 
molecular ion chromatograms of key contaminants) 
norethisterone 
19-norandrostene-dione 
nandrolone 
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The tablet analysis revealed the presence of both nandrolone and 19-
norandrostenedione (see Figure 3.7). These compounds were identified following 
comparison to known reference standards (see Figures 3.8 and 3.9) and were estimated 
to be present at approximately 15 ug per tablet for 19-norandrostenedione and 2 ug per 
tablet for nandrolone. The levels are well below the industry approved level for 
contaminants in pharmaceutical grade preparations of 0.1% [29], and are not considered 
to be likely to have any anabolic effect at these concentrations. 
Clearly, the qualitative administration of both of these compounds would give rise to 
the related metabolites observed in the post administration urine samples. These 
metabolites (or their analogous stereoisomers) have been observed in the human 
following the administration of 19-norandrostenedione[30]. The administration of low 
level amounts of these compounds in humans, comparable to the amounts administered 
to the greyhound in this study, have been shown to produce detectable concentrations 
of nandrolone metabolites similar to those observed here[31] and this appears to be the 
most likely source. However, the presence of 19-norandrosterone has also been shown 
to be present in human urine following the administration of a purified form of 
northisterone[10], and a contribution from the metabolic C-de-ethylynation route 
suggested in this work, although not proven in the greyhound, cannot be ruled out. 
It is interesting to note that the ratio of 19-norepiandrosterone to 19-noretiocholanone 
was in the order of 10:1 suggesting quite a significant bias towards 5α- reduction vs. 
5β- reduction. This was not entirely consistent with nandrolone administration to the 
greyhound where the levels of 5α and 5β reduced metabolites appeared to be more 
comparable (unpublished data) but such a bias has been observed following the 
administration of 19-norandrost-4-ene-3,17-dione in the human[30]. It may therefore in 
theory be possible to distinguish the nandrolone metabolite profile arising from a 
nandrolone administration from that of a norethisterone administration. Nevertheless, in 
the human drug testing arena, where norethisterone has been used by a female athlete, 
this issue is dealt with by WADA, by means of a reporting level for the major 
nandrolone metabolite, 19-norandrosterone[32]. This ensures that no adverse analytical 
finding is reported for levels of nandrolone metabolites that have most likely arisen 
from the ingestion of norethisterone. In this greyhound study, the amounts of 19-
norandrosterone and 19-noretiocholanolone observed were always significantly less 
than the major metabolites of norethisterone. Additionally, in those samples where the 
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presence of 19-norepiandrosterone and 19-noretiocholanolone were observed, the 
estimated concentrations of these substances were always below 2 ngmL-1. The 
concentrations were estimated by comparison with a 2 ngmL-1 extract of 19-
noretiocholanolone glucuronide which was prepared and analysed alongside the post 
administration urine samples. 
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Figure 3.8: Comparison of GC-MS mass spectra of nandrolone from a norethisterone 
tablet extract (A) and a nandrolone reference standard (B) 
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Figure 3.9: Comparison of GC-MS mass spectra of 19-norandrostenedione from a 
norethisterone tablet extract (A) and a 19-norandrostenedione reference standard (B) 
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3.4 CONCLUSIONS 
 
The urinary metabolites identified in this study have provided an understanding of the 
in vivo phase I and phase II metabolism of norethisterone in the greyhound and have 
further increased the overall knowledge of canine steroid metabolism.  Only a limited 
number of reference compounds were available for unequivocal identification of the 
proposed structures of the metabolites, but a number of suitable marker analytes have 
been established to provide effective detection of the administration of norethisterone 
in the routine drug testing environment. One of the major metabolic pathways was 
reduction of the 4-ene-3-one group of the A-ring to produce two –diol metabolites, 
17α-ethynyl-5β-estrane-3α,17β-diol and 17α-ethynyl-5α-estrane-3β,17β-diol. These 
structures were confirmed by comparison of chromatographic and mass spectral data 
with reference compounds. Reduction of the 4-ene-3-oxo group of the A-ring has been 
noted in the metabolism of both testosterone[23] and methyltestosterone[20] in the 
greyhound, with the major stereoisomers being present in the 5α3β and 5β3α 
configuration. The structures of a number of other metabolites have been tentatively 
assigned on the basis of interpretation of mass spectral data and proposed metabolic 
pathways. In addition to reduction of the 4-ene-3-keto moiety, these include oxidation 
at C-16 and C-6 to produce a series of triols, tetrols and hydroxy-keto steroids (see 
Scheme 3.1). The proposed assignment of the stereochemistry at C16 in the alpha 
configuration was based on the lack of acetonide derivative formation, as discussed for 
the metabolites of methyltestosterone in chapter 2. In relation to the nandrolone 
metabolites detected in this study, future in-vitro metabolism studies using canine liver 
microsomes with purified norethisterone, may serve to provide further insight into the 
possibility of C-dealkylation as a minor metabolic pathway in the greyhound. 
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4. ENDOGENOUS STEROID METABOLISM: 
 TESTOSTERONE  
 Determination of endogenous metabolite  levels in a population 
 of greyhound bitches. 
 
 
4.1 INTRODUCTION 
 
Various steroid preparations have been used to delay or suppress oestrus in racing 
greyhound bitches.  As highlighted in previous chapters, of particular concern in this 
area is the use, and possible abuse, of androgenic anabolic steroids due to their 
potential for enhancing performance. Durateston™ (a testosterone ester mix for 
intramuscular administration) has been permitted in the past by some greyhound racing 
jurisdictions for the suppression of oestrus in the greyhound bitch, as it is a licensed 
veterinary preparation for veterinary clinical use.  However, following a ban on the use 
of testosterone in UK racing there is a requirement for methods to detect its potential 
abuse. This particular piece of research addresses the metabolism and detection of 
testosterone in the greyhound. 
Testosterone is a naturally occurring (endogenous) androgenic/anabolic steroid in both 
greyhound dogs and bitches. Therefore research was needed to determine normal 
endogenous concentrations of the parent steroid and/or its major metabolites in order to 
try and establish a threshold level that could potentially be implemented to detect the 
administration of testosterone to the racing greyhound. Knowledge in other species 
such as the horse[1] has shown the levels in male animals to be both high and extremely 
variable, making detection of the use of testosterone in this gender more challenging. 
This is also true for metabolites of testosterone in the male greyhound[2]. Therefore, the 
main focus of this research work was to provide a means for detecting the use of 
testosterone in the female greyhound, following the proposed ban on the use of 
testosterone as an oestrus suppressant. 
Previous studies have reported extensive metabolism of testosterone in the greyhound 
bitch following an administration of 50mg of Durateston™ [3]. The urinary 
concentration of testosterone reached a maximum of only 14 ngmL-1, 26 hours after 
administration. However, the concentrations of the characterised testosterone 
metabolites were significantly higher. The major testosterone metabolite was 
epiandrosterone, which peaked at 1240 ngmL-1, also at 26 hours. Four major 
androstanediol isomers were identified, with one peaking at 266 ngmL-1, again at 26 
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hours. The last testosterone metabolite identified was etiocholanolone, which peaked at 
50 ngmL-1, again at 26 hours. Testosterone and its various metabolites returned to their 
pre-dose concentrations within 4 days. Williams et al. reported the findings of 
additional testosterone metabolites in greyhound urine after oral doses of 1mg/kg bwt 
testosterone to 3 greyhound bitches[4]. The metabolites found were in addition to the 
metabolites described by Brockwell et al.[3]. They were not characterised, although 
mass spectrometry suggested that a hydroxy- and a reduced hydroxy- testosterone were 
present. Studies using incubations of testosterone with microsomal preparations from 
beagle liver, also suggested a hydroxytestosterone metabolite[5]. This was characterised 
as 6β-hydroxytestosterone and accounted for approximately 41% of the total 
testosterone metabolites from the liver incubation. Other significant characterised 
testosterone metabolites from this study were 16α-hydroxytestosterone and 
androstenedione. 
 
 
 
4.2 MATERIALS and METHODS 
 
4.2.1 Solvents and Chemicals 
C18 Sep-Pak Vac SPE cartridges (500mg, 6cc, end capped) and Silica Sep-Pak Vac 
SPE  cartridges (500mg, 6cc) were obtained from Waters Ltd (Hertfordshire, UK).  
Methanol, hexane, diethyl ether, chloroform and ethyl acetate, Analar or HPLC grade, 
were obtained from Rathburn Chemicals Ltd (Walkerburn, Scotland).  Sodium 
hydroxide, disodium hydrogen orthophosphate 2-hydrate and sodium dihydrogen 
orthophosphate 1-hydrate, analar grade, were supplied by BDH (Dorset, UK).  Sigma 
Chemical Co. Ltd (Dorset, UK) supplied sodium sulphate, ammonium iodide β-
Glucuronidase from Eschericia.coli and authentic androstanediol reference standards.  
N-Methyl-n-(trimethylsilyl)-trifluoroacetamide (MSTFA) was obtained from Machery-
nagel (Düren, Germany).  Ethanethiol was supplied by Aldrich Chemical Co. Ltd 
(Dorset, UK). Epiandrosterone was obtained from Steraloids Inc. PO Box 689, 
Newport, RI 02840, USA and 2[H5]-etiocholanolone was obtained from NARL, 
Sydney, NSW 2073, Australia. 2[H3]-androstanediol was prepared at HFL, Camb , UK. 
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4.2.2 Animal administration studies 
Animal administration studies were performed at Racing Chemistry, Iowa State 
University, U.S.A. (see Appendix II regarding ethical considerations). Durateston™ 
(50mg) was administered intramuscularly to two greyhound bitches.  Naturally voided 
urine samples were collected at 0, 2, 4, 8, 24, 32, 48, 56, 72, 79, 96, 104hrs and then 
daily until +18 days after administration. The urines were stored at –20oC awaiting 
analysis. 
 
4.2.3 Collection of ‘normal’ blank urine samples 
Greyhound bitch urine samples were collected by representatives of the NGRC from 
racing kennels. HFL’s request, where possible, was for samples from bitches not being 
suppressed at the time of sampling or from those that had recently been suppressed. 
Many of the bitches had never been suppressed and details of last season date were also 
available for some of the animals. The population comprised 212 samples. 
 
4.2.4 Extraction Method 
Aliquots of canine urine (4mL) were spiked with 2[H5]-etiocholanolone and 2[H3]-
androstanediol (internal standards) at levels of 25 ngmL-1 each.  Extraction cartridges 
(C18 Sep-Pak Vac, 6cc, 500mg) were conditioned with methanol (5mL) and water 
(reagent grade, 5 mL).  Each sample was then passed through a cartridge followed by 
water (5 mL).  The column was washed with hexane (5mL) and then dried with air 
under vacuum for 5 min.  Extracts were then eluted with methanol (4 mL).  The eluates 
were evaporated using oxygen free nitrogen at 80ºC and dissolved in phosphate buffer 
(1mL, pH6.8, 0.1M) containing β-glucuronidase E. coli (250µl, 10units/µL).  The 
extracts were hydrolysed overnight at 37ºC. 
After incubation, sodium hydroxide (50µL, 2M) was added to each sample and the 
sample mixed using a Whirlimixer.  Liquid-liquid extraction was carried using diethyl 
ether (4mL). The ether was removed and washed with sodium hydroxide (2 x 500µl, 
2M).  The ether was dried over anhydrous sodium sulphate and then evaporated to 
dryness under OFN at 40ºC.  The samples were then reconstituted in ether: hexane (1 : 
1; 1mL) and thoroughly mixed. 
A clean up extraction was performed using Silica Sep-Pak Vac cartridges (6cc, 
500mg). These were pre conditioned using chloroform (5mL) and ether: hexane (1:1) 
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5mL.  The reconstituted samples were loaded onto the cartridges and drawn through.  
The extracts were eluted with chloroform: ethyl acetate (1:1) 3mL + 1mL.  The eluants 
were combined and evaporated to dryness under OFN at 80ºC in GC vials. Enol-tms 
derivatisation was performed by adding 30μl of ‘enol-tms reagent’ {MSTFA 1mL: 
Ammonium Iodide 3mg: Ethanethiol 6ul, prepared by heating at 80oC for 20mins to 
dissolve solid material}, capping and heating at 80oC for 1.5 – 2 hours. 
 
4.2.5 GC-MS Method 
Selective Ion Monitoring Gas Chromatography-Mass Spectrometry analysis of each 
batch was carried out in positive ion electron ionisation mode, using a Finnigan 
Voyager bench top instrument with an SGE BPX5 column (approx. 25m, 0.22mm id, 
0.25µm film thickness). Injector temperature was 260oC, splitless for 1.0 minute, and 
the interface temperature was 280oC. Injection volume was 1µL.  The GC temperature 
programme was started at 180oC and held for 0.5 minute.  Initial ramp 180oC to 290oC 
at 5oC min-1 and then further from 290oC to 330oC at 40oCmin-1. The final temp was 
held at 330oC for 3 minutes.   Data was acquired from 6 to 26 minutes. The ions used to 
monitor the derivatised parent steroid and its major metabolites are shown in Table 4.1. 
 
Table 4.1: m/z ions used in Selected Ion Monitoring (SIM) mode to detect the enol-TMS 
derivatives of testosterone and related metabolites. 
m/z IONS 
monitored 
Analytes 
346.30, 421.40 Androstanediols 
349.30 D3 Androstanediol 
417.40, 432.40 Testosterone 
419.40, 434.40 Epiandrosterone 
424.40, 439.40 D5 Etiocholanolone 
 
 
4.2.6 Quantitative GC-MS analysis of the major urinary metabolites 
For the analysis of the population of blank samples, calibration standards were prepared 
in steroid stripped canine urine for the three major metabolites epiandrosterone, 5α-
androstane-3β,17β-diol and 5β-androstane-3α,17β-diol at concentrations 250 pgmL-1,  
500 pgmL-1, 1, 2, 4, 8 and 16 ngmL-1 with quality control samples at 0.375, 3 and 12 
ngmL-1.  For the analysis of the post administration samples, calibrants were prepared 
at concentrations 4, 8, 16, 32, 64 and 128 ngmL-1 with quality control samples at 6 and 
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48ngmL-1.The internal standards 2[H3]-androstanediol and 2[H5]-etiocholanolone were 
added to all samples , quality controls and calibration standards at a concentration of 25 
ngmL-1. The samples, calibration standards and quality control samples were then 
prepared using the method described for quantitative GC-MS analysis in the SIM 
mode. 
 
4.3 RESULTS AND DISCUSSION 
 
4.3.1 Qualitative analysis results 
The major metabolites identified in the post administration urine extracts were 5α-
androstane-3β,17β-diol (αββ-Adiol), 5β-androstane-3α,17β-diol (βαβ-Adiol) and 
epiandrosterone.  Figure 4.1 shows the mass chromatogram of a post administration 
urine extract monitoring the major ions, m/z 241 and m/z 434 for the enol-TMS 
derivative of these major metabolites respectively.  The stereochemistry of the 
androstane-3,17-diol isomers was confirmed by the comparison of the retention times 
and mass spectral data with authentic reference standards. 
 
Figure 4.1: GC-MS analysis of Durateston™ (testosterone esters) post administration 
sample. 
 
 
The full scan mass spectra of 5β-androstane-3α,17β-diol and 5β-androstane-3α,17β-
diol are shown in figures 4.2 and 4.3 respectively. It is worth noting that the intensity of 
the m/z 241 is less than that of the m/z 256 ion in the 5β reduced androstane-3,17-diols 
(4 stereoisomers); the opposite being true of the 5α reduced androstane-3,17-diols (4 
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stereoisomers), a phenomenon previously observed for estranediol isomers[6].  The full 
scan mass spectrum of epiandrosterone is shown in figure 4.4. The structures of the 
major metabolites identified are shown in figure 4.5. 
 
 Figure 4.2: Mass spectrum of 5β-androstane-3α,17β-diol - bis TMS derivative 
 
 
 
 
Figure 4.3: Mass spectrum of 5α-androstane-3α,17β-diol - bis TMS derivative 
 
The mass spectra of the androstanediols show a base peak at m/z 129 which represents 
the D-ring fragment, analogous to the m/z 143 ion observed for 17α-methyl-
androstanediols in the methyltestosterone administration study. The TMS derivatives of 
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fully saturated metabolites are clearly prone to much greater fragmentation than the 
metabolites that retain a degree of unsaturation following derivatisation, where M+ - 15 
and M+. ions are quite stable (see figure 4.4). 
 
Figure 4.4: Mass spectrum of epiandrosterone enol - bis TMS derivative 
 
 
 
 
 
Figure 4.5: Structures of testosterone and the major metabolites identified 
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The levels of etiocholanolone were very low in the post administration samples and 
only those analytes with the most significant change from resting level were selected 
for quantitative analysis. 
 
 
4.3.2 Quantitative analysis results 
The method allowed for the quantification of the three major metabolites in a single 
analysis. Quality control samples were analysed in duplicate with each batch of 
samples. A typical calibration line with quality control data for one of the metabolites, 
5α-androstane-3β,17β-diol, is shown in figure 4.6.  Based upon replicate analysis of the 
calibration standards, the lower limit of quantification (LLOQ) of the assay for all three 
steroids was 250 pgmL-1. Precision and accuracy data at the LLOQ for each analyte is 
shown in Table 4.2. The remaining precision and accuracy and quality control data for 
the developed assay are shown in Appendix I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Example calibration line and quality control data for 5α-androstan-3β,17β-
diol 
 
 
Table 4.2: Summary of calibration sample data at the assay LLOQ 
Batch βαβ-Androstanediol 
(ngmL-1) 
Epiandrosterone 
(ngmL-1) 
αββ-Androstanediol 
(ngmL-1) 
1 0.311 0.292 0.260 0.276 0.254 0.259 
2 0.245 0.266 0.178 0.200 0.277 0.266 
3 0.268 0.273 0.265 0.266 0.207 0.267 
4 0.199 0.179 0.198 0.191 0.231 0.257 
Mean 0.254 0.230 0.252 
Std dev 0.045 0.041 0.023 
%CV 17.676 17.819 8.977 
%RE 1.650 -8.300 0.900 
aBB-A-diol
0 5 10 15
ng/ml
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Ar
ea
 R
at
io
    
 7.86     12.943      12.000  HIGH B 
 3.42     12.411      12.000  HIGH A 
 2.32      3.070       3.000  MED B 
 1.96      3.059       3.000  MED A 
 0.26      0.376       0.375  LOW B 
-0.22      0.374       0.375  LOW A 
%Diff Calculated 
Amount ng/ml 
Specified 
Amount ng/ml 
Sample 
 
LLOQ 250pg/ml 
Equation: Y = -0.0022+0.0389*X   R^2 = 0.9987 
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4.3.2.1 DuratestonTM (testosterone esters) administration results 
 
Figures 4.7 and 4.8 show the urinary metabolite excretion profiles for the two bitches 
following administration of DuratestonTM. All three metabolites reached maximum 
concentrations at approximately 24h post dose. For bitch 7321 5α-androstane-3β,17β-
diol levels peaked at approximately 135 ngmL-1 and returned to resting levels after 14 
days with small amounts still being sporadically excreted for several days until the final 
collection on day 18. Both epiandrosterone and 5β-androstane-3α,17β-diol followed a 
similar trend with the exception that 5β-androstane-3α,17β-diol appeared to return to 
basal levels after 11 days.  
For bitch 7335, 5α-androstane-3β,17β-diol levels peaked much higher at approx. 
220ngmL-1 and did not return to resting levels for the duration of the sample collection. 
Both epiandrosterone and 5β-androstane-3α,17β-diol followed a similar trend with 5β-
androstane-3α,17β-diol appearing to return to basal levels during the final days of 
sample collection. 
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Figure 4.7: Urinary excretion profiles of major testosterone metabolites following the 
administration of DuratestonTM (50mg IM) to greyhound bitch 7321 
Key: aBB-Adiol = 5α-androstane-3β,17β-diol; BaB-Adiol = 5β-androstane-3α,17β-diol 
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Figure 4.8: Urinary excretion profiles of major testosterone metabolites following the 
administration of DuratestonTM (50mg IM) to greyhound bitch 7335 
 
4.3.2.2 Population Study results 
The concentrations of the three metabolites were also determined in 212 “normal” 
samples from untreated bitches.  The concentration for epiandrosterone ranged from 
undetectable (i.e. below the LLOQ of 250 pgmL-1 for the assay) to 13 ngmL-1 and from 
undetectable to 22 ngmL-1 for 5α-androstane-3β,17β-diol.  The distribution of the 
concentrations of 5α-androstane-3β,17β-diol and epiandrosterone in the blank sample 
population are shown in figures 4.9 and 4.10 respectively. With the exception of two 
highly significant outliers at 21 ngmL-1 and 22 ngmL-1 for 5α-androstane-3β,17β-diol, 
the distribution of the two populations is very similar. The stereochemistry of 
epiandrosterone and 5α-androstane-3β,17β-diol is the same at C3 and C5 and the two 
compounds are linked through enzymatic metabolic pathways. 
The distribution of the concentrations of 5β-androstane-3α,17β-diol is shown in Figure 
4.11 and is heavily positively skewed towards the undetectable/low concentrations.  
5β-androstan-3α,17β-diol was detected in only 23 of the 212 samples analysed and in 
only one sample (7.5 ngmL-1) was the concentration greater than 2 ngmL-1.  The low 
excretion of 5β-androstane-3α,17β-diol ties in with the qualitatively observed low 
levels of etiocholanolone, as the stereochemistry of these two compounds is the same at 
C3 and C5. An interesting point to note here is the significant excretion of 5β-
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androstane-3α,17β-diol following administration of testosterone without the 
concomitant excretion of etiocholanolone in similar quantities as these two compounds 
are also expected to be linked through enzymatic pathways. 
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Figure 4.9: Urinary levels of epiandrosterone in a ‘normal’ population of untreated 
greyhound bitches 
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Figure 4.10: Urinary levels of 5α-androstan-3β,17β-diol in a ‘normal’ population of 
untreated greyhound bitches* 
 
*N.B. There were two further significant outliers in the population of values for 5α-androstan-3β,17β-
diol at 21.2 and 22.2 ngmL-1. These have been removed from figure 8 to allow direct comparison with 
the other analyte populations over the same range of concentrations. 
Q1= 0.45ngml-1 
Q3= 1.96ngml-1 
IQR (Q3-Q1) = 1.5ngml-1 
(3 x IQR+Q3) = 6.5ngml-1 
Probable Outlier = > 6.5ngml-1 
 
Q1= 0.46ngml-1 
Q3= 1.80ngml-1 
IQR (Q3-Q1) = 1.34ngml-1 
(3 x IQR+Q3) = 5.8ngml-1 
Probable Outlier = > 5.8ngml-1 
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Figure 4.11: Urinary levels of 5β-androstan-3α,17β-diol in a normal population of 
greyhound bitches 
 
The concentration values of the testosterone metabolites calculated for each individual 
bitch are shown in table 4.5. The results for certain bitches are highlighted where they 
are known to have been in season. Some other samples are also highlighted where the 
values appear elevated and accompanying notes were available from the trainer at the 
time of collection. These notes are highlighted in table 4.6. 
 
Table 4.5: Concentrations of major testosterone metabolites in the population of blank 
bitch urines (ngmL-1) 
Bitch 
No. 
External 
code Epiandro 
αββ –
Adiol 
βαβ –
Adiol 
 Bitch 
No. 
External 
code Epiandro 
αββ –
Adiol 
βαβ –
Adiol 
1 2072es 0.206 0 0  98 2549es 1.59 1.14 0 
5 2070es 1.038 0.798 0  99 2543es 5.066 5.448 0 
7 1909es 0.135 0 0  100 2556es 0.358 0.385 0 
9 1873es 1.115 0.908 0  102 2534es 3.4 2.887 0 
12 1907es 1.281 0.852 0  103 4099es 0.068 0 0 
14 1984es 0.363 0.577 0  104 4085es 0.293 0.325 0 
16 1982es 1.047 0.897 0  105 3731es 5.327 4.627 0 
18 1983es 0.381 0.54 0  106 3729es 7.511 6.051 0 
19 1979es 2.351 1.577 0.26  107 3718es 6.204 7.263 0.594 
20 1901es 4.793 3.618 0  108 4142es 0.949 0.713 0 
23 1765es 1.083 0.93 0  109 4144es 0.688 0.608 0 
24 1744es 4.039 4.455 0  111 4150es 0.958 0.923 0 
25 1754es 1.596 1.198 0  112 4152es 2.852 2.968 0.262 
26 1710es 0.834 1.381 0  113 3722es 0.927 0.92 0 
Q1= 0.00ng/ml 
Q3= 0.25ng/ml 
IQR (Q3-Q1) = 0.25ng/ml 
(3 x IQR+Q3) = 1ng/ml 
Probable Outlier = >1ng/ml 
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Bitch 
No. 
External 
code Epiandro 
αββ –
Adiol 
βαβ –
Adiol 
 Bitch 
No. 
External 
code Epiandro 
αββ –
Adiol 
βαβ –
Adiol 
27 1748es 0.383 0.408 0  115 4145es 1.649 1.189 0 
30 1711es 7.918 11.2 1.417  116 4096es 3.094 2.696 0 
31 1830es 0.329 0.432 0  117 4083es 5.198 6.609 0.284 
32 1760es 2.462 3.104 0.527  118 4084es 0.802 0.526 0 
33 1810es 1.089 1.095 0  119 4109es 0.846 0.897 0 
34 1955es 0.952 1.297 0  122 4154es 0.213 0 0 
36 1735es 0.754 0.388 0  123 4147es 0.083 0 0 
37 1750es 0.544 0.564 0  124 4139es 1.845 1.873 0 
39 1764es 1.586 1.621 0  125 4148es 0.33 0.332 0 
40 1758es 0.403 0.407 0  126 4146es 0.201 0 0 
41 1827es 1.021 0.796 0  127 4125es 1.493 1.646 0 
42 1819es 0.465 0.396 0  128 4140es 0.694 0.785 0 
45 1824es 0.363 0.281 0  129 4137es 0.78 0.393 0 
48 1968es 0.597 0.556 0  130 4138es 0.203 0 0 
49 1730es 0.524 0.628 0  131 4141es 0.534 0.541 0 
50 1741es 0.665 0.504 0  133 4153es 1.038 1.371 0 
51 1728es 1.036 1.309 0  136 3966es 0.128 0 0 
52 1809es 1.569 1.124 0  137 3520es 1.576 2.784 1.971 
53 1969es 0.551 0.493 0  138 3941es 0.351 0.551 0 
60 1726es 1.631 1.028 0  139 3955es 0.628 0.46 0 
62 1708es 0.831 0.875 0  140 3533es 1.398 0.752 0 
63 1731es 0.55 0.657 0  141 3514es 1.267 1.484 0 
65 1715es 1.879 1.751 0  142 3714es 0.692 0.615 0 
66 1721es 1.35 1.226 0  143 3511es 2.484 2.838 0 
68 1713es 0.849 0.852 0  144 3526es 4.415 3.085 0 
75 1790es 0.114 0 0  145 3517es 2.598 3.166 0 
86 1751es 0.477 0.457 0  147 3953es 0.575 0.443 0 
89 1707es 4.333 5.49 0.623  148 3877es 0.083 0 0 
95 1953es 3.891 5.889 0.507  150 3950es 0.352 0.642 0 
Bitch 
No. 
External 
code Epiandro 
αββ –
Adiol 
βαβ –
Adiol 
 Bitch 
No. 
External 
code Epiandro 
αββ –
Adiol 
βαβ –
Adiol 
97 2525es 4.594 3.934 0.455  151 3951es 1.159 0.63 0 
152 3702es 1.43 1.31 0  206 4531es 2.035 1.777 0 
153 3957es 0.137 0 0  209 4850es 1.086 0.96 0 
154 3963es 0.485 0.714 0  211 4404es 3.493 2.876 0 
155 3937es 0.186 0 0  213 4527es 2.512 2.014 0 
156 3959es 0.35 0.441 0  214 4861es 1.526 1.844 0 
157 3967es 0.26 0 0  216 4844es 2.252 4.167 0 
158 3946es 0.841 0.541 0  217 4542es 0.688 0.916 0 
159 3958es 0.391 0 0  218 4372es 2.544 2.599 0 
160 3944es 5.683 3.561 1.88  219 4528es 1.542 1.159 0 
161 3949es 3.358 3.156 0.729  220 4835es 0.583 0.594 0 
162 3962es 0.343 0.311 0  221 4521es 1.069 1.598 0 
164 3942es 1.833 1.948 0  222 4505es 1.042 1.976 0 
166 3994es 1.34 0.998 0  223 4808es 11.886 11.377 0 
167 3991es 1.423 0.873 0  224 4866es 10.955 9.694 7.458 
168 3993es 1.355 0.907 0  225 4385es 1.07 1.254 0 
169 4003es 1.388 1.208 0  226 4526es 2.021 2.776 0.101 
170 3998es 0.783 1.053 0  228 4975es 0.173 0.284 0 
171 3990es 0.713 0.395 0  229 4532es 0.337 0.491 0 
172 4006es 0.839 0.696 0  230 4511es 0.686 0.931 0 
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Bitch 
No. 
External 
code Epiandro 
αββ –
Adiol 
βαβ –
Adiol 
 Bitch 
No. 
External 
code Epiandro 
αββ –
Adiol 
βαβ –
Adiol 
173 4017es 2.589 2.106 0  232 4541es 13.22 21.191 0.731 
174 3996es 0.688 0.514 0  233 4961es 0.662 0.909 0 
175 4031es 0.873 0.666 0  234 4953es 3.346 3.346 0.235 
176 3992es 1.158 0.582 0  235 4955es 2.037 1.71 0 
177 4005es 6.025 3.939 0  236 4964es 7.519 22.165 0 
178 4007es 1.445 1.372 0  237 4957es 0.45 0.48 0 
179 4001es 1.804 1.21 0  238 4978es 2.135 1.926 0 
180 4013es 0.688 0.596 0  239 4947es 0.409 0.605 0 
181 3997es 1.819 1.774 0  240 4380es 0.457 0.654 0 
182 4004es 2.453 1.801 0.928  242 4544es 1.963 2.481 0 
183 4002es 5.287 3.715 0  244 4504es 1.741 2.321 0 
184 4023es 0.771 0.578 0  245 4959es 10.118 8.123 0 
185 3945es 1.852 1.628 0  246 4972es 0.406 0.733 0 
186 4113es 0.637 0.53 0  247 4810es 3.664 3.146 0.215 
187 3926es 2.022 1.654 0  248 4807es 2.216 2.558 0 
188 3907es 0.535 0.298 0  249 4811es 0.19 0 0 
189 4114es 0.383 0 0  250 4830es 2.481 2.946 0.219 
190 3889es 0.432 0.296 0  251 4857es 1.537 1.351 0 
191 3888es 2.992 2.144 0  252 4813es 0.591 0.413 0 
192 3887es 1.954 0.984 0  253 4846es 0.683 0.714 0 
193 3921es 0.425 0 0  254 5049es 0.564 0.957 0 
194 3913es 2.151 1.733 0  255 5045es 0.033 0 0 
195 3903es 1.594 1.144 0  256 5032es 0.567 0 0 
196 3880es 1.281 0.653 0  257 5034es 0.038 0.155 0 
197 3584es 2.028 1.326 0  258 509es 5.234 5.206 1.988 
198 3560es 1.607 1.509 0  259 5091es 1.148 1.359 0 
199 2259es 4.535 5.871 0  260 5001es 0.692 0.615 0 
201 4549es 0.292 0 0  261 5029es 0.183 0 0 
202 4417es 1.656 1.391 0  262 5017es 0.155 0.207 0 
203 4512es 0.878 0.763 0  263 5010es 1.347 1.964 0 
204 4513es 8.923 13.25 1.319  264 5021es 0.964 0.968 0 
265 2026es 0.439 0.979 0  277 4560es 0.47 0.466 0 
266 5088es 0.452 0.511 0  278 4383es 10.354 6.454 0 
267 5094es 4.987 1.118 0.815  279 4583es 0.713 0.545 0 
268 4998es 0.209 0.344 0  280 4563es 0.399 0.467 0 
269 5023es 0.093 0 0  281 4554es 0.102 0.157 0 
270 5039es 0.083 0.223 0  282 4378es 1.197 0.998 0 
271 5087es 0.142 0.193 0  283 4553es 3.509 3.358 0 
272 5053es 1.046 1.162 0  284 4550es 3.867 3.022 0.261 
274 4379es 0.268 0.223 0  285 4573es 1.646 1.625 0 
275 4565es 0.439 0.402 0  286 4572es 0.81 0.868 0 
276 4568es 0.434 0.313 0  287 4382es 0.422 0.228 0 
 
 
(Key: Epiandro = epiandrosterone, αββ-Adiol = 5α-androstane-3β, 17β-diol,  
βαβ-Adiol = 5β-androstane-3α, 17β-diol) 
Bitch known to be in season 
Values elevated / notes available 
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Table 4.6 - Notable samples with available sample collection comments 
Bitch no. Sample collection notes 
30 +6 months after last season (Never Suppressed) 
32 IN SEASON +22 days 
89 IN SEASON +1 day 
95 +3-4 months after last season (Never Suppressed) 
99 +11months after last season (Never Suppressed) 
106 Orandrone +3months 
107 +13months after last season (Never Suppressed) 
117 Comment – Due to ‘break’ in 7 days 
144 IN SEASON +13 days 
160 No info. (Never Suppressed) 
177 No info. (Never Suppressed) 
199 +5 months after last season 
204 +6months after last season (Comment: Never Suppressed) 
223 No season date info. (Comment: Never Suppressed) 
224 No season date info. (Comment: Never Suppressed) 
232 IN SEASON +2 days 
236 IN SEASON +4 days 
245 IN SEASON +4 days 
258 No season date info. (Comment: Never Suppressed) 
278 IN SEASON +5 days 
284 IN SEASON same day 
 
 
 
4.3.3 Statistical evaluation of population data 
When dealing with non-normally distributed data one approach is to transform the data 
using a variety of mathematical conversions e.g. log10X or the cube root of X and test 
the transformed data for normality. However, some data sets are so positively skewed 
that this is not always possible. 
The three metabolites detected in the present study were also below the assay LLOQ of 
250 pgmL-1 in a significant number of “normal” samples. A non-parametric statistical 
model provides an approach whereby the data from these samples can be included in 
the statistical analysis. This non-parametric assessment of the data predicts probable 
outliers using a boxplot and whisker approach[7]. Taking 3x the interquartile range of 
the numerically ranked data and adding the 75th percentile (75thP) gives an 
approximation to 3 sigma or 1/1000 probability that a value exceeding this level would 
be part of the real population. Previous thresholds for other endogenous compounds in 
animal sports testing have been set using 1/10,000 probability where the data showed a 
normal distribution following transformation by various mathematical conversions[8]. 
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This might be considered fairly conservative, but carries weight in an area where data 
might need to withstand legal scrutiny. Using the non-parametric approach the cut-off 
values for probable outliers for epiandrosterone, 5α-androstane-3β,17β-diol and 5β-
androstan-3α,17β-diol are shown in figures 4.9, 4.10 and 4.11 respectively. The 
calculation for 5β-androstan-3α,17β-diol in figure 4.11 assumes the 75thP to be 
250pgmL-1 (the LLOQ of the assay) in order to produce a cut-off value for a probable 
outlier. The 75thP is in fact zero for this population (i.e. 5β-androstan-3α,17β-diol was 
undetectable in greater than 90% of the samples analysed.) 
The single value at 7.5 ngmL-1 for 5β-androstan-3α,17β-diol appears to be a significant 
outlier using the non-parametric approach. It is worth noting that values of 5β-
androstan-3α,17β-diol continue to be above 10 ngmL-1 for up to 10 days post dose in 
both animals administered with Durateston. 
To establish thresholds using the non-parametric approach various multiplications of 
the “far outside value” have been proposed[9,10]. It is obviously desirable when using a 
non-parametric approach for the sample population to be a large number. It may 
therefore be desirable to collect further data for a greater number of ‘normal’ samples 
in order to allow the future setting of an action level (to trigger further investigation of 
a particular test sample) for testosterone metabolites with greater confidence. Figures 
4.12 to 4.14 show the “far outside values” from the non-parametric treatment of the 
population study data, applied to the excretion profiles for the major testosterone 
metabolites following the administration of DuratestonTM to bitch 7335 (see figure 4.8). 
 
Figure 4.12: Urinary excretion profile of 5β-androstane-3α,17β-diol from bitch 7335 
showing far outside value from population study. 
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Figure 4.13: Urinary excretion profile of epiandrostserone from bitch 7335 showing far 
outside value from population study. 
 
 
Figure 4.14: Urinary excretion profile of 5α-androstane-3β,17β-diol from bitch 7335 
showing far outside value from population study. 
 
It was possible to produce a log10X distribution of the epiandrosterone data, as all the 
samples tested gave a detectable value for this analyte that approximated to normal (see 
Figure 4.15). The mean and SD could then be used to estimate a 1 in 10,000 threshold 
for a one tailed test (1.71 log) that equals approximately 52 ngmL-1. The conservative 
degree of ‘confidence’ provides a potential threshold value with a relatively small 
window of ‘functionality’ (see Figures 4.7 and 4.8). 
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Figure 4.15: Normal distribution fit of Log10X epiandrosterone concentrations 
Of significant interest was an observation that several of the ‘probable outliers’ from 
the blank population were bitches that had recently come into season (details of known 
season related occurrences were noted on accompanying sample collection paperwork 
– see table 4.6). It became apparent that further investigations would therefore be 
needed to determine the androgen profile throughout the normal oestrus cycle of the 
bitch in order to establish the possibility of variations in testosterone metabolite 
concentrations throughout this period. Such findings may have implications in relation 
to setting final threshold values for the key testosterone metabolites. 
 
4.3.3.1 ‘βαβ-diol’ 
 
The analyte of greatest interest due to the distinct lack of its presence in over 80% of 
the samples analysed was 5β-androstane-3α,17β-diol (βαβ-diol), suggesting that this 
metabolite is either excreted in very small quantities or not at all (based on assay LOD) 
in greyhound bitches. However, it is not possible to define a threshold value for this 
analyte using routine statistical approaches in the absence of a good fit to a known 
distribution. With such positively skewed data, as well as 80% non-detects or ‘zero-
values’, the only approach (other than the analysis of 10,000 samples with well-known 
provenance) is to apply a statistical formula called the Chebyshev inequality.  
A one-tailed Chebyshev inequality is p <_ 1/(1 + k2) which defines the maximum 
probability p of observing a value, k standard deviations above the mean.  
Following the removal of samples from the population known to be in oestrus, based 
upon the current 21 day layoff rule (see chapter 5), the data was processed using the 
statistical formula as follows:- 
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General Chebyshev formula for an asymmetric distribution: 
 
p
p1
tg
−
σ+µ≤  
 
μ= mean, σ= S.D.,   tu = proposed threshold value 
 
mean = 0.109182 , s.d. = 0.596395, p=0.0001 (1/10,000 probability of a normal sample 
exceeding the threshold value (99.99% confidence) 
 
0.109182 + 0.596395 x √ (1 - 0.0001) / 0.0001   =   60ngmL-1 
This is clearly a very conservative estimate if used as a threshold value, as the variation 
in SD is enhanced by the large number of zero values present in the population and a 
threshold value of 60ngmL-1 would only provide a short window of detection for the 
administration of testosterone (see Figures 4.7 and 4.8). 
The same statistic applied for p1/1000 (99.9% confidence) gives a result of 19ngmL-1. 
It is interesting to note that none of the ‘normal’ cycling and original 212 population 
samples displayed a level anywhere near 19 ngmL-1 or more, for βaβ-diol. However, 
this level was exceeded for up to a week or more in the both of the excretion profiles 
depicted in figures 4.7 and 4.8, as well as in a large number of animals treated with 
Durateston™ in a Short Term Suppression project accompanying the work carried out 
in chapter 5 (not recorded in this thesis). 
Depending upon the level of ‘confidence’ required this value could, at the very least, be 
used as an ‘action level’, to focus on ‘intelligence’ based future testing of certain 
animals. A full statistical review of this data was carried out by a professional 
statistician to check the validity of the approaches used and interpret the data in relation 
to setting threshold/action levels for use by the GBGB to control the use of testosterone 
in the greyhound bitch[11]. The content of this review was discussed in conjunction with 
the GBGB and the outcomes resulted in setting a threshold for epiandrosterone at 
50ngmL-1. The βαβ-diol analyte was suggested for use as action level analyte at 
10ngmL-1. This level was based on an overview of the population data and the fact that 
the highest value observed for βαβ-diol was a potential outlier at 7.5 ngmL-1. 
It may be possible to reanalyse the population of samples using a more sensitive GC-
MS/MS approach. This might involve the use of a TBDMS derivative to enhance the 
available precuror ion for a relevant MS/MS transition. If an increase in sensitivity was 
observed by using this approach this might result in establishing actual values for a 
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number of the original non-detects for the βαβ-diol metabolite. This could serve to 
reduce the variance of the data set based on SD values and produce a less conservative 
threshold value if the data was then applied to the Chebyshev formula or another 
potentially suitable statistical approach. 
Further approaches and evaluations of the population data may be required following 
an assessment of the steroid profile during the oestrus cycle of the bitch. 
Other approaches, such as the ratio of key analytes (an approach used for testosterone 
detection in human sports testing) could also be investigated, along with Isotope Ratio 
Mass Spectrometry, should this technique prove suitable for greyhound urine analysis 
in the future. 
 
4.4 CONCLUSIONS 
 
The metabolite profiles determined following administration of a single dose of 
Durateston™ to two bitches were similar to those reported previously with respect to the 
metabolites identified and their relative abundances[3]. Epiandrosterone, 5α-androstane-
3β,17β-diol and 5β-androstane-3α,17β-diol were identified as the key metabolites. 
Urinary concentrations of these steroids were determined by a validated, quantitative 
GC-MS method in both the post administration samples and a population of urine 
samples from greyhound bitches. Data from this population has been treated using a 
non-parametric statistical approach to provide a cut-off level for probable outliers to 
highlight test samples of potential interest. Some conservative threshold levels for the 
key metabolites have also been calculated and may be implemented if desired, although 
further work may be necessary. 
Some of the ‘outlier’ samples from this population study clearly showed elevated levels 
of testosterone metabolites in relation to the timing of their recorded oestrus. The levels 
of metabolites observed in these samples, despite not breaching either of the tentatively 
proposed and albeit conservative threshold levels, would certainly be of interest as 
potentially originating from ‘testosterone treated’ animals, without any information to 
the contrary. 
Based on the data obtained from this study, longitudinal steroid profiling throughout 
the oestrus cycle of the greyhound bitch could provide valuable information about 
potentially significant variations in urinary androgen levels at different stages of the 
cycle.
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5. STEROID PROFILING THROUGHOUT THE OESTRUS  
      CYCLE OF THE GREYHOUND BITCH 
5.1 INTRODUCTION 
The oestrus cycle of the greyhound bitch has been the subject of a considerable amount 
of discussion and indeed research for many years. The main focus of attention on the 
cycle primarily surrounds two key areas, namely that of the racing performance of the 
animal at different stages of her cycle and a knowledge of the cycle in relation to 
effective breeding from a bitch, particularly if she has been a high class performer on 
the racetrack. The two factors are therefore, to a degree, intrinsically linked. 
Greyhound bitches are known to be essentially mono-oestrus animals as they ovulate 
on average only once per breeding season. The average length of time between cycles 
is around 8 months[1].  
The oestrus cycle is classified into four main phases as previously outlined in chapter 1. 
 
Pro-oestrus: lasts approximately 9 days, during which time the bitch will exhibit both 
anatomical and behavioural changes including the commencement of bleeding, 
increased urination and attractiveness to male dogs (but generally unreceptive). 
Oestrus: which again lasts on average for 9 days, at the outset of which the bitch will 
normally ovulate and be receptive to males; this being a major reason for not allowing 
bitches to race during this time. 
Di-oestrus: (80-90 days) during which post-ovulatory levels of progesterone rise 
(produced from the developing corpus luteum) and ultimately fall back to basal after 
around 3 months. (Note: this stage, or parts of it, is also referred to as Metoestrus by 
some clinicians) 
Anoestrus: the final stage, following luteal regression, which will last for around 4 
months in the average bitch. The bitch will remain sexually inactive during this time 
until the commencement of pro-oestrus returns. 
 
The timeframes for each phase of the cycle are variable, not only from animal to animal 
but also from one cycle to the next for a particular animal as well[1]. 
The greyhound bitch is also recognised as a breed that suffers from having what are 
termed split heats or even silent heats. A split heat is characterised by the bitch going 
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into oestrus but not ovulating. She will then return into oestrus two to four weeks later 
and ovulate normally; upon which progesterone levels should start to rise[1].A silent 
heat is characterised by essentially very little. The bitch will come into season without 
showing any physical external signs to either, the trainer, the vet or indeed any 
attractiveness to male dogs[2]. Her general behaviour can also remain relatively 
normal[1]. 
Research into hormone levels throughout the bitch’s cycle has been achieved over the 
years via the analysis of blood samples[3,4,5]. A schematic hormone profile is shown in 
in figure 5.1 (reproduced from Concannon 2011[6].) 
 
Figure 5.1:  Schematic plasma profile of oestrus cycle hormones 
 
The results of many of these studies are based on RIA and ELISA technology and very 
little, if any data appears to be available from mass spectrometry analysis. 
Over many years, a body of anecdotal evidence has also developed amongst owners 
and trainers, relating the racing performance of greyhound bitches to certain stages of 
the oestrus cycle. Such evidence has suggested that unsuppressed bitches run well 
immediately at the end of their oestrus.  However, it is believed that their performance 
declines from about day 70 and remains poor for a number of weeks before returning to 
normal. Prior to 2004, bitches were also banned from running for 70 days after 
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commencement of their season. An NGRC trial was organised which allowed 
unsuppressed bitches to run during that phase. While the knowledge gained from that 
was not as wide-ranging and full as might have been hoped for, it did indicate that one 
widespread belief was false; this being that the injury rate during that 70 days would be 
significantly elevated. Following this trial, the NGRC altered the rules, allowing 
bitches to run following a now reduced ‘21-day layoff’ period, after they came into heat 
(this rule is still in place today). One point worth considering here is that by not running 
in regular races for 70 days the animals may have returned less fit after that lay-off, 
which could have contributed to the reduced performance assessment for some animals 
on their return to the track. 
The information surrounding the oestrus cycle gathered over the years has therefore led 
to a desire amongst many trainers to suppress the cycle of the bitch thereby minimising 
the variability of her racing performance and allowing her to compete all year round. 
The types of compounds available to suppress oestrus have been discussed in previous 
chapters. The main focus for this research is based on the detection of the 
administration of the endogenous hormone testosterone and research into the hormone 
profiles of bitches throughout their reproductive cycles. The latter has been mainly 
performed on blood samples, urine being primarily used for clinical assessment of LH 
and progesterone by immunoassay[7]. However, the matrix of choice for routine drug 
screening is currently urine. To date, no research has been carried out to determine 
longitudinal androgenic steroid profiles throughout the reproductive cycle of the 
greyhound bitch, using urine as the analytical matrix, coupled with mass spectrometry 
as the analytical technique.  
The generic phases of the cycle have been outlined in this thesis and reviewed 
extensively in relation to clinical aspects of reproduction[8,9,10]. The main analytes of 
interest in relation to routine drug testing are the androgens, along with a possible 
requirement to understand the likelihood of ovulation via detection of progesterone. 
Oestrogens are required for follicular development prior to ovulation and at a key point 
during that development oestrogens are produced at a rapid rate via a positive 
mechanism before production is then rapidly switched off just prior to and triggering 
the LH surge that ultimately stimulates ovulation. A schematic of the overall regulation 
of the oestrus cycle by gonadotrophins via the hypothalamic pituitary axis (HPA) is 
shown in Figure 5.2. Evidence has been provided indicating that in dogs the LH surge 
is activated by a relatively rapid decrease in circulating oestradiol[11]. 
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Figure 5.2: Schematic generic overview of the HPA and gonadotrophic control of the 
oestrus cycle, (reproduced from Essential Reproduction, Johnson M. 1995) 
 
The production of oestrogen is ‘fuelled’ by androgens acting as substrates. Androgens 
are produced in developing theca cells, as these cells contain the necessary enzymes 
required to convert cholesterol through to androgens[12]. Theca cells do not have the 
ability to convert androgens to oestrogens, i.e do not contain aromatase enzymes. 
Therefore the androgens are transported to the granulosa cells which do contain 
aromatase and can therefore convert the androgens substrates into oestrogens. The 
oestrogens are transported to the developing oocyte and also to the bloodstream for 
self-regulation of production via the HPA axis. 
Figure 5.3 shows a schematic of the structure of the developing follicle and the 
theca/granulosa cell interplay of steroidogenesis resulting in production of oestradiol. It 
is not known in what form the androgens are transported from theca cells to granulosa 
cells but since the theca is vascularised these androgens may enter the circulation. 
Elevations in testosterone and androstenedione concentrations have been observed in 
canine serum using RIA techniques[3,4]. 
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(Reproduced from Fahiminiya S. et al. Proteomic analysis of mare follicular fluid during late 
follicle development. Proteome Science 2011, 9:54.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Schematic diagrams of the developing follicle and the associated production 
of androgens as substrates for the production of oestrogens. 
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Previous studies into the ‘normal’ androgen concentrations in a population of 
greyhound bitches (described in chapter 4) had indicated that there may be some 
variation in urinary testosterone metabolite concentrations at different stages of a 
bitch’s oestrus cycle.  
Therefore in order to provide information to support setting a threshold, to enable the 
detection of the administration of testosterone to racing bitches, knowledge of the 
normal androgen profiles throughout the entire oestrus cycle was required. A 
population of greyhound bitches was therefore needed to support such a study, to 
provide an understanding of potential variation between animals, and present a more 
generic understanding of the androgen levels in the ‘normal’ animal. Clearly, the more 
animals the better for research of this type, but establishing a suitable population 
presented its challenges. Following evaluation of a number of possible sources of 
animals for the study, it was decided to set up a quorum of volunteer trainers to support 
the research, who would submit animals in their care into the scheme for the duration 
of the project. 
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5.2 MATERIALS AND METHODS 
 
5.2.1 Solvents and Chemicals 
C18 Sep-Pak Vac SPE cartridges (500mg, 6cc, end capped) and Silica Sep-Pak Vac 
SPE cartridges (500mg, 6cc) were obtained from Waters Ltd (Hertfordshire, UK).  
Methanol, hexane, diethyl ether, chloroform and ethyl acetate, Analar or HPLC grade, 
were obtained from Rathburn Chemicals Ltd (Walkerburn, Scotland).  Sodium 
hydroxide, disodium hydrogen orthophosphate 2-hydrate and sodium dihydrogen 
orthophosphate 1-hydrate, analar grade, were supplied by BDH (Dorset, UK).  Sigma 
Chemical Co. Ltd (Dorset, UK) supplied sodium sulphate, ammonium iodide β-
Glucuronidase from Eschericia.coli and reference standards, 5α-androstane-3β,17β-
diol, 5β-androstane-3α,17β-diol, testosterone, [2H3]-testosterone and etiocholanolone. 
N-Methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) was obtained from Machery-
nagel (Düren, Germany).  Ethanethiol was supplied by Aldrich Chemical Co. Ltd 
(Dorset, UK). Epiandrosterone was obtained from Steraloids Inc. PO Box 689, 
Newport, RI 02840, USA and [2H5]-Etiocholanolone, [2H5]-5β-androstane-3α,17β-diol, 
[2H4]-19-norandrosterone, [2H4]-19-noretiocholanolone and [2H4]-Androsterone were 
obtained from NARL, Sydney, NSW 2073, Australia. [2H3]-16,16,17-5α-androstan-
3α,17β-diol ([2H3]-androstanediol internal standard) was prepared at HFL Sport 
Science, Fordham, Camb., UK. HPLC column ACE C18-HL (150x4.6mm id, 3um) 
was obtained from Advanced Chromatography Technologies, Aberdeen, Scotland. 
 
5.2.2 Urine Sample Collections for cycling bitches 
Urine samples were collected from greyhound bitches throughout their entire oestrus 
cycle. Animals were provided by trainers who stated that they would not be using 
oestrus suppressants in the animals volunteered by them for the scheme. These trainers 
were in the cohort that preferred not to suppress the cycles of their racing animals. 
Sample collection began on the first day of the animals ‘season’. This was based upon 
visual recognition of the cycle status of the bitch, by the trainer concerned, i.e. visible 
and behavioural signs of developing pro-oestrus.  
From this point onwards, urine samples were collected twice a week for 14 weeks and 
then once a week thereafter, until the animal was deemed to be starting its next oestrus 
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cycle (i.e. commencement of pro-oestrus again), at which time urine sample collection 
then ceased.  
This procedure therefore provided samples for each animal from pro-oestrus through 
oestrus and di-oestrus, back into anoestrus and ultimately into pro-oestrus again. In 
general, pro-oestrus bleeding was used as the indicator to trainers that the bitch was 
beginning her seasonal cycle and that sample collection should therefore begin. In the 
case of the return to pro-oestrus, bleeding would indicate that sampling should then 
cease. 
Animals were volunteered into the scheme by trainers who then needed to wait until the 
animal came into season before starting sample collection. Precise knowledge of each 
animals ‘due’ date was not available in many cases. This is not an uncommon situation 
for trainers of racing bitches. Therefore, in a number of instances this resulted in 
several months passing before the first sample could be collected. The average oestrus 
cycle of the greyhound bitch is around 8-9 months. However, many racing bitches will 
have significantly different timespans between their individual cycles, which therefore 
meant that completion of the monitoring process and sample collection throughout the 
cycle, could take up to one year for each animal. 
Longitudinal sample collections were ultimately obtained for 33 bitches over the course 
of several years. More animals started the scheme, but for various reasons, not all of 
them were able to complete the entire sampling programme. Several different trainers 
volunteered to help with the scheme and whilst they were each remunerated for their 
efforts, their willingness to provide such a unique set of urine samples over a long 
period of time was still nevertheless, highly commendable. 
One trainer in particular collected daily urine samples for one animal leading up to the 
start of the bitch’s oestrus and for several weeks thereafter, to try and help provide even 
more detailed information on the urinary hormonal status of the animal during that 
phase of the cycle. 
Trainers were required to fill out forms with the relevant information and return them 
to HFL Sport Science along with the samples upon completion. Urine sample kits were 
provided for each trainer in the scheme, allowing provision for a maximum sample 
volume of 50ml. Trainers were required to add both the date of sampling and the 
animals ear-tag number to pre-printed labels provided for each bitch submitted for the 
cycling study. Sample kits were provided with pre-paid first class postage to assist the 
trainers with returning the samples to the laboratory through the normal postal service, 
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thereby enhancing the efficiency of the process. On arrival at the laboratory samples 
were recorded on a database, dispensed and stored frozen at -20oC until required for 
analysis. The process was extremely efficient and samples were received in good time 
with all the relevant information associated with them. 
5.2.3 Animal Administration - progesterone 
The animal administration was performed at the Racing Chemistry Veterinary 
Diagnostic Laboratory, Iowa State University, U.S.A. Following ethical approval, one 
bitch (7335, Weight 28kg) was administered an intramuscular injection (3mg/kg, total 
84.5mgs) of progesterone in sesame oil. The animal was selected at a time when she 
was believed to be in anoestrus to try and provide a greater distinction between the 
steroid levels in the pre-dose and post dose samples. A naturally voided blank urine 
sample was obtained prior to administration. Post administration urine samples were 
collected at +8, 24hrs and +2, 3, 4, 21 and 28 days after the dose. The urine samples 
were stored at -20oC awaiting analysis. 
 
5.2.4 Qualitative Sample Analysis  
5.2.4.1 Progesterone metabolism 
To assist with the identification of suitable marker metabolites of progesterone in post 
ovulatory greyhound urine, samples from the intramuscular progesterone 
administration study were analysed alongside urine samples from some of the normal 
cycling bitches. Urine samples from the cycling bitches were chosen at time points that 
were considered likely to present the highest possible levels of progesterone 
metabolites, in order to try and identify suitable markers for monitoring throughout the 
oestrus cycle. These were selected at approximately 3-4 weeks after the onset of pro-
oestrus. 
5.2.4.2 Sample extraction 
Aliquots of canine urine (4 mL) were spiked with internal markers [2H3]-androstanediol 
and [2H5]-etiocholanonlone at a level of 25 ng mL-1.  Extraction cartridges (C18 Sep-
Pak Vac, 6 cc, 500 mg) were conditioned with methanol (5 mL) and water (reagent 
grade, 5 mL). The urine samples were then passed through the cartridges followed by 
water (5 mL).  The column was washed with hexane (5 mL) and then dried with air 
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under vacuum for 5 min. The cartridge was eluted with methanol (5 mL). The methanol 
was mixed and split into 2 equal portions. The eluates were evaporated using OFN at 
80ºC, the residue dissolved in phosphate buffer (1 mL, pH 6.8, 0.1 M). β-glucuronidase 
E. coli (250 µl, 10 units µL-1) was added to one of the extracts and the solution 
incubated overnight at 37ºC. 
After incubation, sodium hydroxide (500 µl, 2 M) was added to all sample extracts and 
mixed using a whirlimixer. Liquid-liquid extraction was carried out using tertiary butyl 
methyl ether (TBME, 4 mL). The aqueous layer was removed and the organic solvent 
washed with sodium hydroxide (2 x 500 µL, 2 M).  The TBME was dried over 
anhydrous sodium sulphate and then evaporated to dryness under OFN at 40ºC in a low 
volume vial. 
5.2.4.3 Derivatisation 
The enol-tms derivatisation reagent was prepared from MSTFA (1 mL), ammonium 
iodide (3 mg) and ethanethiol (6 µL); the mixture being heated at 80ºC for 20 mins to 
dissolve solid material. The derivatising reagent (30 µL) was added to the urinary 
extracts and the solution heated at 80oC for 1.5 – 2 hours, and a 1 µl aliquot injected on 
to GC-MS for analysis. 
 
5.2.4.4 GC-MS analysis 
Full Scan GC-MS analysis was carried out in positive ion electron ionisation mode, 
using a Thermo Finnigan (Austin, Texas, USA) DSQII bench top mass analyser 
instrument fitted with an SGE (SGE Europe Ltd, Milton Keynes, U.K.) 5% phenyl 
polysilphenylene-siloxane (BPX5) column, (approx. 29 m, 0.25 mm id, 0.25 µm film 
thickness). The temperature of the split/splitless injector was 260ºC. Injections were 
made in the splitless mode which was maintained for 1.0 minute. The interface 
temperature was 260ºC. Injection volume was 1 µL.  The GC temperature programme 
was started at 180ºC and held for 0.5 min.  Initial ramp 180ºC to 290ºC at 5ºC min-1 
and then further from 290ºC to 330ºC at 40 ºC min-1. The final temp was held at 330ºC 
for 4 min.  
5.2.4.5 Evaluation of C18 / Silica Sep-Pak extraction for the cycle sample analyses 
Samples were extracted using the original procedure developed for the testosterone 
population study in chapter 4 (section 4.2.4) to establish whether this method was 
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suitable for the analysis of the progesterone metabolites. This method involves the use 
of C18 and silica SPE. The C18 Sep-Pak methodology has historically shown high, 
stable and reproducible recoveries (80-90%) for all the various androgenic anabolic 
steroid metabolites, including 17-hydroxy-3-keto steroids, 3-hydroxy-17-keto steroids, 
androstanediols, estranediols and various -triols of differing stereochemistries[13,14]. 
However, analysis of the progesterone metabolites observed in the administration study 
had not been previously investigated. 
 
5.2.4.6 HPLC Fractionation 
Sample extracts were also purified using an LC fractionation procedure utilising an 
Agilent 1100 series HPLC system with Diode Array coupled to a Gilson FC204 
Fraction Collector, as an alternative approach to providing clean sample extracts for 
quantitative analysis of all the analytes of interest.  
Following sample extraction using C18 Sep-pak/liquid liquid preparation only, extracts 
were reconstituted in methanol:water 80:20 (100ul) and injected onto an HPLC system 
utilising an ACE C18-HL column (150x4.6mm ID, 3 um), flow rate 500 ul/min with 
mobile phase start conditions 80:20 methanol:water, isocratic for 5 mins, rising to 
100% methanol at 5.1 mins held to 17 mins, before re-equilibrating to start conditions 
(total cycle time 24 mins). 
The fraction between 5-11 mins was collected for each sample. The collected fraction 
was evaporated to dryness in a GC vial and the extract derivatised as detailed in section 
5.2.4.3. 
5.2.5 Quantitative Sample Analysis 
Previous research (see chapter 4) had indicated that the major observed metabolites 
following the administration of testosterone to the greyhound were 5α-androstane-
3β,17β-diol, epiandrosterone and 5β-androstane-3β,17β-diol.  These metabolites were 
therefore selected for quantitation in the oestrus cycle urine samples, along with some 
other analytes of interest, namely testosterone, etiocholanolone and epitestosterone. 
An appropriate metabolite of progesterone (M1 – see section 5.3.1) was selected for 
detection alongside the androgens, but no reference standard was available for 
quantitation. 
Steroid stripped bitch urine was prepared and used for calibration and quality control 
samples. Calibration standards were prepared for testosterone, epitestosterone, 
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etiocholanolone, epiandrosterone, 5α-androstane-3β,17β-diol and 5β-androstane-
3α,17β-diol at concentrations 125 pgml-1, 250 pgml-1, 500 pgml-1, 1, 2, 4, and 8 ngml-1 
with quality control samples at 0.375 and 3 ngml-1 
Repeat analyses were performed on urine samples that had concentrations of analytes 
above the top point of the calibration curve. These samples were re-analysed alongside 
a higher range calibration curve to ensure that higher concentrations obtained for each 
analyte at certain timepoints, were not derived from extrapolation. The calibration 
range used was that applied to the analysis of the Durateston™ post administration 
samples (chapter 4, section 4.2.6). Details of the batch acceptance data are shown in 
appendix III. Samples with apparently ‘unusual’ results, following data interpretation, 
were also reanalysed to ensure that no inappropriate conclusions were drawn regarding 
these findings. 
 
5.2.5.1 Sample extraction 
All urine samples, calibration and QC samples were spiked with internal markers [2H4]-
androsterone, [2H3]-testosterone and [2H5]-5β-androstane-3α,17β-diol at a concentration 
of 25ng/mL. Extraction cartridges (C18 Sep-Pak Vac, 6cc, 500mg) were conditioned 
with methanol (5 mL) and water (reagent grade, 5 mL).  Each sample (4 mL) was then 
passed through a cartridge followed by water (5 mL).  The cartridge phase was washed 
with hexane (5 mL) and then dried with air under vacuum for 5 min.  Extracts were 
then eluted with methanol (4 mL).  The eluates were evaporated using oxygen free 
nitrogen at 80ºC and dissolved in phosphate buffer (1mL, pH6.8, 0.1M) containing β-
glucuronidase E. coli (250µl, 10units/µl).  The extracts were hydrolysed overnight at 
37ºC. 
After incubation, sodium hydroxide (500 µL, 2 M) was added to all sample extracts and 
mixed using a whirlimixer. Liquid-liquid extraction was carried out using tertiary butyl 
methyl ether (TBME, 4 mL). The aqueous layer was removed and the organic solvent 
washed with sodium hydroxide (2 x 500 µl, 2 M).  The TBME was dried over 
anhydrous sodium sulphate and then evaporated to dryness under OFN at 40ºC in a low 
volume vial. The resulting extracts were reconstituted in mobile phase (100 uL 
methanol:water, 80:20)  and further purified using the LC fractionation procedure 
described in section 5.2.4.6. The final collected fractions were then evaporated and 
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enol-tms derivatives were formed prior to GC-MS analysis as described in section 
5.2.4.3. 
5.2.5.2 GC-MS analysis 
Data was acquired in the Selected Ion Monitoring mode for the quantitative analysis of 
testosterone metabolites in the oestrus cycle urine sample extracts.  From 18 minutes 
onwards until the end of the run, data was acquired in full scan mode to monitor the 
progesterone related metabolites. 
Gas Chromatography-Mass Spectrometry (GC-MS) analysis of each batch was carried 
out in positive ion electron ionisation mode, using a Thermo DSQII bench top mass 
analyser instrument, fitted with an SGE BPX5 column (approx. 29m, 0.25mm id, 
0.25µm film thickness). The injector temperature was 260oC, splitless for 1.0 minute, 
and the interface temperature was set at 330oC. Injection volume was 1µl.  The GC 
temperature programme was as follows: initial temperature 180oC, held for 0.5 minute, 
then ramping from 180oC to 290oC at 5oCmin-1 followed by 40oCmin-1 from 290oC to 
330oC, with a final hold time of 3 minutes. The ions acquired in Selected Ion 
Monitoring (SIM) mode for the relevant analytes are shown in Table 5.1. 
 
Table 5.1: GC-MS (SIM) method acquisition ions 
Ions Monitoring 
256.1, 346.2, 
421.3 
Androstanediols 
351.2, 426.3 [2H5]-Androstanediol 
417.3, 432.3 Testosterone, 
epitestosterone 
419.3, 434.3 Epiandrosterone 
420.3, 435.3 [2H3]-Testosterone 
423.3, 438.3 [2H4]-Androsterone 
 
Each analyte had two appropriate fragment ions selected for analysis, one as the main 
ion for quantitation and the other as a qualifier ion to support the identification of each 
compound, so that the correct analyte was being quantified at all times. Ions were 
chosen based on optimum sensitivity and selectivity for the assay. 
Full scan spectra for the trimethylsilyl derivatives of the major testosterone metabolites 
in the greyhound as well as those of testosterone itself, epitestosterone and 
etiocholanolone showing the relevant fragment ions, are presented in Figure 5.4. 
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Figure 5.4: Trimethylsilyl derivative mass spectra of the major androgens quantified 
throughout the oestrus cycle of the greyhound bitch 
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5.3 RESULTS AND DISCUSSION 
5.3.1 Metabolism of progesterone 
Figures 5.5 and 5.6 show pre-dose and post-dose ion chromatograms proposed major 
metabolites observed following the administration of progesterone to the greyhound 
The pre-dose urine sample clearly contained small quantities of the progesterone 
metabolites as they are naturally occurring endogenous compounds in the greyhound 
bitch. The amounts observed in the pre-dose sample are likely to represent the latter 
stages of dioestrus/early anoestrus as they were collected at around 90 days post season 
for the bitch used in the study. They are probably not absolute basal anoestrus amounts 
but nevertheless allowed for discrimination between pre and post dose samples. Four 
key metabolites were detected (assigned M1-M4). The first metabolite (M1) has a mass 
spectrum dominated by the base ion m/z 117 which is a characteristic fragment ion 
generated from trimethylsilyl derivatised pregnanes with a reduced keto function at C-
20 (see figure 5.7). Figure 5.8 shows a zoomed in spectrum to display the lower 
intensity, higher mass, fragment ions to aid structural elucidation. . The metabolite was 
proposed as a pregnanetriol (see scheme 5.1) with a suspected derivatised molecular 
weight of 552 mass units. Fragment ions were observed at m/z 537 (M+-15), 462 (M+.-
90), 447 (M+-15+90), 435 (M+-117), 372 (M+.-90+90) and 282 (M+.-90+90+90).  
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Figure 5.5:  Ion chromatograms for progesterone pre-dose urine (glucuronide fraction) 
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Figure 5.6: Ion chromatograms for progesterone post-dose (+8hrs) urine (glucuronide) 
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Figure 5.7: Mass spectrum of ?pregnanetriol metabolite (M1) of progesterone post-dose 
        (+8hrs) urine (glucuronide fraction) 
 
The loss of three TMSiOH groups (M-90) indicated the presence of three aliphatic 
hydroxyl functions in the molecule suggesting reduction at C3 in addition to reduction  
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 m/z 117 
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at C20 and mono-hydroxylation at possibly C6. The intensity of the 357 ion (M+-
15+90+90) is less than that of the 372 (M+.-90+90). This might suggest that this is a 5β-
reduced metabolite, analogous to the same losses for the androstanediol metabolites 
described in chapter 4. 
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Figure 5.8: ‘Zoomed in’ mass spectrum of putative pregnanetriol metabolite (M1) of 
progesterone post-dose (+8hrs) urine extract (glucuronide fraction) 
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Figure 5.8a: Mass spectrum of 17α-hydroxy-5α-pregnane-3β,20B-triol reference std. 
314+6H+16(O)+216(3tms) = 552 
? m/z 552 (M+.) 
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The M1 metabolite was not considered to be a 17-hydroxy compound as such analytes 
are known to give qualitatively different mass spectra as TMS derivatives than that 
observed for M1, with major fragment ions at 255, 345 and 435. See figure 5.8a. 
Figure 5.9 shows the mass spectrum of M2 with a derivatised molecular weight of 550 
mass units. The fragment ion of m/z 117 again indicated that the keto function at C-20 
had been reduced. The compound was postulated as a mono-hydroxy bis reduced 
metabolite. No reference standards were available for comparison. Figure 5.10 shows 
the mass spectrum of M3 indicating a derivatised molecular weight of 638 mass units. 
This represents a possible bis-hydroxy-bis-reduced metabolite. The fragment ion at m/z 
231 suggests possible hydroxylation of the D-ring, probably at C-16. Figure 5.11 shows 
the mass spectrum of M4 indicating a mono-hydroxy, mono-reduced metabolite, with a 
derivatised molecular weight of 548 mass units. The fragment ion at m/z 157 shows 
that the D-ring is unaltered. Suggested structures for M1–M4 are shown in scheme 5.1. 
An excretion profile for M1-M4 is also shown in figure 5.12. The profile indicates that 
progesterone is cleared relatively quickly following intramuscular administration. This 
has previously been observed by during a pharmacokinetic study in canine serum[15].  
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Figure 5.9: Mass spectrum of proposed progesterone metabolite (M2) (glucuronide 
fraction) 
 
314+4H+16(O)+216(3tms) = 550 
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Figure 5.10: Mass spectrum of proposed progesterone metabolite (M3) (glucuronide 
fraction) 
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Figure 5.11: Mass spectrum of progesterone metabolite (M4) (glucuronide fraction) 
314+2H+16(O)+216(3tms) = 548 
m/z 638 
314+4H+32(O2)+216(4tms) = 638 
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Scheme 5.1: Summary of proposed major progesterone metabolites 
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Figure 5.12: Urinary excretion profile of proposed progesterone metabolites following 
intramuscular administration to the greyhound 
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All of the metabolites were detected in the hydrolysed fraction and were therefore 
considered to be glucuronic acid conjugates. No significant quantities of these 
metabolites were observed in the urinary free fraction.  
 
 
5.3.1.1 Analysis of oestrus cycle samples for progesterone metabolites. 
Several of the urine samples analysed from bitches at 3-4 weeks into their oestrus 
cycles gave indications for the presence of all of the major progesterone  metabolites to 
a lesser or greater extent. The most significant marker metabolite present in all of the 
bitches was the proposed pregnanetriol (M1). Figure 5.13 shows an example of 
extracted ion chromatograms for the major progesterone metabolites in the +26days 
post season urine sample from Queen of Stout. The chromatograms indicate the M1 
metabolite as the most abundant marker metabolite. This pregnanetriol metabolite was 
therefore selected as the analyte to monitor in the cycling bitches in order to determine 
their progesterone production throughout the cycle and provide indication that they had 
ovulated during oestrus and subsequently formed a corpus luteum. 
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Figure 5.13: Ion chromatograms for Queen of Stout (+26 days in season) urine 
(glucuronide fraction). 
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 Progesterone - M3 
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5.3.2 Results of C18/Silica Sep-Pak extraction evaluation (cycle samples) 
The m/z 117 ion chromatogram in figure 5.14 shows the detection of the major 
pregnanetriol (M1) urinary progesterone metabolite, following the C18/liquid-liquid 
extraction procedure only. Metabolite M1 is clearly present. 
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Figure 5.14: Urine extract using solid phase/liquid-liquid extraction only 
 
The m/z 117 ion chromatogram in Figure 5.15 shows that following further clean-up of 
the C18/liquid-liquid extract using the silica clean-up procedure, the major 
progesterone metabolite was not recovered. This silica clean-up method was therefore 
not suitable to recover all the compounds of interest in the oestrus cycle profile analysis 
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Figure 5.15: Urine extract using solid phase/liquid-liquid extraction and silica clean-up 
Major pregnanetriol (M1) 
Loss of major pregnane triol 
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It is interesting to note that previous experience with 6-hydroxy steroids has shown 
these compounds to bind to silica quite readily, even for di-hydroxy 3-keto structures, 
whereas 3,16,17-triols are recovered using the silica clean up. This may be due to an 
increased ‘coverage’ of the ring structure leading to an increase in polar behaviour of 
the analyte under these extraction conditions.  
 
5.3.3 C18 Sep-Pak / liquid-liquid method re-evaluation 
Having established that the major progesterone metabolite to be monitored was not 
recovered using the silica-clean-up procedure, further development work was needed to 
establish a clean-up method for the extracts that recovered all the analytes of interest. 
The data in Figures 5.16-5.19 shows that the combination of C18 and liquid/liquid 
extraction, for sample extract preparation, did not appear to be sufficient for accurate 
quantitation of some of the key analytes of interest. On inspection of the full scan data, 
it was shown that there were co-eluting analytes for both epiandrosterone (Figures 5.16 
and 5.17) and 5α-androstane-3β,17β-diol (Figures 5.18-5.19).  For epiandrosterone, an 
isotope ion from the co-eluting analyte could give rise to falsely elevated values.  For 
the analysis of 5α-androstane-3β,17β-diol, the co-eluting compound appears to contain 
the same ion that is monitored for this particular androstanediol isomer resulting in 
even greater potential for false elevation of the concentration of this analyte. Therefore, 
a further clean-up method was investigated involving HPLC fractionation prior to GC-
MS quantitation, in order to aid the quantitation of low level concentrations of analytes 
in untreated animals. 
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Figure 5.16: Ion chromatograms for epiandrosterone and co-eluting compound 
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Figure 5.17: Mass spectra for epiandrosterone and co-eluting compound 
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Figure 5.18: Ion chromatograms for 5α-androstane-3β,17β-diol and co-eluting 
compound 
 
 
100 150 200 250 300 350 400 450 500
m/z
0
20
40
60
80
100
0
20
40
60
80
100
R
el
at
iv
e 
A
bu
nd
an
ce
281.05
207.05 369.07
239.15
421.23
183.12105.05 311.15 430.26393.15 493.91
129.06
241.16
149.11
416.22215.16 256.22 346.24
161.12 421.29
436.28318.21 402.21 504.39
NL: 1.97E6
CC_3wk_C18_FS#860
  RT: 16.95  AV: 1 SB: 
2  12.00  , 12.00 T: + c 
Full ms [ 
100.00-750.00] 
NL: 9.92E6
CC_3wk_C18_FS#876
  RT: 17.05  AV: 1 SB: 
2  12.00  , 12.00 T: + c 
Full ms [ 
100.00-750.00] 
 
Figure 5.19: Mass spectra for 5α-androstane-3β,17β-diol and co-eluting compound 
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5.3.4 HPLC fractionation sample clean-up 
Figures 5.20 and 5.21 show the HPLC chromatograms generated from a urine extract 
and a reference standard respectively. By collecting the fraction between 5-11 minutes 
all the steroids of interest were able to be analysed in one single quantitative GCMS 
run. The co-eluting compounds were removed in the fractionation process. Example 
chromatograms following the HPLC clean-up are shown in figures 5.22 and 5.23. 
 
Figure 5.20: Chromatogram from HPLC fractionation clean up analysis – urine extract 
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Figure 5.21: Chromatogram from HPLC fractionation clean-up process – reference 
standard 
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Figure 5.22: Ion chromatogram and mass spectrum for epiandrosterone and ion 
chromatogram at m/z 417 for originally co-eluting compound. 
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Figure 5.23: Ion chromatogram and mass spectrum for 5α-androstane-3β,17β-diol and 
ion chromatogram at m/z 281 for originally co-eluting compound. 
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Table 5.2 summarises the chromatographic separation obtained on the HPLC system 
for the main steroid analytes of interest. When derivatised and analysed by GCMS 
individually, these cleaner fractions provided further spectral information for some of 
the analytes of interest. Fraction 6 was analysed to try and detect the molecular ion of 
progesterone M1 and therefore support the interpretation that this compound was a 
pregnanetriol. 
Table 5.2: Summary of HPLC fractions 
LC Fraction Analyte MW Ions Comments 
5  
(4-5mins) 
cortico-related 636   
?Pregnane 550 117, 371, 460 
* not in all 
bitches 
unknown  117  
6 
(5-6mins) 
?11B-OH epietio or related  168, 522  
Major pregnanetriol 552 117, 372, 435, 537 
* breaking 
through 
into 
fraction 7 
Pregnanetriol 552 117, 435,  
? 550 407, 521 * 143 loss 
7 
(6-7mins) 
Major pregnanetriol 552 117, 372, 435, 537  
?unknown 638 231  
8 
(7-8mins) 
norepiandrosterone 420 420, 405, 315  
aBB-Adiol 436 421, 346, 241  
[2H3]-testosterone 435 435, 420  
testosterone 432 432, 417  
9 
(8-9mins) 
[2H4]-noretiocholanolone 424 424, 409, 319  
noretiocholanolone 420 420, 405, 315  
epiandrosterone 434 434, 419, 329  
epitestosterone 432 432, 417  
10 
(9-10mins) 
[2H4]-norandrosterone 424 424, 409, 319  
aBa-Adiol 436 421, 346, 241  
[2H5]-etiocholanolone 439 439, 424, 334  
etiocholanolone 434 434, 419, 329 
* breaking 
through 
into 
fraction 11 
[2H3]-androstanediol 439 439, 424, 349  
11 
(11-12mins) 
[2H4]-androsterone 438 438, 423, 333  
etiocholanolone 434 434, 419, 329  
[2H5]-BaB-Adiol 441 426, 351, 261  
BaB-Adiol 436 421, 346, 241  
17a-OH pregnanetriol 552 117, 255, 435, 537  
17a-OH pregnanetriol 552 117, 255, 435, 537  
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The analysis of the individual fraction from the HPLC clean-up procedure enabled the 
molecular ion to be determined for this compound, due to the overall reduction in 
background noise from the mass spectrum (figure 5.24). The increase in the detected 
signal of this metabolite, observed in the +3 week samples (after the onset of season) 
compared with the -6 week samples (prior to the onset of pro-oestrus), was on average 
100 fold, for the 33 bitches analysed. This therefore reinforced the choice of this 
metabolite as the most significant urinary marker metabolite for monitoring 
progesterone changes throughout the oestrus cycle of the greyhound bitch. 
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Figure 5.24: Zoomed in spectrum of proposed pregnanetriol metabolite (M1) 
 
 
Figure 5.25 shows ion chromatograms for a mixed standard containing all the 
androgens and internal standards monitored on the quantitative analysis. Figure 5.26 
shows ion chromatograms for a urine extract from Queen of Stout (+8days after the 
onset of her season), indicating the presence of the various androgens to be monitored 
along with the major pregnanetriol (progesterone metabolite M1). Both of these 
extracts were generated using the developed SPE/LC clean-up sample preparation 
procedure.  
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Figure 5.25: Extracted standard (7B): LC fractionation (5-11 incl.) 
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Figure 5.26:  Queen of stout – 8 days post season: LC fractionation (5-11incl.) 
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5.3.5 Quantitative GC-MS analyses 
Table 5.3 shows the final analyte retention times and relative retention times used for 
the quantitative steroid profiling. 
 
Table 5.3: Summary of analyte retention times for the quantitative steroid analysis 
Analyte 
  
Retention Time  
(min) 
Relative Retention Time 
  
[2H4]-androsterone (IM) 15.45 1.000 
etiocholanolone 15.65 1.013 
epiandrosterone 16.68 1.080 
[2H5]-BaB-androstanediol (IM) 15.89 1.000 
BaB-androstanediol 15.94 1.003 
aBB-androstanediol 16.93 1.065 
[2H3]-testosterone (IM) 17.66 1.000 
epitestosterone 17.02 0.964 
testosterone 17.69 1.002 
Progesterone metabolite Pregnanetriol (M1)* 19.70 1.116 
* The analysis of pregnanetriol was semi-quantitative as no certified reference standard was available for calibration 
 
Unless repeat analyses were required, all the samples from the complete longitudinal 
profile of a particular animal were analysed in a single run to reduce analytical 
variation. 
The three major testosterone metabolites epiandrosterone, 5α-androstane-3α,17β-diol 
and 5β-androstane-3α,17β-diol along with testosterone, epitestosterone and 
etiocholanolone were quantified in all the urines collected from 33 greyhound bitches 
throughout their oestrus cycles. The major pregnanetriol (M1) was not available as a 
reference standard and the analysis was therefore only semi-quantitative for this 
compound.  
The total number of urine samples analysed by this quantitative procedure involving 
SPE/Liquid-liquid extraction, HPLC fractionation, derivatisation and GC-MS analysis 
for all the samples collected for each bitch throughout her cycle was in excess of 1500. 
 
5.3.5.1 Batch acceptance 
For each batch of samples extracted, a calibration line was generated and quality 
control samples were analysed alongside.  Three out of four correct values were 
required for batch acceptance with a pass for at least one duplicate at each level. The 
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lowest level quality controls were required to fall within a ±20% error range and the 
other two within ±15%. The LLOQ of the assay was 125 pgmL-1.  
Percentage error, mean, coefficient of variation (CV) and relative error (RE) were 
calculated for each analyte at each calibration and quality control level for all batches 
analysed. Acceptance criteria were ±15% for all criteria. These tabulated values are 
detailed in Appendix III. 
 
Example calibration data for 5α-androstane-3β,17β-diol and table showing calculated 
amounts from quality control samples 
aBB_Adiol
0 2 4 6 8
ng/ml
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
A
re
a 
R
at
io
 
Equation: Y = 0.00344154+0.048*X   R^2 = 0.999 
 
Sample Specified Amount Calculated Amount % Difference 
LOW A 0.375 ngml-1 0.387 ngml-1 3% 
LOW B 0.375 ngml-1 0.368 ngml-1 2% 
HIGH A 3.000 ngml-1 3.084 ngml-1 3% 
HIGH B 3.000 ngml-1 3.169 ngml-1 6% 
 
Details and values for the quantitative assay quality control and precision and accuracy 
data are shown in Appendices IV and V.  
 
LLOQ = 125pgml-1 
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5.3.6 Oestrus Cycle Endogenous Steroid Profiles: Results 
Urine samples from a total of 33 greyhounds were analysed throughout their oestrus 
cycle in order to determine the basal levels for each target analyte. The testosterone 
metabolites were quantified using calibration standards prepared from certified 
reference standards.  However, due to the fact that there were no authentic reference 
standards available for the progesterone metabolites, a semi-quantitative analysis was 
performed and area ratios were calculated against the deuterated internal marker for the 
major progesterone metabolite (M1) detected in urine. This provided a trend for the 
relative amounts of progesterone metabolite that were excreted throughout the oestrus 
cycle for each animal.  The raw data values for each analyte, in each individual bitch 
analysed, are shown in Appendix VII. 
Figure 5.27 shows the results of the quantitative analysis of the daily sampling profile 
for Black Pansy. The daily sampling data enabled a clear picture of the steady rise in 
testosterone metabolites, in the lead up to the onset of oestrus, to be displayed. It is felt 
that the peak maximum level for testosterone may well be linked to the marked 
increase in secretion of LH prior to ovulation. However, it was not possible to establish 
a direct time link, as no commercial kit was available for the analysis of LH in canine 
urine. It has also been suggested that intact LH is not excreted into canine urine, which 
may explain the lack of available urinalysis LH kits available on the market[16]. 
However, data has been published relating to the detection of LH in both plasma and 
urine using a plasma RIA, with some apparent success, although no androgen data was 
obtained, precluding any direct link being made between the two analytes[17]. An 
oestradiol analysis in the cycle urines might provide some insight in the future, bearing 
in mind the link between the rapidly decreasing levels of oestradiol and the pre 
ovulatory LH surge. Figures 5.27 to 5.34 illustrate the quantitative excretion profiles of 
the major testosterone metabolites and semi-quantitative profiles of the major 
progesterone metabolite throughout the oestrus cycle of a selection of individual 
animals. The remaining profiles are located in appendix VI. N.B. The timeframe 
between urine sample collections (i.e. several days) means that the maximum 
concentration observed for the major androgen metabolites e.g. 5α-androstane-3α,17β-
diol and epiandrosterone may well be less than the maximum concentration actually 
reached in urines that would have been voided on days just before or just after the urine 
sample with the highest concentration of metabolite in the profiles. 
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Oestrus Cycle: androgen and progesterone metabolite profiles - Black Pansy (Daily sampling)
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Figure 5.27
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Oestrus Cycle: androgen and progesterone metabolite profiles - Black Pansy
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Figure 5.28 
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Oestrus Cycle: androgen and progesterone metabolite profiles - Queen of Stout 
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Figure 5.29 
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Oestrus Cycle: androgen and progesterone metabolite profiles - Full Nosey
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Figure 5.30 
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Oestrus Cycle: androgen and progesterone metabolite profiles - Winefell Nikita
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Figure 5.31 
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Oestrus Cycle: androgen and progesterone metabolite profiles - Fair Head
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Oestrus Cycle: androgen and progesterone metabolite profiles - Lochbo Amy
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
0 20 40 60 80 100 120 140 160 180 200
Time (days post recorded onset of season)
A
nd
ro
ge
n 
co
nc
en
tr
at
io
ns
 (n
g/
m
l)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
A
re
a 
ra
tio
 o
f p
ro
ge
st
er
on
e 
m
et
ab
ol
ite
testosterone
epitestosterone
aBB_Adiol
epiandrosterone
BaB_Adiol
etiocholanolone
Progesterone metabolite
  
Figure 5.33 
   
149 
 
Oestrus Cycle: androgen and progesterone metabolite profiles - Flo Jo
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5.3.7 Oestrus Cycle Endogenous Steroid Profiles: Interpretation 
The data generated from the population of bitches analysed has produced some trends 
for a large percentage of the population, but has also served to show that there appears 
to be marked variation from one animal to another in relation to the hormone activity in 
a given oestrus cycle. This is not necessarily that unusual, given the general knowledge 
of the greyhound’s oestrus cycle[1,8,9,10,11]. Examples of the oestrus cycle profiles are 
shown in figures 5.27 to 5.34. The remaining profiles are shown in appendix VI.  
 
In most of the bitches the urinary androgen profiles were characterised by a marked 
increase in epiandrosterone and 5α-androstane-3α,17β-diol approximately 7 days into 
oestrus. It is reasonable to interpret that these metabolites are most likely derived from 
the surge in circulatory testosterone and androstenedione linked with the surge of LH 
prior to ovulation[3]. That being the case, it is therefore interesting to observe that in 
nearly all the bitches, the surge in epiandrosterone and 5α-androstane-3α,17β-diol is not 
accompanied by an equivalent surge in levels of 5β-androstane-3α,17β-diol. All three 
metabolites are excreted in similar quantities to one another, following the 
intramuscular administration of testosterone to the greyhound bitch (see chapter 4). 
This is likely to arise as a result of liver metabolism of the circulating levels of 
testosterone present following the drug administration. As such, it would be reasonable 
to assume that the liver would metabolise circulating testosterone, related to ovulation, 
in the same way, but this does not appear to be the case in the bitch during oestrus. 
Following the surge in metabolites there follows a period of several months of slightly 
elevated excretion of epiandrosterone and 5α-androstane-3α-17β-diol (see figure 5.28). 
These levels return to basal during anoestrus, i.e. when progesterone levels have 
returned to basal, signalling the end of the luteal phase of the cycle. The levels 
therefore appear to be linked with the duration of excretion of progesterone in di-
oestrus. In this case these metabolites are likely to be derived from metabolism of 
androstenedione which is thought to be prevalent throughout di-oestrus in the 
greyhound[3]. Once again there is very little 5β-androstane-3α,17β-diol excreted by 
comparison to the other two metabolites.  
The difference in metabolism during the oestrus cycle compared with drug 
administration may be linked to the activity of 5α- and 5β- reductases and their relative 
tissue locations. No significant quantities or indeed changes in level of urinary 
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testosterone itself were observed throughout the cycle. The androgen profiles were 
considered ‘normal’ when similar to those discussed, e.g. profiles such as that obtained 
for Black Pansy (Figure 5.28), Queen of Stout (Figure 5.29), Full Nosey (Figure 5.30), 
Fair Head (Figure 5.32) and Flo Jo (Figure 5.34). 
The lack of 5β reduced metabolites could be indicative of an alternative substrate to 
testosterone entering the circulation during the androgen surge to produce primarily 5α 
metabolic products. This could be androstenedione. Following the administration of 
testosterone to the bitch, 5α and 5β metabolites were produced in similar amounts and 
the ratio 5α:5β was similar throughout the excretion profile (see chapter 4 Figures 4.7 
and 4.8). Thus, following administration of testosterone, it appears that the metabolic 
process, to induce alternative pathways, is not influenced by changes in circulating 
levels of testosterone. This would imply that the liver is not switching to 5β reductase 
activity due to saturation of 5α-reductase pathways, following an administration of 
testosterone. There is no ‘lag phase’ of induction of 5β activity in the drug 
administration, as 5β-androstane-3α,17β-diol is excreted in equal quantities to the 5α 
metabolites at 2 hours post dose. 
Another explanation might be that androstenedione is indeed the majority androgen 
released from the ovary at the time of the surge and that it is then preferentially 
metabolised by 5α reductase in the canine liver. The structural specificity of this 
enzyme in the canine may be different than other species. The oral administration of 
androstenedione in humans, certainly gives rise to a large amount of 5β reduced 
metabolites excreted in the urine[18]. It seems unlikely that the liver would metabolise 
androstenedione in a different way when presented with it via the hepatic portal vein as 
opposed to the hepatic artery, but there are no known studies of intravenous 
androstenedione administration to the greyhound of which the author is aware that 
could provide the answer. It is also not known whether the androstenedione and/or 
testosterone that enter the circulation from the developing theca cells in the ovarian 
follicle are in the free form or bound to protein or sulphate, which would influence their 
ability to be metabolised. The data from this longitudinal cycle study certainly supports 
the observation that 5β-androstane-3α,17β-diol was undetectable in 80% of the samples 
analysed in the population study. 
The progesterone metabolite profiles rose steadily following the first week of sample 
collection and remained elevated for up to three months in many of the bitches profiled. 
This was interpreted as a successful ovulation, as the developing corpora lutea for these 
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animals should continue to secrete progesterone for this length of time. Where levels 
returned to basal at approx 90-100 days the bitch was considered to have had a 
‘normal’ cycle. Based upon these criteria, observations for the bitches profiled are 
listed in Table 5.4 and Table 5.5 provides a summary of interpretations and trainer 
observations (where applicable) for the oestrus cycle of each animal. 
 
Table 5.4: Observations from the urinary profiles of the population of cycling bitches 
Bitch name 
(listed in data profile 
report order) 
“Normal” 
androgens 
“Normal” 
progesterone 
metabolite (P-M1) 
levels 
Max androgen 
conc. above 
postulated 
threshold 
Progesterone: 
Ratio of max P-M1 
level vs basal P-M1 
level 
Black Pansy   No 100:1 
Queen of Stout   Yes 50:1 
Suitable Choice   No 300:1 
Full Nosey   (No) 100:1 
Fair Head   Yes 100:1 
Lochbo Amy   Yes 30:1 
BPIMA   No 60:1 
Saunders Pet   No 150:1 
Whitefort Euro   Yes 100:1 
Flo Jo   (No) 150:1 
Tonightsthenight   No 50:1 
Miss Honcho   Yes 75:1 
Giveherthevote   Yes 75:1 
Ringlestown Flos   Yes 35:1 
Langies Posh Girl   No 50:1 
Queen Boadicea   No 12:1 
Queen of the Bar   (No) 100:1 
Little Reaction   Yes 50:1 
BPXYP   No 400:1 
Cannon Clover () () (No) 75:1 
Wideopenspaces () () No 30:1 
Standard Whisper   No 150:1 
Chop and Change ?  Yes 70:1 
Supreme Madonna ()  No 25:1 
Distant Pearl ?  (No) 50:1 
Marshalls Promise ?  No 150:1 
Sparky Pacific () () No 400:1 
Cullane Chief  ? (No) 2:1 
Drumpark Access   No 20:1 
Queen Sally   No 50:1 
Whinefell Nikita   (No) 50:1 
The Alarm’s On   No 25:1 
Bolly for Molly (P) ? ? No 125:1 
(No) = level below but close to the postulated threshold for αββ-A-diol in urine.
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Table 5.5: Summary of interpretations observations including season dates for all bitches in the cycling programme (I) 
Bitch Season 1 Season 2 Cycle length Comments 
Black Pansy 31-Jul-05 12-Mar-06 224 Normal 
Black Pansy(2) 12-Mar-06 22-Nov-06 255 Normal 
BollyforMolly 15-Jan-07 12-Sep-07 240 Mated D12, had pups D75 
Bonny BPIMA 04-Aug-05 30-May-06 299 very oscillating androgen and progesterone 
Cannon Clover 09-May-07 19-Feb-08 286 
?anovulation  2nd heat was silent as trainer did not report in season  
and very long subsequent luteal phase 100+ to 200+ 
Chop & Change 08-Mar-06 10-Nov-06 247 biphasic and anovulatory 
Cullane Chief 10-Dec-05 02-Jun-06 174 very variable progesterone profile 
distant pearl 24-Mar-07 05-Jul-08 469 very short luteal phase. Androgens biphasic - ?non ovulator 
Drumpark access 24-Jul-07 22-Mar-08 242 very odd androgens during luteal phase / early completion 
Fair Head 16-Jan-07 15-Sep-07 242 Normal (S.G.readings account for Progesterone M1 dip @D29) 
FloJo 12-Jun-06 22-Nov-06 163 Normal 
Fully Nosey (Daisy) 10-Nov-06 01-Sep-07 295 Normal 
Giveherthevote 17-Mar-07 19-Dec-07 277 Normal 
Honeywick Cleo 28-Sep-05 not known 224  
jess BPXYP 31-Jul-05 12-Mar-06 255 prolonged androgens and short luteal phase 
Langies Posh Girl 12-Mar-06 22-Nov-06 240 activity before return season 
Little Reaction 15-Jan-07 12-Sep-07 299 Normal 
Lochbo Amy ALDLH 04-Aug-05 30-May-06 286 Activity before return season. Oscillating progesterone 
marshall's promise 09-May-07 19-Feb-08 247 Normal although Progest. bit short? Split heat with 1st bit silent? 
Miss Honcho EDH9 08-Mar-06 10-Nov-06 174 Normal 
Posh Girl Honey 10-Dec-05 02-Jun-06 469  
 154 
Table 5.5: Summary of interpretations observations including season dates for all bitches in the cycling programme (II) 
Bitch Season 1 Season 2 Cycle length Comments 
Queen Boadicea 24-Mar-07 05-Jul-08 242 Ovulation before signs of season 
Queen of Stout 04-Oct-05 21-May-06 229 Normal 
Queen of the Bar 12-Dec-05 03-Jul-06 203 Normal 
Queen Sally 07-Jan-06 
no return 
for 2 years  
No return – died about 2 years later. Silent heat – non-ovulatory at 
about 250 days. 
Ringlestown Flos 09-Jul-05 28-Feb-06 234 Normal 
Riverview Gypsy 21-Apr-08 13-Feb-09 298  
Riverview Slick 11-Feb-08 03-Aug-08 174  
Saunders Pet 25-Jul-05 31-Mar-06 249 Normal 
Sparky Pacific 17-May-07 26-Dec-07 223 Normal 
Standard Whisper 02-Mar-06 20-Sep-06 202 Normal 
Suitable Choice 03-Aug-05 03-Mar-06 212 Normal 
Supreme Madonna 23-Aug-07 28-Apr-08 249 
Androgen activity in anoestrus – follicular activity ?silent split 
heat? 
The alarms on 23-Sep-05 02-Jul-06 282 Silent heat about 100days after premature luteal regression 
tonightsthe night 03-Sep-06 13-May-07 252 Normal 
Uluru Baby 15-Jun-07 28-Apr-08 318 Not analysed 
Whinfell Nikita 29-Jan-07 20-Sep-07 234 
Follicular activity about day 130 ?Silent anovulatory heat (S.G. 
readings account for dips in progesterone) 
Whitefort Euro 26-Nov-05 07-Sep-06 285 Normal 
Wideopenspaces 20-Mar-07 11-Sep-07 175 Fair bit of androgen activity during luteal and anoestrus phases 
     (Average Cycle duration: 253 days) 
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The profiles for some of the bitches gave some markedly fluctuating values at certain 
time points during the oestrus cycle. Some of these could be explained in relation to the 
level of diuresis observed in some of the urine samples compared with other samples in 
the longitudinal profile which has clearly had an impact on the concentrations of steroid 
analytes detected during the analysis. Specific Gravity measurements were taken for 
the profiles of some of the bitches, where dramatic changes in analyte levels were 
observed and difficult to rationalise. As an example Figure 5.35 shows the specific 
gravity (S.G.) readings for each sample in the cycle of the greyhound Fair Head (profile 
in figure 5.32), plotted alongside her progesterone metabolite profile. The SG reading 
at day 29 shows the effect of the marked diuresis for that urine sample on the level of 
analyte recorded. This profile was therefore interpreted as ‘normal’ without the need to 
rationalise why there may have been a marked dip in progesterone at that stage of the 
bitch’s cycle. The ‘normalised’ profile is shown in figure 5.36. Specific gravity values 
have shown good correlation with hormone levels in previous studies[19]. 
 
Oestrus Cycle: progesterone metabolite profile and Specific gravity - Fair Head
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Figure 5.35: Progesterone metabolite (M1) profiled with Specific Gravity (S.G.) values 
 
This marked diuresis was apparent for several other samples in a number of other 
greyhounds; Suitable Choice day 29 (Appendix VI); Saunders Pet day 46 (Appendix 
VI); Full Nosey day 81 (Figure 5.30); Chop and Change day 50 (Appendix VI); 
Langies Posh Girl day 40 (Appendix VI); Lochbo Amy day 195 (Figure 5.33) and 
Whinfell Nikita days 53 and 74 (Figure 5.31). 
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Figure 5.36: Progesterone metabolite (M1) profile normalised with Specific Gravity 
(S.G.) values for greyhound bitch Fair Head. 
 
However, not all of the unusual observations could be explained by specific gravity, not 
least for the last named bitch, Whinfell Nikita. This was only one of only two bitches to 
excrete higher than average levels of 5β-androstane-3α,17β-diol at certain time points 
during her cycle. The first was at day 4. This sample gave an S.G reading off the scale 
on the refractometer, as it was extremely concentrated and above the top end of the 
normal clinical range for dogs of 1.065[19]. The second unusual sample was at day 129. 
This sample gave a normal S.G. reading in line with all the samples voided before and 
after. It was also re-analysed to check the concentrations of the androgens observed 
resulting in similar levels being quantified. This could represent a silent anovulatory 
heat, as no rise in progesterone was observed and no information was forthcoming from 
the trainer in relation to change in behaviour for this animal at the time of sampling. 
Despite this being unusual, the concentration of 5β-androstane-3α,17β-diol was no 
greater than10ng/ml at the time of sampling. This animal did appear to exhibit a greater 
propensity for excreting 5β-reduced metabolites overall. It could be that she has a 
particular condition resulting in this enzyme activity. 
What did appear to be relatively ‘normal’ as it did occur in a number of bitches was the 
appearance of small quantities of 5β-androstane-3α,17β-diol at the point of the 
androgen surge. This was also observed for Lochbo Amy (Figure 5.33), but on day 195, 
which actually represented the first sample collected at the onset of her next season.  
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As previously discussed, the normal reproductive cycle of the bitch consists of a 
number of endocrinologically distinct parts, namely pro-oestrus, oestrus, di-oestrus and 
anoestrus. Of these, only the first two are detectable clinically, lasting on average 21 
days and indicated by bleeding and attractiveness to male dogs. Di-oestrus, the 
progesterone producing phase, lasts about two to three months and the balance of the 
cycle is made up of anoestrus. 
It is considered that if the bitch ovulates and therefore enters di-oestrus, the cycle 
length cannot be less than about four months.  An interval less than this, is usually 
suspected as being either a split heat, a condition which is relatively common and 
presents as a bitch entering into a normal cycle which then stops and the bitch does not 
ovulate. This is then followed by a full, normal cycle, some 1-2 months later[20]. This 
was apparent for the bitch The Alarms On (Appendix VI). Clinically it is considered 
that bitches should cycle at least every 12 months and if it longer than this, the bitch 
has either been treated with hormones or may have some underlying physiological 
issue. 
The results of the longitudinal sample collection and analysis throughout the oestrus 
cycle in this study have shown that urinary testosterone/androstenedione metabolites 
are elevated significantly during the early part of the cycle. Figures 5.37 to 5.40 show 
consolidated data plots (Box and Whisker plots) of the combined data for all 33 bitches 
in the longitudinal cycling study. These data show the considerable variation between 
animals that is apparent when measuring hormone concentrations. The elevated 
metabolite level trends at the early part of the cycle coincide with the current 21-day 
lay-off rule operated by the greyhound regulatory authority, where a bitch is not 
permitted to race for the first 3 weeks after the commencement of her oestrus cycle. 
The original population study to determine suitable threshold values for androgen 
metabolites (Chapter 4), contained some animals that were known to be in season at the 
time of their sampling. Therefore, as these samples represent animals that should not be 
on the racetrack, it was considered that they should be removed from the dataset prior 
to statistical analysis, such that the final dataset is more representative of the actual 
racing population available to be sampled at the racetrack. 
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Figure 5.37: Box and whisker plot of epiandrosterone levels in 33 bitches throughout the entire oestrus cycle. 
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Figure 5.38: Box and whisker plot of 5a-androstane-3B,17B-diol levels in 33 bitches throughout the entire oestrus cycle. 
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Figure 5.39: Box and whisker plot of 5B-androstane-3a,17B-diol levels in 33 btches throughout the entire oestrus cycle. 
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Figure 5.39: Box and whisker plot of progesterone M1 metabolite levels in 33 btches throughout the entire oestrus cycle. 
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The results from this cycling study, and those from an adjoining study, on short term 
suppression of oestrus in racing bitches (Chapter 1[24]), reinforce the fact that 
greyhound bitches can, and indeed do, have an incidence of both split heat and silent 
heat. These phenomena are clearly not uncommon considering the size of the 
populations involved in the oestrus cycle studies, where at least 10% of the animals 
appeared to have a ‘non-standard’ cycle (as defined by the urinary profiles of the 
majority of the animals), including two animals that clearly had silent heats, as they 
went through an entire ‘hormonal cycle’ unbeknown to their trainers. 
Whilst there is no reason to suspect any of the trainers involved in the cycling study of 
wilfully administering any drugs to their animals at any stage, without declaration, it 
should be noted that in essence, the data has been acquired from a non-scientifically 
controlled environment. However, such a collection of data may well not have been 
possible at all, without the co-operation of such a large number of trainers. 
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5.4 CONCLUSIONS 
 
The greyhound bitch has been studied throughout her oestrus cycle to determine 
reference concentrations of steroid hormones during this time.  
When considering that the average cycle time for the bitch is considered to be 8-9 
months, then a number of the bitches observed in this study appeared to conform to 
this. The study is the first of its kind to look at the urinary metabolites of testosterone 
and progesterone throughout the entire cycle of greyhound bitches. Knowing that the 
cycle is already a variable one from animal to animal and indeed within a particular 
animal then it is not straightforward to say what constitutes ‘normal’ for the urinary 
profile. However, there would appear to be a number of bitches that have shown 
profiles that could be proposed as normal/reference profiles in relation to existing 
knowledge.  
Following on from the original testosterone metabolite population study (chapter 4) one 
of the main aims of this study was to establish whether or not there were particular time 
points in a bitch’s cycle where urinary testosterone metabolite levels could be expected 
to be elevated. The answer to this question has been provided by this work. At the onset 
of the cycle there are marked increases of urinary testosterone metabolite levels within 
the first week in most of the bitches analysed. The metabolites that were elevated were 
primarily the 5α-androstane-3β,17β-diol and epiandrosterone, with a slight elevation in 
5β-androstane-3α,17β-diol in one or two instances. The levels are elevated for a period 
of about 7-10 days. This is best shown in Black Pansy’s profile (Figure 5.27) where 
daily sample collections were available for analysis. As samples were collected 
intermittently (twice a week) for the majority of the animals in the scheme the peak 
maximum levels observed at the time of the testosterone surge cannot be assumed to 
represent the maximum as this may have been reached on one of the days in between 
sample collections.  
The elevated level of androgen metabolites is probably related to the LH surge that 
occurs prior to ovulation in the bitch as a result of the shut-down in production of 
oestrogens, resulting in a surplus of substrates that are no longer converted to 
oestrogen.  
Under the current rules greyhound bitches should not be racing for 21 days after the 
onset of their seasons, which would mean that they should not be sampled at the track 
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during this time and therefore would not present a false positive result for elevated 
testosterone metabolites. This is based on the assumption that the animal has exhibited 
external signs of coming into season during pro-oestrus to the trainer and/or the 
racetrack veterinary steward.  
Lochbo Amy (Figure 5.33), Tonightsthenight, Little Reaction, Wideopenspaces, 
Marshalls Promise, Cullane Chief, Drumpark Access, Queen Sally and The Alarms On 
(all figures in Appendix VI), were all bitches that either did not show an obvious surge 
in androgens or did, but it may have been at maximum the day before the first sample 
collection. This may be due to the bitch not showing visible signs of being in season or 
may simply be related to the sampling regime and the time that the trainer/handler was 
available to inspect the animals. Nevertheless some consideration needs to be given to 
the possibility that a bitch may undergo a ‘silent heat‘ that results in her being at the 
races and available for testing when her urine might contain levels of androgen 
metabolites that would be above a proposed threshold for a positive finding. Such a 
finding could be overcome by collecting a subsequent urine sample 2 to 3 weeks later 
and checking for the presence of elevated progesterone metabolites to indicate that the 
bitch had ovulated.  
However, although informative for some animals this would not be a completely 
failsafe approach, as indicated by the progesterone metabolite profiles for some of the 
bitches in the scheme, where the levels of progesterone were variable at this time. This 
was most apparent for Cannon Clover (Appendix VI), who appeared to undergo a 
possible premature luteal regression as her progesterone metabolite levels returned to 
basal for two months after her initial testosterone surge, implying that she had either 
not ovulated or that she had ovulated but there was no subsequent development of a 
corpus luteum. A few of the bitches also showed variable testosterone metabolite levels 
at certain times during anoestrus (Distant Pearl, Marshalls Promise, Queen Sally, 
Whinfell Nikita). Of these Whinfell Nikita and Queen Sally displayed the most unusual 
elevations of metabolites. Repeat analyses of the urine samples showed these values to 
be correct. Whinfell Nikita’s profile (Figure 5.31) is probably of greatest interest in 
relation to the levels of 5β-androstane-3α,17β-diol (βαβ-diol), observed at 4 and 130 
days in the cycle. These are the two highest values observed for any untreated animal in 
this study as well as those analysed during the population study of more than 200 
urines. However, the values are still below the ‘action’ and threshold levels tentatively 
proposed from the testosterone population study. The levels of epiandrosterone 
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observed for some of the bitches at the point of their androgen surge are close to the 
proposed threshold level for epiandrosterone. Whether it is possible for this level to be 
breached during a silent heat is not known. It could be that silent or split heats are 
characterised by different levels of hormones, but should that be proved, it would 
almost certainly be variable from one bitch to another.   
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6. CONCLUSIONS 
 
Gas chromatography-mass spectrometry and selected derivatisation techniques have 
been applied to the identification and structural elucidation of anabolic and 
progestagenic steroids in the greyhound. Coupled with a variety of sample extraction 
and preparation methods, the successful use and value of these techniques, for the study 
of steroid metabolism, has been demonstrated in this thesis. 
The requirement to control the use of various steroidal preparations in racing 
greyhounds, and in particular greyhound bitches, from both a regulatory and a welfare 
perspective, has been discussed throughout, and this need has directed the vast majority 
of the work that has been carried out in this body of research. 
Following the administration of proprietary steroid preparations to the greyhound, urine 
samples were collected and prepared for analysis using solid phase and liquid-liquid 
extraction techniques. After oral administration of methyltestosterone to the greyhound, 
several metabolites were identified, including reduced, mono-, di- and tri-hydroxylated 
steroids. The major metabolites observed were 17α-methyl-5β-androstan-3α-17β-diol, 
17α-methyl-5β-androstan-3α,16α,17β-triol and a further metabolite tentatively 
identified as 17α-methyl-5z-androstan-6z,17β-triol. The most abundant of these was 
the 17α-methyl-5β-androstan-3α,16α,17β-triol. This metabolite was identified by 
comparison with a reference standard synthesised using a Grignard procedure and 
characterised using trimethylsilyl (TMS) and acetonide-TMS derivatisation techniques. 
The structures of the major metabolites 17α-methyl-5β-androstan-3α-17β-diol and 
17α-methyl-5β-androstan-3α,16α,17β-triol have been fully elucidated. There did not 
appear to be any evidence for 16β-hydroxylation as a phase one metabolic 
transformation in the greyhound. However significant quantities of 16α-hydroxy 
metabolites were detected. Selective enzymatic hydrolysis procedures indicated that the 
major metabolites identified were excreted as glucuronic acid conjugates and their 
detection and identification in urinary extracts by mass spectrometric techniques will 
provide an effective approach to screening and confirmatory analysis for the control of 
methyltestosterone use in the greyhound. 
Similar approaches were used to identify urinary metabolites of norethisterone, a 
progestagenic compound recently permitted for use as an oestrus suppressant by the 
GBGB. Following oral administration to the greyhound, several metabolites were 
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identified including reduced, mono-, di- and tri-hydroxylated steroids. The major 
metabolites observed were 17α-ethynyl-5β-estrane-3α,17β-diol, 17α-ethynyl-5α-
estrane-3β,17β-diol, three 17α-ethynylestranetriol stereoisomers and two 17α-
ethynylestranetetrol stereoisomers. The major metabolites were predominantly excreted 
as glucuronic acid conjugates, as observed for methyltestosterone, and detection of the 
administration of norethisterone was possible for up to 8 days post dose using the 
methods described. The nandrolone metabolites, 19-norepiandrosterone and 19-
noretiocholanolone were also identified in the post administration urine samples 
collected up to 8 hours after dosing the treated animals. The detection of these 
metabolites resulted in an investigation into minor contaminants of the norethisterone 
tablet preparation itself, which included nandrolone and 19-norandrostenedione. Their 
presence was considered the most likely cause for the detection of 19-
norepiandrotserone and 19-noretiocholanolone in the post administration urines. 
The urinary metabolites identified in these two particular studies have provided an 
understanding of the in vivo phase I metabolism of methyltestosterone and 
norethisterone in the greyhound. The metabolic pathways include reduction of the 4-
ene-3-one group of the A-ring, and oxidations at C16 and probably C6. The 5α3β and 
5β3α stereochemistry of the fully A-ring reduced metabolites is comparable to the 
stereochemistry of the major metabolites observed in the metabolism of testosterone in 
the greyhound namely, epiandrosterone, 5β-androstane-3α,17β-diol and 5α-androstane-
3β,17β-diol. The urinary metabolites identified in these studies have therefore further 
enhanced the general knowledge of steroid metabolism in the greyhound, providing 
information to support routine drug testing programmes. 
To support the detection of the naturally occurring endogenous hormone testosterone, a 
quantitative GC-MS method was developed to determine the concentrations of the 
major metabolites of testosterone in a population of “normal” untreated animals. These 
data were compared with results from the analysis of post-administration urine 
samples, following the intramuscular administration of testosterone esters to the 
greyhound.  Some approaches for statistical treatment of the population data have been 
proposed to establish threshold values for the major metabolites, with a view to 
providing a routine methodology for discriminating between ‘normal’ and ‘positive’ 
post administration samples, thereby detecting the abuse of testosterone in the racing 
greyhound bitch. 
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During the course of the analysis of the normal population samples it became apparent 
that the metabolites of testosterone were potentially elevated at certain stages of the 
oestrus cycle in the greyhound bitch. Therefore in order to provide a greater 
understanding of the profile of endogenous hormones in the bitch, the major 
metabolites of testosterone and progesterone were quantified throughout the entire 
oestrus cycle in a population of 33 greyhound bitches. 
A preliminary study of the metabolism of progesterone resulted in the identification of 
a suitable pregnanetriol metabolite to monitor alongside the androgen metabolites, 
thereby providing information on the hormonal status of the bitch at the various stages 
of her cycle. A normal progesterone profile, i.e. the excretion of progesterone 
metabolites for two to three months, provided likely indications that ovulation had 
occurred. 
The results of the study clearly indicate a surge in androgen metabolites during the first 
7-10 days of the oestrus cycle, in particular epiandrosterone and 5α-androstane-3β,17β-
diol, both of which are 5α reduced analytes. The stereo chemistries of the metabolites 
observed have indicated that the source of these metabolites may well be 
androstenedione as opposed to testosterone. This conclusion was drawn due to the fact 
that only minor amounts of 5β-reduced metabolites were observed in the majority of 
bitches during their normal oestrus cycles. However, the 5β-reduced metabolite, 5β-
androstane-3α,17β-diol was observed in significant, and equal quantities to the 5α 
metabolites following the administration of testosterone to the greyhound bitch. It is not 
known whether the canine liver metabolises androstenedione in a different manner to 
testosterone and the possibility of other androgens being released from the ovary 
cannot be ruled out, although most serum based studies in this area of research suggest 
testosterone and androstenedione to be the major androgens. 
The androgen surge takes place during the current 21 day layoff period enforced by the 
rules of the GBGB, once the bitch comes into season. In some animals the peak levels 
of 5α-androstane-3β,17β-diol and epiandrosterone, at this time were close to the 
proposed action level/threshold for the detection of testosterone administration. 
Many of the bitches involved in the study showed similar trends in their longitudinal 
steroid profiles and the data from these animals has been considered to represent the 
profile of a bitch going through a ‘normal’ oestrus cycle of known average length. 
There are also several examples amongst the population of where the steroid profiles 
are variable, with some animals showing signs of having had either a silent heat or a 
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split heat. This is not unusual for greyhound bitches and the resulting variation in 
steroid profiles needs significant consideration in relation to future data interpretation 
as part of routine drug screening. 
This thesis contains a unique set of data and is the first of its kind relating to the study 
of urinary steroid profiles in greyhound bitches. The data acquired is invaluable in 
relation to increasing the understanding of the hormonal status of racing bitches at 
various times throughout the racing calendar and it may even be possible with good 
record keeping to maintain a database of longitudinal values obtained from particular 
greyhounds of interest to the racing authorities. This may help to increase the ability of 
the authorities to direct their sampling strategy in relation to suspicious findings for 
particular animals or indeed trainers.  
Due to the complexity and variability of the hormonal profile in certain animals 
observed in this study, urinary thresholds and/or action levels may prove challenging, 
though not insurmountable, in relation to providing a relevant and useful detection 
period following testosterone administration. The key analyte appears to be the 5β-
androstane-3α,17β-diol (βαβ-diol). Further work with more sensitive methods may 
provide a more workable and useful threshold level for this metabolite, and this will 
definitely be suggested. 
It may also be of interest to investigate the detection of intact testosterone esters in 
canine plasma as a potential associated means of detecting testosterone administration 
to the greyhound. This will also be of interest in relation to testosterone abuse in the 
male greyhound as well.  
Another approach may be the use of carbon isotope ratio mass spectrometry to evaluate 
whether the androgen metabolites detected above an implemented action level to 
highlight suspicious samples, are actually from an exogenous source. This technique is 
powerful but by no means mainstream in the industry as yet. 
  
Detecting the administration of endogenous hormones to animals is probably one of the 
greatest analytical challenges faced by testing laboratories. The greyhound bitch is no 
exception, but the data obtained from this study have provided a firm foundation on 
which to base a future testing strategy both in the UK and internationally. 
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APPENDIX III: QUALITY CONTROL AND PRECISION AND 
ACCURACY DATA FROM QUANTITATIVE TESTOSTERONE 
METABOLITE ASSAY. 
 
βαβ-Androstanediol: 
βαβ-Androstanediol βαβ-Androstanediol βαβ-Androstanediol R2 Batch 
QC Low 0.375ng/ml QC Med 3.000ng/ml QC High 12.000ng/ml   
Amount %Error Amount %Error Amount %Error   
0.400 7% 3.268 9% 11.579 -4% 0.9952 1 
0.390 4% 3.051 2% 12.230 2%   
0.445 19% 3.045 2% 11.643 -3% 0.9978 2 
0.391 4% 3.182 6% 11.397 -5%   
0.306 -19% 2.878 -4% 11.493 -4% 0.9966 3 
0.384 2% 2.631 -12% 11.683 -3%   
0.408 9% 2.956 -1% 11.790 -2% 0.9992 4 
0.364 -3% 2.836 -5% 11.027 -8%   
0.386  2.981  11.605  Mean 
0.040  0.202  0.343  Std Dev 
10.312  6.787  2.954  %CV 
2.933  -0.638  -3.290  %RE 
 
 
Epiandrosterone: 
Epiandrosterone: Epiandrosterone: Epiandrosterone: R2 Batch 
QC Low 0.375ng/ml QC Med 3.000ng/ml QC High 12.000ng/ml   
Amount %Error Amount %Error Amount %Error   
0.410 9% 3.155 5% 12.716 6% 0.9984 1 
0.420 12% 3.188 6% 12.902 8%   
0.323 -14% 2.866 -4% 12.000 0% 0.9988 2 
0.331 -12% 2.938 -2% 13.545 13%   
0.384 3% 3.011 0% 11.876 -1% 0.9992 3 
0.372 -1% 2.892 -4% 12.193 2%   
0.314 -16% 3.146 5% 12.534 4% 0.9990 4 
0.317 -15% 3.161 5% 13.397 12%   
0.359  3.045  12.645  Mean 
0.043  0.133  0.618  Std Dev 
12.001  4.376  4.885  %CV 
-4.300  1.488  5.378  %RE 
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αββ--Androstanediol: 
αββ--Androstanediol: αββ--Androstanediol: αββ--Androstanediol: R2 Batch 
QC Low 0.375ng/ml QC Med 3.000ng/ml QC High 12.000ng/ml   
Amount %Error Amount %Error Amount %Error   
0.384 2% 3.434 14% 13.527 13% 0.9970 1 
0.432 15% 3.441 15% 14.265* 19%*   
0.400 7% 2.961 -1% 12.538 4% 0.9976 2 
0.386 3% 3.227 8% 12.276 2%   
0.315 -16% 3.176 6% 12.850 7% 0.9922 3 
0.401 7% 2.989 0% 12.854 7%   
0.374 0% 3.059 2% 12.411 3% 0.9987 4 
0.376 0% 3.070 2% 12.943 8%   
0.384  3.170  12.772  Mean 
0.033  0.187  0.4170  Std Dev 
8.691  5.905  3.265  %CV 
2.267  5.654  6.427  %RE 
 
βαβ-Androstanediol: 
Batch 0.250ng/ml 0.500ng/ml 1.000ng/ml 2.000ng/ml 4.000ng/ml 8.000ng/ml 16.000ng/ml 
1 0.311 0.292 0.580 0.545 1.025 0.982 1.828 1.905 4.159 3.609 8.605 7.754 16.743 15.162 
2 0.245 0.266 0.556 0.542 1.126 1.080 1.958 2.064 3.880 4.041 8.239 7.246 16.418 15.840 
3 0.268 0.273 0.501 0.521 0.948 0.913 2.036 1.942 4.156 3.859 8.857 7.293 16.104 15.828 
4 0.199 0.179 0.415 0.451 1.007 0.989 2.013 1.910 4.019 4.258 7.888 8.341 15.734 16.098 
Mean 0.254 0.514 1.009 1.957 3.998 8.029 15.991 
Std 
dev 0.045 0.056 0.069 0.078 0.209 0.587 0.474 
%CV 17.676 10.873 6.812 3.987 5.225 7.308 2.966 
%RE 1.650 2.775 0.875 -2.150 -0.060 0.349 -0.057 
 
Epiandrosterone 
Batch 0.250ng/ml 0.500ng/ml 1.000ng/ml 2.000ng/ml 4.000ng/ml 8.000ng/ml 16.000ng/ml 
1 0.260 0.276 0.549 0.610 1.085 0.995 2.010 1.996 4.030 3.979 8.040 7.409 16.457 15.805 
2 0.178 0.200 0.431 0.445 0.993 0.969 1.918 1.903 4.043 4.169 8.205 8.342 15.704 14.722* 
3 0.265 0.266 0.515 0.522 1.058 0.997 2.008 2.020 4.233 3.999 7.775 7.589 16.168 16.083 
4 0.198 0.191 0.421 0.441 1.010 0.985 2.014 2.114 3.762 4.215 7.833 8.472 15.915 15.929 
Mean 0.230 0.492 1.012 1.998 4.054 7.958 16.009 
Std 
dev 0.041 0.068 0.039 0.065 0.154 0.371 0.252 
%CV 17.819 13.787 3.901 3.270 3.796 4.668 1.574 
%RE -8.300 -1.650 1.150 -0.106 1.343 -0.523 0.054 
 
αββ-Androstanediol: 
Batch 0.250ng/ml 0.500ng/ml 1.000ng/ml 2.000ng/ml 4.000ng/ml 8.000ng/ml 16.000ng/ml 
1 0.254 0.259 0.531 0.525 1.033 0.938 1.770 1.967 4.194 3.667 8.284 7.371* 16.170 14.763* 
2 0.277 0.266 0.437 0.458 1.129 1.037 1.863 2.029 3.800 3.914 8.738 7.948 15.893 15.831 
3 0.207 0.267 0.492 0.407 1.013 1.078 2.046 2.270 4.362 4.161 9.301 7.199 15.647 15.446 
4 0.231 0.257 0.501 0.485 1.023 1.084 2.077 1.973 3.710 4.199 7.840 8.364 15.982 15.843 
Mean 0.252 0.480 1.042 1.999 4.001 8.239 15.830 
Std 
dev 0.023 0.043 0.057 0.149 0.261 0.673 0.232 
%CV 8.977 8.951 5.472 7.449 6.522 8.172 1.468 
%RE 0.900 -4.100 4.188 -0.031 0.022 2.989 -1.061 
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APPENDIX IV: QUALITY CONTROL DATA - OESTRUS CYCLES 
βαβ-Androstanediol: 
QC Low 0.375ng/ml QC High 3.000ng/ml R2 Batch 
Amount %Error Amount %Error   
0.373 0% 2.899 3% 0.9992 1 
0.393 5% 3.010 0%    
0.411 10% 3.046 2% 0.9996 2 
0.402 7% 3.058 2%    
0.345 8% 2.931 2% 0.9993 3 
0.406 8% 3.039 1%    
0.346 8% 2.945 2% 0.9989 4 
0.388 3% 3.036 1%    
0.353 6% 2.917 3% 0.999 5 
0.384 2% 2.923 3%    
N/A N/A N/A N/A N/A 6 
N/A N/A N/A N/A    
0.397 6% 2.850 5% 0.9994 7 
0.369 2% 2.910 3%    
0.371 1% 2.862 5% 0.9997 8 
0.391 4% 2.690 10%    
0.421 12% 3.114 4% 0.9996 9 
0.384 2% 3.114 4%    
0.355 5% 2.826 6% 0.9996 10 
0.340 9% 2.707 10%    
0.427 14% 3.004 0% 0.9997 11 
0.397 6% 2.761 8%    
N/A N/A N/A N/A N/A 12 
N/A N/A N/A N/A    
N/A N/A N/A N/A N/A 13 
N/A N/A N/A N/A    
N/A N/A N/A N/A N/A 14 
N/A N/A N/A N/A    
N/A N/A N/A N/A N/A 15 
N/A N/A N/A N/A    
N/A N/A N/A N/A N/A 16A 
N/A N/A N/A N/A    
N/A N/A N/A N/A N/A 17 
N/A N/A N/A N/A    
N/A N/A N/A N/A N/A 18 
N/A N/A N/A N/A    
0.407 8% 2.895 3% 0.9961 19 
0.317 16% 2.597 13%    
0.381   2.915   Mean 
0.03   0.14   Std Dev 
7.54   4.73   %CV 
-1.54   2.82   %RE 
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Epiandrosterone: 
QC Low 0.375ng/ml QC High 3.000ng/ml R2 Batch 
Amount %Error Amount %Error   
0.348 7% 2.813 6% 0.9975 1 
0.368 2% 3.4 13%    
0.375 0% 3.146 5% 0.9866 2 
0.364 3% 3.075 3%    
0.373 0% 3.370 12% 0.9983 3 
0.413 10% 3.428 14%    
0.366 3% 3.294 10% 0.9983 4 
0.370 1% 3.374 12%    
0.389 4% 3.359 12% 0.9912 5 
0.440 17% 3.270 9%    
0.306 18% 2.963 1% 0.9941 6 
0.319 15% 2.775 7%    
0.362 4% 3.092 3% 0.9981 7 
0.379 1% 4.724* 57%    
0.402 7% 3.174 6% 0.9986 8 
0.373 1% 2.805 7%    
0.377 0% 3.110 4% 0.9993 9 
0.417 11% 3.110 4%    
0.375 0% 3.097 3% 0.9992 10 
0.391 4% 4.599* 53%    
0.390 4% 3.233 8% 0.9981 11 
0.409 9% 3.152 5%    
0.382 2% 2.971 1% 0.9965 12 
0.373 1% 2.955 2%    
0.360 4% 3.089 3% 0.9802 13 
0.402 7% 3.285 9%    
0.386 3% 2.783 7% 0.9923 14 
0.350 7% 2.830 6%    
0.373 0% 3.021 1% 0.9925 15 
0.394 5% 3.001 0%    
0.375 0% 2.799 7% 0.9872 16B 
0.416 11% 2.770 8%    
0.328 13% 2.663 11% 0.9885 17 
0.385 3% 2.603 13%    
0.354 6% 2.723 9% 0.9857 18 
0.307 18% 2.638 12%    
0.377 0% 2.874 4% 0.9992 19 
0.386 3% 2.680 11%    
0.375   3.020  Mean 
0.03   0.24  Std Dev 
7.63   8.02  %CV 
-0.03   -0.67  %RE 
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αββ--Androstanediol: 
QC Low 0.375ng/ml QC High 3.000ng/ml R2 Batch 
Amount %Error Amount %Error   
0.434 16% 2.688 10% 0.9977 1 
0.435 16% 2.892 4%    
0.361 4% 2.908 3% 0.9936 2 
0.349 7% 2.878 4%    
0.307 18% 2.920 3% 0.9915 3 
0.330 12% 3.174 6%    
0.333 11% 3.242 8% 0.9977 4 
0.355 5% 3.412 14%    
0.332 11% 3.001 0% 0.9969 5 
0.340 9% 2.748 8%    
0.377 1% 2.695 10% 0.9943 6 
0.337 10% 2.568 14%    
0.449 20% 2.912 3% 0.9997 7 
0.384 2% 3.375 12%    
0.430 15% 2.908 3% 0.999 8 
0.372 1% 3.287 10%    
0.378 1% 2.938 2% 0.9995 9 
0.372 1% 2.938 2%    
0.387 3% 3.084 3% 0.9999 10 
0.368 2% 3.169 6%    
0.432 15% 3.429 14% 0.9954 11 
0.432 15% 3.962* 32%    
0.384 2% 3.028 1% 0.9971 12 
0.360 4% 2.868 4%    
0.302 20% 2.786 7% 0.9993 13 
0.357 5% 3.139 5%    
0.382 2% 2.998 0% 0.9977 14 
0.369 2% 2.966 1%    
0.383 2% 3.174 6% 0.9937 15 
0.394 5% 2.905 3%    
0.384 2% 2.941 2% 0.9858 16 
0.373 0% 2.880 4%    
0.371 1% 2.86 5% 0.9899 17 
0.431 15% 2.669 11%    
0.335 11% 2.894 4% 0.996 18 
0.311 17% 2.614 13%    
0.325 13% 2.953 2% 0.9795 19 
0.370 1% 2.577 14%    
0.372   2.957  Mean 
0.04   0.22  Std Dev 
10.27   7.46  %CV 
0.87   1.43  %RE 
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APPENDIX V: PRECISION AND ACCURACY DATA – OESTRUS CYCLES 
βαβ-Androstanediol: 
Batch 0.125ng/ml 0.250ng/ml 0.500ng/ml 1.000ng/ml 2.000ng/ml 4.000ng/ml 8.000ng/ml 
1 0.157* 0.162* 0.281 0.283 0.492 0.459 1.035 1.03 1.965 1.969 3.816 3.873 8.039 8.125 
2 0.121 0.131 0.230 0.239 0.467 0.516 1.003 0.933 1.990 1.991 3.955 4.025 7.990 8.158 
3 0.124 0.139 0.253 0.222 0.515 0.525 0.955 0.962 1.963 1.958 3.999 4.124 8.128 7.881 
4 0.126 0.129 0.273 0.245 0.528 0.495 0.903 0.900 1.969 2.070 4.050 4.039 7.984 8.039 
5 0.147 0.128 0.226 0.222 0.498 0.492 1.028 1.043 2.012 1.923 4.000 3.922 7.885 8.223 
6 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
7 0.142 0.121 0.234 0.219 0.541 0.502 1.023 0.976 2.013 1.990 3.931 4.101 7.934 8.025 
8 0.118 0.129 0.230 0.265 0.499 0.528 0.994 1.012 1.981 1.982 3.924 4.054 7.981 8.054 
9 0.116 0.132 0.261 0.243 0.507 0.508 1.043 0.990 1.900 1.980 3.941 4.014 8.104 8.010 
10 0.108 0.131 0.275 0.247 0.517 0.499 1.008 1.010 1.949 1.948 3.934 4.048 8.062 8.014 
11 0.132 0.123 0.237 0.245 0.508 0.506 1.020 1.004 2.001 1.971 4.042 3.871 8.114 7.974 
12 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
13 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
14 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
15 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
16 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
17 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
18 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
19 0.115 0.138 0.262 0.253 0.521 0.502 1.105 1.001 1.738 1.929 4.399 4.207 7.568 8.012 
Mean 0.128 0.248 0.506 0.999 1.963 4.012 8.014 
Std 
dev 0.01 0.02 0.02 0.05 0.06 0.13 0.13 
%CV 7.59 7.95 3.74 4.73 3.12 3.12 1.63 
%RE -2.00 1.00 -1.14 0.10 1.84 -0.31 -0.17 
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Epiandrosterone: 
Batch 0.125ng/ml 0.250ng/ml 0.500ng/ml 1.000ng/ml 2.000ng/ml 4.000ng/ml 8.000ng/ml 
1 0.160* 0.161* 0.266 0.26 0.476 0.452 0.951 0.956 1.914 1.849 4.062 4.085 9.363* 9.187 
2 0.124 0.132 0.236 0.278 0.454 0.434 0.889 0.905 1.889 2.075 4.406 4.035 9.196 8.680 
3 0.163* 0.122 0.284 0.238 0.506 0.505 0.907 1.085 1.748 2.042 4.043 4.088 7.791 8.195 
4 0.158* 0.124 0.258 0.245 0.520 0.473 0.907 1.059 1.769 2.053 3.992 4.290 7.878 8.030 
5 0.169* 0.149 0.226 0.253 0.477 0.462 0.864 1.131 1.815 2.130 4.054 4.227 8.640 7.198 
6 0.079* 0.128 0.228 0.269 0.521 0.458 0.972 0.931 1.933 1.940 4.163 4.445 7.994 8.286 
7 0.119 0.118 0.240 0.247 0.493 0.503 1.086 1.053 2.170 1.990 3.827 4.007 8.198 7.699 
8 0.131 0.113 0.232 0.257 0.510 0.495 1.070 1.033 1.908 1.905 4.131 4.097 7.666 8.202 
9 0.113 0.113 0.241 0.247 0.496 0.474 1.005 1.019 2.130 1.999 3.889 3.917 7.952 8.155 
10 0.125 0.122 0.239 0.253 0.492 0.488 1.042 1.060 2.153 2.020 3.972 3.872 8.039 7.875 
11 0.128 0.117 0.242 0.245 0.514 0.490 0.998 1.035 1.991 1.821 3.975 4.017 7.690 8.488 
12 0.136 0.112 0.258 0.258 0.493 0.476 0.990 0.963 2.073 2.046 3.927 3.938 8.139 8.120 
13 0.104 0.148 0.281 0.244 0.477 0.459 0.853 0.879 1.911 1.969 4.296 4.094 8.827 9.160 
14 0.160 0.104 0.257 0.283 0.507 0.504 0.983 1.002 2.032 2.046 3.911 3.730 7.956 7.757 
15 0.126 0.137 0.233 0.214 0.486 0.488 1.002 0.983 2.175 2.139 4.149 4.022 8.450 7.293 
16 0.123 0.111 0.290 0.272 0.477 0.334* 1.045 1.103 2.034 2.109 3.670 4.107 7.222 6.903 
17 0.112 0.126 0.293* 0.252 0.465 0.324* 1.050 1.108 2.045 2.106 3.772 4.068 7.135 7.173 
18 0.127 0.122 0.218 0.280 0.458 0.559 1.092 1.016 2.094 1.842 3.469 3.643 9.190 7.868 
19 0.121 0.104 0.279 0.305* 0.514 0.558 1.141 0.919 2.045 1.872 3.875 3.903 6.834 7.239 
Mean 0.123 0.253 0.489 1.002 1.994 4.004 8.008 
Std 
dev 0.01 0.02 0.03 0.08 0.12 0.20 0.64 
%CV 10.40 7.72 5.54 7.66 5.80 4.97 7.96 
%RE 1.22 -1.14 2.14 -0.23 0.29 -0.11 -0.10 
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αββ-Androstanediol: 
Batch 0.125ng/ml 0.250ng/ml 0.500ng/ml 1.000ng/ml 2.000ng/ml 4.000ng/ml 8.000ng/ml 
1 0.399* 0.393* 0.358* 0.360* 0.54 0.537 0.975 0.921 1.834 1.83 3.824 3.861 8.142 8.101 
2 0.121 0.124 0.213 0.218 0.416* 0.454 0.879 0.843 1.852 1.892 4.064 3.897 8.542 8.389 
3 0.149 0.143 0.236 0.219 0.512 0.461 0.951 1.041 1.721 2.086 4.079 4.090 8.361 7.306 
4 0.117 0.114 0.228 0.192* 0.517 0.464 0.980 1.096 1.773 2.109 4.111 4.172 8.170 7.711 
5 0.142 0.106 0.257 0.266 0.431 0.515 1.165 1.013 1.924 1.797 3.988 3.849 8.137 8.160 
6 0.144 0.156 0.698* 0.282 0.561 0.532 0.919 0.920 1.911 1.804 3.915 4.457 7.591 8.307 
7 0.171* 0.145 0.262 0.280 0.473 0.477 0.987 0.972 1.894 1.946 3.977 4.073 8.043 7.978 
8 0.137 0.135 0.232 0.261 0.523 0.481 1.010 0.965 1.901 1.936 3.958 4.242 7.863 8.081 
9 0.153* 0.147 0.275 0.270 0.519 0.502 1.040 0.965 1.942 1.910 3.852 4.009 8.030 8.072 
10 0.134 0.132 0.250 0.263 0.526 0.480 1.049 1.005 1.968 1.960 3.918 4.008 8.023 8.025 
11 0.132 0.109 0.231 0.224 0.500 0.470 1.040 1.018 2.007 1.971 4.083 4.234 8.572 8.879 
12 0.120 0.106 0.260 0.269 0.519 0.505 0.997 0.979 2.115 2.048 3.867 3.920 8.216 7.991 
13 0.085* 0.159 0.315* 0.267 0.534 0.443 1.059 0.997 1.984 1.977 3.937 3.843 8.134 7.978 
14 0.132 0.085* 0.266 0.274 0.464 0.509 0.947 0.950 1.994 2.022 3.920 3.833 8.054 7.920 
15 0.141 0.150 0.253 0.233 0.504 0.480 0.972 0.949 2.061 2.010 3.877 3.923 7.879 6.899 
16 0.109 0.121 0.295 0.286 0.497 0.305* 1.025 0.990 2.005 2.023 3.682 4.370 7.503 6.886 
17 0.137 0.111 0.276 0.231 0.466 0.267* 1.046 1.136 1.971 2.102 3.763 4.093 7.707 7.316 
18 0.205* 0.149* 0.260 0.258 0.460 0.492 0.915 0.931 2.112 1.987 3.772 3.658 8.176 8.456 
19 0.213* 0.141 0.240 0.256 0.426 0.520 0.918 0.948 2.083 2.018 3.983 4.179 7.859 8.055 
Mean 0.132 0.254 0.494 0.987 1.960 3.981 7.987 
Std 
dev 0.02 0.02 0.03 0.07 0.10 0.17 0.41 
%CV 11.80 8.52 6.64 6.64 5.08 4.36 5.14 
%RE -5.21 -1.71 1.18 1.28 2.00 0.47 0.16 
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APPENDIX VI: OESTRUS CYCLE STEROID PROFILES 
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Oestrus Cycle: androgen and progesterone metabolite profiles - Chop and Change
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Oestrus Cycle: androgen and progesterone metabolite profiles - Tonightsthenight
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Oestrus Cycle: androgen and progesterone metabolite profiles - BPIMA
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Oestrus Cycle: androgen and progesterone metabolite profiles - The Alarm's On
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Oestrus Cycle: androgen and progesterone metabolite profiles - Saunders Pet
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Oestrus Cycle: androgen and progesterone metabolite profiles - Standard Whisper
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Oestrus Cycle: androgen and progesterone metabolite profiles - Cullane Chief
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Oestrus Cycle: androgen and progesterone metabolite profiles - Whitefort Euro
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Oestrus Cycle: androgen and progesterone metabolite profiles - Queen of the Bar
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Oestrus cycle: androgen and progesterone profiles - Queen Boadicea
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Oestrus Cycle: androgen and progesterone metabolites - Langies Posh Girl
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Oestrus Cycle: androgen and progesterone metabolite profiles - Ringlestown Flos
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Oestrus Cycle: androgen and progesterone metabolite profiles - Giveherthevote
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Oestrus Cycle: androgen and progesterone metabolite profiles - Wideopenspaces
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Oestrus cycle: androgen and progesterone metabolite profiles - Marshalls Promise
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Oestrus Cycle: androgen and progesterone metabolite profiles - Distant Pearl
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Oestrus Cycle: androgen and progesterone metabolite profiles - Drumpark Access
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Oestrus cycle: androgen and progesterone metabolite profiles - Cannon Clover
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Oestrus Cycle: androgen and progesterone metabolite profiles - Miss Honcho
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Oestrus Cycle: androgen and progesterone metabolite profiles - Sparky Pacific
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Oestrus cycle: androgen and progesterone metabolite profiles - Queen Sally
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Oestrus Cycle: androgen and progesterone metabolite profiles - BPXYP
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Oestrus Cycle: androgen and progesterone metabolite profiles - Supreme Madonna
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Oestrus Cycle: androgen and progesterone metabolite profiles - Little Reaction
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Oestrus Cycle: androgen and progesterone metabolite profiles - Bolly for Molly - (Pregnant)
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APPENDIX VII: RAW DATA FOR OESTRUS CYCLE STEROIDS 
• The highlighted results are those which had a repeat analysis 
Black Pansy testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Area 
Ratio 
-32 0.045 0.291 0.882 1.301 0.142 0.225 0.103 
-31 0.049 0.290 0.847 1.437 0.131 0.237 0.107 
-30 0.037 0.310 0.860 1.240 0.160 0.231 0.071 
-29 0.027 0.291 0.697 0.877 0.169 0.266 0.073 
-28 0.029 0.294 0.963 1.334 0.107 0.264 0.095 
-27 0.023 0.311 0.749 0.850 0.166 0.257 0.061 
-26 0.038 0.328 0.986 1.308 0.129 0.251 0.071 
-25 0.027 0.304 0.899 1.250 0.137 0.241 0.053 
-24 0.037 0.319 0.889 1.070 0.153 0.245 0.063 
-23 0.035 0.298 0.869 1.146 0.144 0.236 0.064 
-22 0.020 0.332 0.607 1.117 0.065 0.245 0.064 
-21 0.042 0.287 1.008 1.611 0.165 0.244 0.097 
-20 0.032 0.288 0.806 1.081 0.109 0.245 0.065 
-19 0.019 0.323 0.962 1.218 0.178 0.250 0.084 
-18 0.035 0.295 0.843 1.217 0.118 0.243 0.089 
-17 0.045 0.313 0.817 1.242 0.182 0.240 0.083 
-16 0.039 0.286 1.131 1.679 0.162 0.264 0.100 
-15 0.049 0.290 1.318 1.863 0.194 0.288 0.074 
-14 0.054 0.294 0.988 1.440 0.152 0.245 0.067 
-13 0.049 0.275 0.770 1.156 0.126 0.233 0.063 
-12 0.043 0.275 0.998 1.620 0.196 0.290 0.075 
-11 0.034 0.275 0.963 1.476 0.102 0.251 0.067 
-10 0.038 0.283 1.213 1.892 0.154 0.263 0.079 
-9 0.042 0.271 1.058 1.655 0.164 0.265 0.102 
-8 0.033 0.311 1.490 2.467 0.244 0.269 0.122 
-7 0.029 0.298 1.162 1.805 0.169 0.260 0.093 
-6 0.018 0.262 1.651 2.592 0.195 0.307 0.116 
-5 0.020 0.248 1.579 2.349 0.176 0.251 0.178 
-4 0.030 0.251 1.966 3.086 0.194 0.263 0.205 
-3 0.030 0.248 1.677 2.801 0.216 0.276 0.278 
-2 0.052 0.253 2.497 4.285 0.275 0.286 0.427 
-1 0.072 0.256 3.593 5.986 0.412 0.357 1.005 
0 0.023 0.247 1.967 3.809 0.221 0.295 0.921 
1 0.061 0.244 3.099 4.819 0.442 0.372 1.162 
3 0.062 0.256 4.448 7.851 0.300 0.402 1.912 
4 0.076 0.245 4.714 8.050 0.457 0.355 1.947 
5 0.100 0.240 7.929 13.755 0.950 0.474 2.404 
6 0.068 0.249 6.380 8.907 1.820 0.380 2.787 
7 0.076 0.248 3.957 7.124 0.232 0.365 4.928 
8 0.057 0.244 4.519 7.079 0.652 0.356 5.670 
9 0.035 0.240 2.229 3.653 0.125 0.330 5.926 
10 0.065 0.259 2.948 5.442 0.151 0.337 11.154 
11 0.063 0.245 2.778 5.197 0.190 0.332 15.828 
12 0.050 0.255 2.369 4.232 0.141 0.280 13.291 
13 0.076 0.257 2.403 4.232 0.343 0.330 16.928 
 216 
 
14 0.048 0.252 1.587 2.458 0.192 0.273 16.770 
15 0.074 0.249 2.066 2.578 2.150 0.355 19.770 
16 0.077 0.248 2.211 3.705 0.261 0.395 22.366 
17 0.055 0.248 1.064 1.891 0.214 0.258 20.845 
18 0.048 0.250 1.101 1.959 0.188 0.282 17.875 
19 0.056 0.248 1.097 1.834 0.290 0.279 17.225 
20 0.029 0.247 0.806 1.349 0.152 0.268 14.513 
21 0.068 0.247 1.035 1.526 0.840 0.265 22.861 
22 0.070 0.250 1.729 2.496 0.781 0.308 38.715 
23 0.075 0.247 1.323 2.471 0.025 0.250 36.383 
24 0.080 0.251 1.330 2.363 0.128 0.275 43.702 
25 0.076 0.248 1.184 2.145 0.173 0.269 41.945 
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Black Pansy testosterone aBB_Adiol epiandro BaB_Adiol 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Area 
Ratio 
2 0.176 12.606 9.156 0.377 3.778 
6 0.239 25.717 23.500 0.664 7.592 
10 0.136 5.200 5.111 0.144 20.274 
13 0.184 5.813 5.549 0.269 35.613 
17 0.156 3.407 2.491 0.183 36.288 
20 0.203 2.892 2.348 0.168 47.067 
23 0.156 2.443 2.183 0.157 57.624 
28 0.229 4.508 3.205 0.286 96.004 
31 0.175 1.860 1.681 0.152 N/A 
34 0.242 4.048 3.450 0.193 90.536 
38 0.271 3.000 3.000 0.141 62.369 
41 0.345 1.803 2.407 0.102 N/A 
45 0.268 2.292 2.053 0.107 44.997 
48 0.307 3.755 2.939 0.185 59.307 
52 0.248 3.146 2.716 0.176 39.683 
55 0.284 3.495 2.914 0.122 45.578 
59 0.296 2.570 2.527 0.143 29.935 
62 0.298 3.974 3.398 0.148 41.280 
66 0.315 3.845 3.242 0.207 28.279 
69 0.287 3.304 2.539 0.164 23.851 
73 0.425 3.780 3.254 0.168 28.770 
76 0.309 2.974 2.813 0.049 24.573 
81 0.404 2.955 2.232 0.186 24.366 
84 0.373 3.463 3.310 0.149 21.878 
87 0.387 2.884 2.472 0.146 10.654 
90 0.369 2.392 2.273 0.161 6.086 
94 0.338 1.119 1.062 0.156 1.755 
97 0.331 1.396 1.212 0.126 2.068 
102 0.380 0.919 0.897 0.124 0.887 
104 0.370 1.304 1.135 0.260 1.354 
111 0.398 1.326 1.129 0.092 0.995 
114 0.423 1.035 1.029 0.191 0.710 
122 0.440 1.129 1.099 0.155 0.748 
130 0.465 1.242 1.342 0.082 0.656 
143 0.438 1.272 1.252 0.175 0.840 
150 0.507 1.234 1.232 0.136 0.750 
157 0.496 1.104 1.040 0.044 0.581 
165 0.534 0.973 1.112 0.178 0.687 
171 0.490 0.897 0.873 0.209 0.576 
178 0.556 1.454 1.493 0.134 0.723 
185 0.545 0.967 1.522 0.251 0.337 
192 0.517 1.392 1.386 0.260 0.492 
200 0.605 1.282 1.422 0.154 0.444 
206 0.613 1.845 2.138 0.196 0.606 
213 0.575 2.513 2.677 0.202 0.587 
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Queen of 
Stout testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
0 0.005 0.066 1.692 1.645 0.119 0.062 1.598 
4 0.045 0.104 5.156 3.284 0.333 0.297 10.319 
8 0.334 0.392 46.743 28.729 3.244 1.107 38.799 
12 0.055 0.146 3.447 2.068 0.155 0.193 32.346 
16 0.029 0.123 2.349 1.723 0.307 0.321 47.467 
19 0.055 0.143 2.252 1.672 0.072 0.288 34.606 
26 0.052 0.131 1.941 1.456 0.083 0.195 72.221 
29 0.051 0.122 1.403 1.074 0.180 0.173 51.223 
33 0.055 0.123 2.340 1.563 0.189 0.228 70.238 
37 0.037 0.107 1.690 1.215 0.111 0.173 57.801 
39 0.063 0.125 2.498 1.459 0.238 0.395 63.904 
43 0.069 0.137 2.378 1.445 0.219 0.392 53.847 
47 0.047 0.120 1.832 1.272 0.076 0.210 24.507 
49 0.067 0.138 3.029 2.030 0.170 0.302 34.806 
53 0.067 0.116 1.996 1.335 0.116 0.506 13.445 
57 0.055 0.106 2.199 1.386 0.084 0.368 18.551 
61 0.064 0.116 2.326 1.437 0.122 0.363 17.247 
65 0.087 0.169 2.001 1.434 0.160 0.580 6.859 
67 0.049 0.111 1.530 1.199 0.070 0.296 6.260 
71 0.030 0.092 1.156 0.730 0.069 0.219 4.190 
75 0.042 0.118 1.227 0.720 0.099 0.148 5.042 
78 0.041 0.160 1.308 0.756 0.082 0.155 3.802 
82 0.037 0.119 0.960 0.529 0.080 0.076 2.242 
89 0.022 0.085 0.988 0.586 0.065 0.070 1.035 
96 0.052 0.164 1.508 0.898 0.148 0.131 2.204 
102 0.030 0.162 0.741 0.418 0.095 0.056 0.655 
108 0.036 0.146 0.909 0.597 0.023 0.054 1.300 
123 0.033 0.125 1.401 0.951 0.119 0.076 0.662 
130 0.099 0.020 2.262 1.675 0.073 0.089 1.392 
144 0.034 0.123 1.804 1.765 0.092 0.096 1.385 
151 0.022 0.103 1.117 1.126 0.106 0.098 0.933 
158 0.019 0.091 1.130 1.131 0.096 0.060 0.793 
172 0.045 0.153 2.489 2.426 0.163 0.137 1.941 
179 0.022 0.103 1.945 1.687 0.050 0.070 1.229 
186 0.046 0.114 2.348 1.569 0.117 0.075 0.966 
200 0.023 0.116 1.663 0.981 0.068 0.069 1.777 
207 0.025 0.090 1.638 0.945 0.068 0.055 1.550 
221 0.040 0.137 3.065 2.314 0.192 0.142 3.759 
228 0.024 0.104 2.110 1.104 0.063 0.112 2.242 
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Suitable 
Choice testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
0 0.001 0.071 0.586 0.680 0.012 0.019 0.225 
3 0.030 0.218 2.563 1.921 0.130 0.064 2.305 
7 0.032 0.079 5.255 6.518 0.384 0.129 2.325 
11 0.064 0.291 2.032 1.606 0.123 0.095 12.850 
14 0.081 0.298 2.351 2.414 0.069 0.152 44.166 
18 0.115 0.614 2.289 2.117 0.173 0.169 59.366 
25 0.123 0.381 2.441 2.124 0.156 0.174 72.613 
29 0.063 0.131 0.857 0.801 0.051 0.047 31.493 
31 0.139 0.376 2.171 2.088 0.137 0.190 70.239 
39 0.215 0.477 2.191 4.019 0.204 0.160 60.793 
42 0.091 0.246 1.244 1.532 0.081 0.119 22.975 
46 0.174 0.355 2.080 2.392 0.212 0.215 36.793 
49 0.106 0.368 1.896 2.675 0.194 0.169 26.700 
53 0.122 0.575 1.788 1.896 0.148 0.126 18.777 
56 0.105 0.429 1.818 2.803 0.383 0.179 13.669 
60 0.110 0.530 1.471 1.653 0.168 0.139 7.808 
63 0.173 0.816 2.091 2.374 0.359 0.175 5.612 
67 0.082 0.419 1.045 1.228 0.125 0.116 2.152 
70 0.111 0.454 1.173 1.645 0.219 0.174 2.083 
74 0.053 0.320 0.707 0.798 0.097 0.079 0.592 
78 0.040 0.180 0.661 0.923 0.129 0.113 0.450 
81 0.042 0.534 0.802 0.823 0.067 0.091 0.579 
88 0.016 0.379 0.457 0.556 0.099 0.045 0.249 
95 0.053 0.535 0.896 1.034 0.360 0.102 0.391 
101 0.017 0.196 0.393 0.482 0.067 0.032 0.177 
109 0.030 0.362 0.671 0.634 0.059 0.061 0.198 
111 0.053 0.456 0.791 0.817 0.093 0.072 0.174 
115 0.033 0.305 0.670 0.746 0.067 0.054 0.128 
122 0.012 0.265 0.520 0.507 0.027 0.031 0.110 
136 0.026 0.337 0.577 0.535 0.122 0.066 0.177 
150 0.005 0.120 0.461 0.807 0.088 0.015 0.100 
157 0.033 0.434 0.985 1.009 0.118 0.070 0.362 
164 0.043 0.386 1.338 1.152 0.150 0.079 0.255 
178 0.043 0.201 0.712 1.154 0.073 0.079 0.081 
192 0.028 0.368 1.026 0.964 0.089 0.064 0.169 
199 0.028 0.266 1.267 1.094 0.079 0.054 0.196 
206 0.014 0.241 1.387 1.175 0.045 0.044 0.187 
213 0.034 0.283 2.210 1.842 0.113 0.118 1.117 
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Full 
Nosey  
(Daisy) testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days 
post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
0 0.061 NA 6.266 7.448 0.559 0.403 4.382 
4 0.063 0.087 4.365 2.283 0.380 0.319 16.019 
8 0.080 NA 7.752 4.613 0.783 0.388 16.068 
11 0.156 0.133 23.937 12.507 1.717 0.633 27.150 
15 0.065 0.068 2.788 3.157 0.100 0.182 29.803 
17 0.097 0.166 5.394 6.473 0.321 0.588 66.409 
22 0.061 0.138 2.911 3.735 0.207 0.312 67.655 
24 0.076 0.137 2.864 2.912 0.102 0.261 59.233 
28 0.091 0.149 3.958 4.898 0.237 0.350 99.582 
32 0.054 NA 1.553 2.079 0.050 0.283 60.353 
35 0.059 NA 3.212 3.989 0.140 0.252 112.835 
39 0.047 NA 2.416 2.827 0.097 0.207 74.931 
42 0.068 0.047 4.658 5.448 0.244 0.409 135.354 
46 0.121 0.049 3.487 3.685 0.175 0.295 116.912 
49 0.096 0.056 3.873 4.096 0.121 0.385 128.044 
53 0.100 0.076 3.997 4.001 0.108 0.452 102.564 
56 0.127 0.086 4.355 4.578 0.145 0.422 94.222 
60 0.102 0.087 4.774 5.526 0.103 0.531 100.932 
63 0.136 0.091 5.229 5.120 0.116 0.384 90.446 
70 0.084 0.081 4.242 4.239 0.412 0.470 45.356 
74 0.126 0.073 4.052 3.626 0.352 0.435 36.426 
77 0.113 0.079 5.975 5.383 0.380 0.465 30.256 
81 0.069 0.031 2.003 1.443 0.081 0.093 12.463 
84 0.092 0.091 5.010 4.399 0.130 0.442 25.551 
88 0.158 0.083 3.797 3.931 0.466 0.529 23.341 
95 0.096 0.055 2.892 3.220 0.140 0.304 15.033 
102 0.089 0.055 2.141 2.146 0.216 0.178 11.184 
115 0.085 0.096 1.749 1.341 0.232 0.206 7.199 
129 0.061 NA 1.678 1.446 0.190 0.122 2.929 
143 0.052 0.049 0.910 0.524 0.051 0.074 1.110 
157 0.043 NA 1.190 0.849 0.081 0.058 1.093 
178 0.038 NA 1.336 0.403 0.043 0.036 0.446 
192 0.057 0.073 1.675 1.572 0.194 0.112 1.141 
206 0.049 NA 1.405 0.806 0.081 0.046 0.908 
220 0.057 NA 1.887 1.502 0.067 0.100 1.288 
234 0.069 NA 2.327 1.424 0.067 0.165 1.384 
249 0.043 NA 1.692 1.419 0.082 0.105 1.231 
262 0.054 0.077 1.710 1.412 0.139 0.052 0.960 
276 0.056 0.086 1.600 1.504 0.067 0.046 1.268 
290 0.056 0.115 3.384 3.447 0.160 0.113 2.755 
296 0.077 0.093 7.625 8.291 0.424 0.203 6.836 
 
  
 221 
 
Chop & 
Change testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days 
post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Area 
Ratio 
-13 0.081 0.087 9.806 6.523 0.490 0.623 3.579 
-6 0.067 0.076 10.183 6.595 0.344 0.755 4.201 
0 0.037 0.048 4.458 2.286 0.149 0.206 3.196 
4 0.098 0.074 28.640 17.269 0.954 1.068 26.395 
7 0.080 0.084 13.939 8.988 0.516 0.694 30.862 
11 0.069 0.088 7.307 5.309 0.157 0.456 32.308 
15 0.076 0.084 6.720 5.037 0.261 0.638 40.783 
17 0.138 0.092 9.957 6.326 0.200 0.729 37.297 
21 0.182 0.111 14.305 8.704 0.369 0.849 77.762 
25 0.169 0.081 14.492 8.395 0.251 0.725 62.985 
28 0.162 0.095 13.992 8.684 0.288 0.840 63.467 
32 0.162 0.116 15.209 8.832 0.417 1.036 66.537 
35 0.215 0.132 25.344 14.303 0.558 1.216 109.602 
39 0.215 0.145 23.277 13.804 0.458 1.326 110.028 
42 0.195 0.132 14.874 7.939 0.352 1.176 86.804 
46 0.183 0.108 12.856 7.647 0.208 0.629 82.629 
50 0.133 0.049 4.851 2.244 0.062 0.405 21.872 
52 0.178 0.083 13.628 7.221 0.191 0.541 66.602 
56 0.149 0.083 9.984 5.512 0.220 0.517 44.083 
60 0.174 0.090 13.106 6.562 0.182 0.867 39.821 
63 0.141 0.072 7.428 3.938 0.147 0.547 18.464 
67 0.158 0.079 7.635 4.369 0.093 0.620 16.390 
70 0.159 0.206 8.973 4.385 0.148 0.795 19.148 
74 0.156 0.084 10.937 5.238 0.253 1.051 22.083 
80 0.127 0.050 4.283 2.007 0.054 0.384 6.585 
88 0.120 0.059 3.612 1.596 0.068 0.288 3.243 
95 0.142 0.054 4.257 1.645 0.044 0.319 2.521 
108 0.133 0.054 4.105 1.758 0.071 0.321 1.302 
122 0.115 0.060 4.986 2.089 0.069 0.395 1.696 
136 0.140 0.050 3.918 1.713 0.117 0.312 1.189 
150 0.137 0.057 4.902 1.737 0.091 0.330 1.500 
164 0.126 0.134 4.527 1.917 0.095 0.340 1.753 
178 0.117 0.117 2.727 1.245 0.140 0.154 0.649 
192 0.125 0.099 4.363 1.710 0.071 0.325 1.191 
206 0.135 0.116 7.468 3.436 0.114 0.559 2.229 
220 0.130 0.077 5.627 2.460 0.125 0.403 1.648 
227 0.139 0.082 6.457 3.535 0.140 0.503 1.729 
234 0.145 0.070 8.642 4.011 0.161 0.504 2.005 
241 0.152 0.066 9.428 4.927 0.137 0.670 3.837 
 
  
 222 
 
Whinfell 
Nikita testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
0 0.116 0.074 4.192 3.340 0.149 0.368 0.517 
4 0.191 0.138 17.190 13.326 11.279 3.917 0.431 
7 0.152 0.081 16.362 14.086 2.264 0.623 0.722 
11 0.165 0.095 13.375 12.202 0.744 0.286 1.692 
14 0.153 0.067 4.203 4.130 0.696 0.244 2.143 
18 0.107 NA 2.676 2.781 0.110 0.338 1.909 
21 0.153 0.140 1.948 1.636 0.227 0.177 1.611 
25 0.135 0.069 1.777 1.734 0.154 0.121 1.779 
28 0.126 0.055 1.713 1.820 0.138 0.112 2.001 
32 0.188 0.139 2.699 2.518 0.291 0.231 2.285 
35 0.182 0.065 2.494 2.882 2.548 0.169 2.771 
39 0.107 0.040 2.388 2.485 0.097 0.189 2.290 
42 0.235 0.072 4.244 4.299 0.149 0.163 3.712 
49 0.200 0.067 4.148 4.447 0.088 0.197 2.556 
53 0.004 NA 0.462 0.313 0.004 0.035 0.090 
56 0.204 0.060 4.827 6.255 0.129 0.173 1.836 
60 0.250 0.097 4.380 3.504 0.228 0.260 1.368 
67 0.209 0.065 5.649 5.008 0.196 0.245 2.189 
74 0.011 0.038 1.033 1.196 0.005 0.088 0.318 
81 0.156 0.173 12.399 11.940 2.635 2.372 1.333 
88 0.141 0.078 3.450 2.813 0.057 0.123 1.253 
91 0.187 0.100 2.626 2.073 0.070 0.136 0.763 
95 0.124 0.060 1.288 1.110 0.008 0.078 0.510 
102 0.117 0.060 0.968 0.972 0.036 0.072 0.114 
108 0.096 0.091 1.450 1.326 0.099 0.183 0.073 
122 0.078 0.117 0.944 0.938 0.092 0.088 0.046 
129 0.156 0.188 18.989 21.619 7.744 3.012 0.041 
136 0.074 0.090 0.923 0.660 0.072 0.082 0.064 
150 0.111 0.066 2.564 1.799 0.203 0.061 0.066 
157 0.029 0.044 0.476 0.393 0.057 0.026 0.032 
164 0.142 0.135 0.893 0.673 1.945 0.261 0.070 
171 0.147 0.096 1.205 0.709 0.559 0.162 0.067 
178 0.085 0.042 1.007 1.036 0.059 0.050 0.098 
185 0.076 0.068 0.763 0.836 0.040 0.093 0.060 
192 0.136 0.180 1.480 1.428 0.116 0.094 0.074 
199 0.103 0.074 1.354 1.370 0.040 0.104 0.073 
206 0.095 0.120 1.399 1.240 0.040 0.138 0.110 
213 0.076 0.080 1.806 1.889 0.021 0.150 0.141 
220 0.124 0.179 2.578 2.513 0.163 0.123 0.083 
234 0.091 0.177 4.473 4.674 0.226 0.207 0.184 
 
 
 
 
  
 223 
 
tonightsthe 
night testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
0 0.098 0.125 6.463 4.585 0.242 0.740 0.847 
4 0.063 0.088 6.399 4.724 0.493 0.224 1.116 
8 0.049 0.125 5.614 3.946 0.414 0.194 1.507 
10 0.057 0.099 5.341 4.462 0.362 0.210 2.188 
14 0.038 0.055 7.886 4.612 0.787 0.249 1.865 
18 0.042 0.042 2.568 2.267 0.092 0.156 1.553 
21 0.079 0.087 3.806 2.792 0.403 0.262 3.308 
28 0.047 0.038 2.270 1.595 0.138 0.172 2.320 
32 0.056 0.050 3.082 2.183 0.261 0.215 3.359 
35 0.210 0.063 5.177 4.622 0.496 0.449 5.344 
39 0.052 0.034 2.600 2.450 0.231 0.176 2.681 
42 0.024 0.040 1.656 1.527 0.225 0.170 1.618 
46 0.093 0.051 2.795 2.522 0.298 0.262 2.846 
49 0.092 0.089 2.908 2.374 0.277 0.303 3.492 
53 0.076 0.046 3.473 3.006 0.229 0.244 1.681 
56 0.062 0.046 1.590 1.388 0.123 0.130 1.281 
60 0.053 0.058 2.910 2.226 0.252 0.301 1.684 
67 0.066 0.067 2.466 1.822 0.236 0.259 0.925 
70 0.096 0.071 2.762 2.353 0.254 0.492 0.801 
74 0.048 0.053 1.599 1.316 0.130 0.224 0.504 
77 0.069 0.077 2.640 1.890 0.244 0.235 0.745 
84 0.015 NA 0.502 0.454 0.011 0.120 0.141 
91 0.079 0.163 1.716 0.892 0.226 0.198 0.306 
98 0.045 0.059 1.429 0.999 0.178 0.130 0.143 
105 0.044 0.118 1.919 1.453 0.275 0.252 0.168 
112 0.029 0.045 1.311 1.077 0.146 0.115 0.095 
123 0.050 0.063 1.252 0.803 0.059 0.122 0.144 
129 0.042 0.064 1.908 1.461 0.136 0.059 0.129 
143 0.044 0.102 1.205 0.817 0.186 0.174 0.107 
157 0.035 0.098 1.506 1.182 0.242 0.196 0.062 
164 0.043 0.034 1.182 0.807 0.103 0.206 0.052 
178 0.067 0.133 3.279 2.553 0.442 0.610 0.055 
192 0.009 0.025 0.427 0.336 0.047 0.021 0.031 
206 0.028 0.047 0.999 0.747 0.104 0.095 0.082 
221 0.042 0.067 2.216 1.245 0.149 0.105 0.135 
227 0.030 0.064 1.893 1.547 0.185 0.098 0.158 
234 0.022 0.053 1.584 1.205 0.120 0.067 0.137 
241 0.057 0.107 4.488 3.874 0.473 0.325 0.164 
248 0.127 0.057 5.626 7.893 0.676 0.273 0.217 
253 0.029 0.054 5.048 4.101 0.500 0.271 0.896 
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Fair 
Head testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days 
post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Area 
Ratio 
1 0.066 0.046 4.795 2.373 0.240 0.096 0.399 
4 0.349 0.143 44.551 18.458 5.550 0.540 1.700 
8 0.151 0.036 1.434 0.979 0.221 0.102 1.029 
11 0.120 0.046 1.443 1.397 0.391 0.265 2.120 
15 0.118 NA 1.075 1.385 0.505 0.364 2.644 
16 0.174 NA 1.334 1.071 0.321 0.165 3.221 
22 0.123 0.038 1.402 1.562 0.642 0.342 3.581 
26 0.261 NA 1.797 1.640 0.580 0.486 4.511 
29 0.058 0.037 0.832 0.939 0.145 0.165 0.812 
33 0.252 NA 2.207 2.339 0.721 0.911 3.677 
36 0.247 0.039 2.455 2.086 0.382 0.492 4.379 
40 0.152 NA 2.099 1.797 0.520 0.371 1.865 
43 0.107 NA 1.561 2.124 0.268 0.425 1.479 
47 0.172 0.032 1.822 1.462 0.184 0.329 1.662 
50 0.234 0.061 2.531 2.116 0.312 0.440 1.684 
54 0.244 0.041 3.479 2.653 0.244 0.454 1.268 
57 0.190 0.034 3.271 2.703 0.183 0.630 1.172 
61 0.105 0.032 3.118 2.446 0.251 0.480 1.303 
64 0.078 0.033 1.274 1.062 0.178 0.342 0.428 
68 0.130 NA 2.424 2.036 0.365 0.574 0.672 
71 0.126 0.036 2.801 2.170 0.414 0.538 0.824 
75 0.106 0.035 2.343 1.872 0.244 0.455 0.604 
82 0.138 0.046 2.133 1.998 0.319 0.375 0.572 
89 0.079 NA 0.925 1.212 0.419 0.556 0.135 
96 0.065 NA 0.697 0.676 0.257 0.207 0.052 
99 0.107 0.037 0.782 0.632 0.309 0.293 0.098 
106 0.063 0.041 0.839 0.830 0.353 0.172 0.026 
113 0.056 0.029 1.029 0.774 0.319 0.063 0.052 
127 0.078 NA 1.213 1.199 0.247 0.204 0.066 
141 0.046 NA 0.642 0.793 0.482 0.211 0.034 
155 0.063 0.026 0.867 1.249 0.594 0.309 0.036 
169 0.079 0.024 0.996 0.835 0.276 0.121 0.036 
183 0.077 NA 1.477 1.210 0.228 0.098 0.035 
197 0.078 0.028 1.572 1.361 0.273 0.409 0.040 
204 0.029 NA 0.801 0.915 0.111 0.110 0.020 
211 0.037 0.026 0.747 0.847 0.146 0.134 0.028 
218 0.029 0.031 0.906 0.844 0.094 0.127 0.029 
225 0.048 NA 0.970 1.263 0.296 0.204 0.042 
232 0.038 NA 0.893 0.842 0.210 0.216 0.047 
241 0.072 0.046 4.018 3.595 0.387 0.144 0.214 
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Lochbo 
Amy testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
0 0.025 0.028 2.391 2.828 0.111 0.107 0.209 
5 0.080 0.056 8.759 10.053 0.642 0.120 0.568 
9 0.059 0.059 7.535 7.797 0.393 0.128 0.811 
12 0.097 0.120 4.410 3.795 0.279 0.263 1.064 
16 0.060 0.047 2.552 2.093 0.216 0.236 0.998 
19 0.028 0.033 1.191 1.038 0.027 0.107 0.410 
23 0.084 0.035 3.661 3.013 0.377 0.254 1.192 
26 0.017 0.028 0.517 0.641 0.015 0.062 0.206 
30 0.022 0.028 0.849 0.971 0.024 0.059 0.361 
33 0.020 0.028 0.791 0.819 0.002 0.048 0.371 
37 0.039 0.034 1.001 0.916 0.044 0.086 0.543 
40 0.056 0.037 1.824 1.789 0.050 0.164 1.064 
44 0.030 0.028 2.309 2.167 0.167 0.113 0.558 
48 0.075 0.064 5.383 4.739 0.222 0.311 1.290 
50 0.053 0.037 2.329 2.366 0.096 0.138 0.846 
54 0.039 0.028 3.510 1.644 0.471 0.085 N/A 
58 0.134 0.072 5.110 3.377 0.301 0.807 1.234 
61 0.097 0.036 2.791 2.875 0.155 0.213 0.658 
65 0.054 0.027 2.171 2.244 0.069 0.134 0.460 
68 0.166 0.070 5.159 3.462 0.169 0.478 1.014 
72 0.130 0.028 5.373 3.374 0.359 0.329 0.562 
75 0.120 0.045 13.930 6.802 2.671 0.942 0.439 
79 0.088 0.044 0.730 0.338 0.038 0.087 0.117 
82 0.118 0.049 2.056 1.649 0.125 0.302 0.210 
86 0.143 0.028 1.977 1.494 0.256 0.281 0.199 
93 0.140 0.036 2.067 1.457 0.199 0.208 0.096 
100 0.279 NA 2.946 3.334 0.899 0.754 0.155 
107 0.130 NA 1.227 1.507 0.568 0.519 0.070 
114 0.094 0.026 1.300 1.410 0.198 0.203 0.032 
117 0.049 0.028 2.114 2.225 0.349 0.399 0.045 
125 0.037 NA 1.041 1.471 0.097 0.191 0.050 
132 0.094 NA 4.161 2.882 0.395 0.174 0.033 
139 0.026 NA 1.903 1.541 0.095 0.065 0.020 
153 0.093 0.023 3.189 2.322 0.464 0.227 0.034 
160 0.024 NA 0.734 0.612 0.040 0.057 0.019 
167 0.068 0.049 2.385 1.942 0.108 0.159 0.026 
174 0.099 0.021 3.218 2.469 0.516 0.291 0.016 
181 0.011 0.025 0.395 0.352 0.004 0.036 0.007 
188 0.108 0.089 6.422 4.323 0.377 0.398 0.052 
195 0.179 0.100 32.010 17.574 14.415 1.464 0.180 
 
  
 226 
 
BPIMA testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Area 
Ratio 
0 0.022 0.003 2.755 3.082 NA NA 0.901 
4 0.070 0.030 4.626 8.059 0.258 0.314 3.482 
8 0.025 0.037 3.147 3.078 0.049 0.185 1.309 
11 0.022 0.041 5.430 6.827 0.183 0.100 1.917 
15 0.084 0.031 4.293 2.571 0.039 0.157 8.680 
18 0.026 0.012 0.839 0.618 0.077 0.030 5.787 
22 0.032 0.015 2.202 1.780 0.122 0.074 10.427 
25 0.022 0.014 0.783 0.483 0.055 NA 3.336 
29 0.046 0.017 1.298 0.935 0.068 NA 10.692 
32 0.062 0.022 2.643 1.765 0.062 0.110 17.192 
36 0.106 0.030 0.713 0.376 NA 0.331 21.133 
41 0.193 0.017 3.274 2.150 0.088 0.171 23.920 
46 0.032 0.009 1.279 1.136 NA 0.051 7.870 
50 0.154 0.023 3.706 2.378 0.144 0.205 19.970 
53 0.035 0.011 1.488 1.351 0.007 0.064 4.280 
57 0.049 0.014 1.693 1.202 0.052 0.263 5.019 
64 0.068 0.011 1.891 1.463 0.073 0.058 5.164 
71 0.066 0.017 1.912 1.354 0.075 0.126 4.140 
78 0.034 0.012 1.790 1.380 0.030 0.033 2.132 
84 0.073 0.015 2.142 1.126 0.025 0.129 2.749 
92 0.081 0.028 1.255 0.634 0.066 0.141 1.578 
99 0.058 0.011 1.227 0.449 NA 0.086 0.824 
106 0.068 0.016 1.277 0.653 0.019 0.084 0.437 
123 0.048 0.007 0.423 0.363 NA NA 0.315 
137 0.095 0.022 1.457 0.984 0.139 0.096 0.198 
151 0.060 0.017 1.438 0.747 NA 0.055 0.109 
166 0.057 0.018 1.249 0.647 0.107 NA 0.105 
173 0.067 0.026 1.525 0.878 NA 0.085 0.136 
194 0.056 0.017 1.566 0.807 0.069 0.053 0.121 
208 0.085 0.016 2.169 1.185 0.061 0.113 0.201 
222 0.084 0.020 2.175 1.379 0.081 0.123 0.252 
236 0.052 0.015 1.247 0.658 0.155 0.044 0.336 
250 0.063 0.024 1.360 0.705 NA NA 0.383 
264 0.077 0.021 1.904 1.093 0.061 0.061 0.593 
271 0.068 0.014 1.558 0.962 0.061 0.057 0.634 
278 0.073 0.014 1.362 1.002 NA 0.057 0.642 
285 0.073 0.019 1.895 1.248 0.082 0.060 0.658 
294 0.070 0.015 2.404 1.530 0.060 0.079 0.686 
299 0.063 0.022 5.462 3.226 0.124 0.219 2.229 
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The Alarm's 
On testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Area 
Ratio 
4 0.050 0.170 7.637 3.899 0.264 0.129 0.521 
6 0.021 0.113 4.482 2.975 0.096 0.072 0.446 
10 0.030 0.132 6.242 3.961 0.190 0.061 0.551 
14 0.051 0.173 7.383 3.297 0.279 0.110 1.406 
18 0.060 0.175 7.888 3.972 0.328 0.149 1.446 
21 0.034 0.150 6.467 4.473 0.129 0.144 0.466 
25 0.070 0.182 6.709 3.103 0.689 0.219 0.308 
28 0.036 0.151 3.544 2.761 0.128 0.142 0.127 
32 0.054 0.167 5.580 4.077 0.186 0.193 0.213 
36 0.084 0.184 6.428 4.446 0.253 0.243 0.411 
39 0.057 0.159 6.334 5.314 0.239 0.212 0.315 
43 0.043 0.168 3.601 2.314 0.179 0.169 0.218 
46 0.023 0.136 2.201 2.108 0.103 0.098 0.114 
48 0.011 0.113 1.189 0.980 0.050 0.055 0.046 
53 0.030 0.174 2.585 2.389 0.115 0.134 0.081 
57 0.034 0.179 2.817 2.064 0.073 0.117 0.058 
60 0.023 0.138 1.552 1.567 0.069 0.083 0.042 
62 0.017 0.144 1.166 1.038 0.028 0.073 0.040 
67 0.033 0.165 1.965 1.333 0.070 0.098 0.045 
71 0.049 0.208 3.708 2.601 0.187 0.132 0.057 
74 0.034 0.227 1.687 1.363 0.092 0.088 0.048 
81 0.031 0.168 2.184 1.412 0.085 0.094 0.045 
89 0.015 0.385 1.893 2.008 0.120 0.150 0.047 
91 0.024 0.491 1.876 1.747 0.030 0.132 0.042 
95 0.027 0.300 4.273 2.797 0.165 0.167 0.082 
98 0.068 0.225 5.324 2.857 0.153 0.171 0.077 
102 0.061 0.212 7.558 3.961 0.181 0.249 0.291 
105 0.023 0.151 2.931 2.268 0.087 0.099 0.098 
109 0.053 0.168 4.820 3.078 0.195 0.101 0.288 
113 0.027 0.118 4.543 2.795 0.213 0.065 0.243 
117 0.081 0.227 9.640 4.038 1.675 0.149 1.339 
126 0.059 0.189 6.208 4.165 0.252 0.225 0.496 
133 0.075 0.190 6.120 4.154 0.306 0.188 0.556 
140 0.065 0.191 6.119 4.301 0.269 0.205 0.919 
146 0.151 0.206 7.590 4.908 0.444 0.313 1.112 
154 0.025 0.069 1.906 1.223 0.041 0.166 0.188 
161 0.059 0.104 2.709 1.662 0.176 0.159 0.189 
168 0.065 0.079 3.060 2.352 0.056 0.133 0.228 
175 0.051 0.047 2.741 1.875 0.112 0.141 0.175 
189 0.074 0.067 2.883 2.053 0.108 0.209 0.079 
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Saunders 
Pet testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days 
post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Area 
Ratio 
4 0.021 0.045 2.883 1.434 0.056 0.079 0.061 
7 0.019 0.045 3.876 1.903 0.144 0.092 0.122 
14 0.055 0.080 9.643 3.296 0.738 0.141 0.742 
22 0.063 0.105 3.723 1.833 0.174 0.153 1.255 
24 0.018 0.058 1.895 1.285 0.062 0.101 1.536 
28 0.044 0.128 2.931 1.538 0.112 0.147 1.609 
32 0.046 0.085 2.962 1.667 0.109 0.133 2.010 
36 0.027 0.068 1.732 1.061 0.078 0.085 1.647 
40 0.034 0.175 1.711 1.205 0.048 0.089 2.156 
42 0.016 0.067 2.062 1.302 0.030 0.107 1.158 
46 0.020 0.052 1.288 0.822 0.051 0.075 0.898 
50 0.080 0.181 3.834 1.986 0.089 0.143 2.161 
54 0.050 0.103 2.937 1.176 0.061 0.101 1.535 
57 0.033 0.070 1.773 1.005 0.062 0.077 0.881 
59 0.015 0.057 1.183 0.649 0.026 0.050 0.424 
63 0.025 0.063 1.388 0.845 0.044 0.076 0.480 
67 0.030 0.045 1.560 0.839 0.071 0.084 0.477 
70 0.024 0.038 1.687 0.887 0.020 0.078 0.322 
74 0.024 0.062 1.220 0.727 0.008 0.059 0.212 
78 0.012 0.029 1.146 0.663 0.018 0.043 0.205 
84 0.037 0.108 2.399 1.124 0.036 0.075 0.338 
92 0.035 0.108 2.503 0.967 0.024 0.100 0.388 
99 0.028 0.120 1.890 0.717 0.001 0.087 0.157 
106 0.030 0.072 1.942 0.787 0.030 0.104 0.085 
116 0.008 0.064 0.583 0.407 0.017 0.033 0.012 
130 0.011 0.043 1.064 0.681 0.024 0.045 0.025 
136 0.009 0.057 0.725 0.480 0.019 0.038 0.013 
151 0.007 0.077 0.705 0.372 0.014 0.035 0.005 
158 0.021 0.068 1.068 0.572 0.033 0.053 N/A 
173 0.004 0.030 1.045 0.408 0.040 0.067 N/A 
177 0.011 0.088 0.889 0.535 0.047 0.045 0.013 
193 0.034 0.094 1.733 1.056 0.064 0.132 0.011 
200 0.026 0.065 1.416 0.991 0.063 0.074 0.010 
214 0.010 0.056 1.036 0.684 0.056 0.057 0.011 
235 0.008 0.048 1.206 0.578 0.042 0.049 0.016 
249 0.012 0.053 1.818 0.924 0.063 0.053 0.014 
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Standard 
Whisper testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
0 0.032 0.078 2.588 2.116 0.388 0.295 1.183 
2 0.055 0.116 5.723 4.195 0.545 0.184 2.415 
6 0.098 0.141 17.877 10.247 1.670 0.240 4.354 
10 0.108 0.134 7.982 6.334 0.303 0.385 1.051 
13 0.115 0.048 4.265 2.879 0.124 0.400 0.891 
17 0.082 0.039 6.925 2.032 0.378 0.268 1.040 
21 0.153 0.005 2.826 1.443 0.130 0.257 0.278 
23 0.118 0.279 3.052 3.394 0.286 0.489 14.140 
27 0.174 0.106 3.835 3.632 0.163 0.430 14.267 
31 0.150 0.297 2.636 2.298 0.123 0.317 7.303 
34 0.157 0.187 1.837 1.635 0.226 0.318 6.096 
38 0.206 0.288 3.244 2.886 0.171 0.406 10.813 
41 0.365 0.556 5.847 4.630 0.286 0.676 29.057 
45 0.266 0.128 5.849 4.524 0.235 0.523 32.064 
48 0.234 0.081 6.674 1.554 0.690 0.224 0.936 
52 0.268 0.337 4.391 4.006 0.225 0.326 11.612 
56 0.059 0.015 1.900 1.008 0.060 0.078 0.498 
58 0.246 0.418 2.532 2.069 0.501 0.259 4.925 
62 0.168 0.229 4.106 3.307 0.166 0.285 4.633 
66 0.121 0.148 2.697 1.634 0.087 0.173 1.333 
69 0.123 0.177 1.984 1.222 0.108 0.167 1.035 
73 0.180 0.236 3.322 1.716 0.108 0.150 0.873 
76 0.188 0.143 2.143 0.709 0.311 0.201 0.422 
80 0.088 0.215 1.323 1.069 0.152 0.168 4.367 
84 0.079 0.057 1.372 0.890 0.201 0.157 2.137 
86 0.062 0.161 0.999 0.650 0.139 0.148 1.501 
90 0.089 0.303 1.102 0.772 0.331 0.151 1.473 
97 0.040 0.175 0.665 0.428 0.101 0.086 0.406 
104 0.034 0.093 0.844 0.555 0.098 0.087 0.393 
111 0.031 0.158 0.905 0.628 0.119 0.111 0.282 
126 0.027 0.019 0.780 0.516 0.143 0.096 0.312 
132 0.029 0.138 0.700 0.421 0.146 0.109 0.219 
139 0.047 0.121 0.655 0.464 0.163 0.123 0.232 
146 0.040 0.151 0.692 0.524 0.141 0.124 0.228 
153 0.009 0.027 0.346 0.231 0.075 0.053 0.164 
160 0.053 0.068 0.643 0.438 0.126 0.085 0.212 
167 0.071 0.040 0.997 0.647 0.117 0.101 0.277 
174 0.041 0.042 0.987 0.529 0.155 0.114 0.198 
181 0.011 0.018 0.696 0.393 0.128 0.078 0.179 
184 0.024 0.009 0.304 0.196 0.097 0.031 0.129 
188 0.020 0.030 1.266 0.843 0.122 0.095 0.230 
195 0.037 0.040 1.535 1.184 0.165 0.133 0.274 
202 0.074 0.064 3.975 2.351 0.276 0.227 1.448 
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Cullane Chief testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
0 0.120 0.033 7.981 7.477 0.387 0.405 1.228 
4 0.143 0.046 20.313 10.517 0.721 0.814 4.438 
8 0.137 0.079 6.952 5.101 0.284 0.661 5.109 
11 0.240 0.113 12.544 7.874 0.501 1.130 16.311 
15 0.269 0.124 18.260 9.040 0.741 1.331 16.471 
18 0.357 0.132 16.624 9.978 0.451 1.395 13.102 
22 0.169 0.059 5.258 4.180 0.212 0.355 1.875 
25 0.274 0.134 10.355 7.741 0.392 0.682 3.892 
33 0.184 0.092 5.696 4.857 0.250 0.568 4.673 
35 0.251 0.106 13.418 7.129 0.378 1.201 27.659 
39 0.247 0.031 4.517 3.668 0.906 0.580 13.361 
41 0.269 0.043 5.648 3.785 0.273 0.919 9.306 
46 0.302 0.121 7.126 4.606 0.323 0.932 8.514 
50 0.300 0.079 4.906 2.838 0.290 0.724 2.739 
60 0.260 0.016 2.920 1.957 0.470 0.490 0.663 
64 0.228 0.017 4.079 1.481 0.117 0.286 0.478 
68 0.122 0.040 1.977 1.484 0.548 0.385 1.259 
70 0.128 0.016 2.078 1.272 0.153 0.458 1.444 
74 0.145 0.036 2.627 1.920 0.354 0.457 1.175 
78 0.088 0.008 1.779 1.028 0.106 0.261 0.318 
81 0.111 0.059 3.127 2.087 0.280 0.362 2.815 
85 0.069 0.055 2.831 1.654 0.146 0.309 2.045 
88 0.054 0.035 1.559 0.976 0.094 0.197 1.207 
92 0.046 0.062 2.473 1.564 0.158 0.220 1.798 
95 0.065 0.051 2.460 1.619 0.186 0.251 1.818 
99 0.045 0.066 2.336 1.402 0.161 0.230 1.582 
105 0.049 0.070 2.059 1.978 0.183 0.229 1.599 
109 0.060 0.061 2.109 1.235 0.152 0.195 1.400 
116 0.033 0.044 1.569 1.002 0.122 0.157 0.850 
130 0.051 0.074 2.314 1.407 0.160 0.184 1.427 
138 0.009 0.008 0.307 0.268 0.060 0.140 0.297 
144 0.059 0.071 2.695 1.510 0.179 0.295 1.406 
151 0.036 0.040 1.976 1.212 0.210 0.211 1.181 
158 0.036 0.060 1.939 1.148 0.150 0.222 1.445 
166 0.034 0.054 2.405 1.385 0.142 0.230 1.557 
172 0.053 0.069 4.546 2.342 0.202 0.289 4.064 
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Flo Jo testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
Area 
Ratio 
0 0.015 0.033 1.295 0.979 0.112 0.016 0.062 
5 0.024 0.052 4.055 1.620 1.020 0.028 0.166 
9 0.134 0.102 17.020 6.247 1.527 0.209 1.353 
13 0.019 0.060 1.921 0.638 0.853 0.046 4.494 
16 0.017 0.097 1.320 0.652 0.308 0.064 16.011 
20 0.031 0.123 1.143 0.726 0.351 0.133 21.264 
24 0.051 0.040 2.827 1.593 0.353 0.420 43.741 
26 0.038 0.193 1.694 1.076 0.207 0.205 39.087 
30 0.064 0.198 2.625 1.481 0.794 0.273 58.619 
34 0.068 0.308 1.910 1.359 0.509 0.206 49.661 
41 0.073 0.328 1.461 2.761 0.338 0.141 33.952 
44 0.033 0.160 1.102 0.938 0.193 0.083 22.616 
48 0.051 0.158 1.426 1.142 0.098 0.133 33.224 
51 0.068 0.181 1.382 1.173 0.229 0.110 15.307 
55 0.055 0.227 1.627 1.142 0.241 0.182 18.752 
58 0.046 0.225 1.213 0.785 0.220 0.095 11.397 
62 0.047 0.230 1.434 0.932 0.322 0.154 12.121 
65 0.044 0.097 1.223 0.904 0.388 0.128 10.428 
69 0.053 0.168 2.096 1.561 0.388 0.191 12.716 
72 0.052 0.165 0.638 0.514 0.193 0.134 3.159 
76 0.048 0.153 1.546 0.852 0.466 0.218 5.851 
79 0.035 0.153 0.912 0.691 0.175 0.135 3.605 
83 0.040 0.099 1.177 0.668 0.299 0.205 4.454 
86 0.029 0.023 0.474 0.344 0.088 0.092 1.139 
90 0.021 0.065 0.634 0.365 0.124 0.104 0.981 
93 0.028 0.047 0.479 0.285 0.116 0.077 0.594 
97 0.008 0.061 0.347 0.261 0.111 0.062 0.488 
100 0.017 0.114 0.362 0.243 0.136 0.060 0.443 
104 0.017 0.053 0.631 0.316 0.130 0.093 0.303 
107 0.017 0.064 0.427 0.257 0.070 0.074 0.259 
110 0.022 0.066 0.375 0.295 0.075 0.059 0.279 
117 0.020 0.045 0.377 0.285 0.049 0.078 0.146 
124 0.020 0.026 0.453 0.277 0.046 0.049 0.153 
131 0.017 0.023 0.388 1.234 0.075 0.063 0.122 
159 0.032 0.030 1.807 0.468 0.274 0.189 0.345 
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Whitefort 
Euro testosterone epitest aBB_Adiol epiandro BaB_Adiol etio 117 ion 
Days post 
season (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Area Ratio 
4 0.028 0.122 3.897 3.614 0.376 0.260 2.008 
8 0.044 0.219 7.515 5.627 0.596 0.429 4.971 
12 0.152 0.028 31.846 15.939 1.409 0.801 14.349 
14 0.045 0.117 5.560 4.233 0.364 0.403 14.889 
18 0.091 0.288 7.349 3.365 0.801 1.013 34.256 
22 0.043 0.192 5.023 3.429 0.382 0.410 25.828 
25 0.017 0.049 2.300 1.649 0.285 0.232 16.536 
29 0.032 0.163 3.109 2.329 0.366 0.412 24.059 
32 0.079 0.323 4.918 3.252 0.202 0.622 34.879 
36 0.026 0.190 2.048 2.040 0.139 0.198 17.021 
39 0.021 0.059 1.882 1.389 0.069 0.193 16.932 
43 0.050 0.252 2.847 2.514 0.152 0.366 23.343 
47 0.016 0.015 1.212 0.995 0.083 0.105 10.359 
49 0.029 0.018 2.393 1.991 0.135 0.275 20.680 
53 0.057 0.381 2.739 2.395 0.137 0.309 15.808 
55 0.062 0.266 2.839 2.200 0.112 0.380 20.662 
60 0.089 0.370 4.990 3.929 0.226 0.485 25.632 
64 0.056 0.377 3.833 2.870 0.108 0.374 16.921 
71 0.059 0.332 2.352 2.361 0.154 0.256 8.640 
78 0.024 0.171 1.667 1.204 0.114 0.190 5.521 
84 0.046 0.237 2.214 1.274 0.155 0.244 5.620 
92 0.032 0.255 0.937 0.726 0.186 0.119 1.753 
99 0.048 0.205 1.582 1.002 0.057 0.172 1.977 
106 0.021 0.131 1.175 1.172 0.088 0.181 1.238 
117 0.320 0.053 1.000 0.614 0.055 0.288 0.701 
130 0.040 0.232 1.525 1.213 0.037 0.214 0.561 
144 0.021 0.089 1.231 0.903 0.133 0.198 0.420 
158 0.019 0.132 1.010 0.701 0.058 0.141 0.339 
172 0.018 0.096 1.759 1.137 0.105 0.166 0.369 
186 0.018 0.109 1.078 0.721 0.068 0.104 0.231 
200 0.027 0.126 1.068 0.731 0.084 0.156 0.369 
214 0.017 0.140 1.288 0.950 0.117 0.197 0.309 
228 0.059 0.259 3.585 1.880 0.171 0.350 0.628 
242 0.050 0.215 2.931 1.826 0.319 0.226 0.455 
249 0.001 0.033 0.893 0.493 0.100 0.058 0.167 
256 0.043 0.183 3.109 2.052 0.169 0.301 2.917 
263 0.031 0.109 5.673 3.383 0.298 0.403 0.638 
270 0.036 0.118 3.521 2.157 0.210 0.345 0.341 
277 0.043 0.145 2.939 1.874 0.258 0.309 0.598 
285 0.050 0.044 7.438 4.711 0.781 0.531 0.957 
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Queen of the Bar aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 0.466 0.852 0.056 
4 7.317 3.098 0.110 
8 24.607 9.134 0.169 
11 4.678 1.618 0.641 
15 7.023 1.499 1.100 
18 5.492 1.590 3.362 
22 4.002 1.192 0.783 
25 6.029 1.273 2.634 
29 1.596 0.780 0.873 
33 1.576 1.136 1.684 
35 4.040 0.991 1.196 
39 4.528 0.904 3.331 
41 5.441 1.066 2.750 
46 6.610 1.241 1.518 
50 4.159 1.055 0.810 
53 11.065 1.113 0.384 
57 0.930 0.839 0.353 
60 1.891 0.975 0.321 
64 2.461 1.187 0.033 
68 1.492 1.144 0.223 
70 1.335 0.940 0.133 
74 2.453 1.444 0.147 
78 1.305 0.941 0.110 
81 1.428 1.146 0.108 
88 2.101 1.462 0.068 
95 1.362 1.122 0.040 
103 0.301 0.601 0.023 
109 1.358 0.928 0.019 
123 0.652 0.671 0.039 
130 1.332 0.928 0.029 
144 1.238 0.925 0.010 
151 0.834 0.792 0.033 
158 1.812 1.043 0.016 
166 0.502 0.647 0.018 
172 0.951 0.763 0.050 
179 2.084 1.410 0.034 
186 1.727 1.446 0.041 
193 2.714 1.768 0.043 
200 3.317 1.757 0.124 
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Queen Boadicea aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
-15 0.978 0.936 0.009 
-8 1.122 1.098 0.013 
-1 2.489 1.493 0.036 
0 N/A N/A N/A 
1 4.188 2.237 0.038 
5 7.739 4.252 0.045 
9 6.329 3.610 0.084 
13 1.016 1.021 0.152 
15 1.451 1.311 0.280 
19 0.326 0.583 0.174 
23 1.066 1.341 0.389 
26 0.935 0.964 0.346 
30 0.961 1.009 0.492 
33 1.946 1.628 0.610 
37 1.971 1.661 0.521 
40 1.737 1.273 0.482 
44 1.544 1.176 0.536 
50 1.607 1.161 0.404 
54 1.546 1.285 0.293 
58 1.762 1.255 0.355 
61 4.203 2.198 0.050 
65 1.310 1.267 0.023 
68 0.724 0.817 0.021 
72 1.106 0.878 0.021 
76 0.978 0.871 0.040 
78 0.697 0.723 0.027 
85 1.230 0.981 0.051 
106 0.459 0.637 0.009 
127 1.150 0.986 0.037 
141 0.241 0.704 0.054 
148 0.311 0.670 0.035 
155 0.994 0.931 0.053 
162 0.756 0.777 0.069 
169 1.121 0.873 0.116 
183 0.503 0.611 0.087 
190 1.031 0.874 0.155 
197 0.828 0.826 0.238 
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Langies Posh Girl aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
5 1.868 1.563 0.040 
9 2.571 1.899 0.187 
12 1.103 0.792 0.733 
16 1.454 1.128 0.840 
19 0.768 0.637 1.030 
23 1.133 0.810 1.190 
26 1.975 1.708 0.888 
30 0.631 0.347 0.607 
33 1.112 0.859 0.724 
37 0.999 0.853 1.389 
40 0.573 0.325 0.344 
44 1.161 0.906 1.429 
47 1.026 0.846 0.547 
51 0.805 0.514 0.316 
54 0.700 0.370 0.211 
58 1.001 0.413 0.270 
65 0.878 0.625 0.254 
72 0.727 0.449 0.104 
79 0.294 0.058 0.073 
82 0.547 0.437 0.062 
91 0.456 0.256 0.117 
96 0.484 0.304 0.049 
100 0.600 0.579 0.042 
107 0.648 0.849 0.058 
124 0.616 0.426 0.033 
138 0.697 0.478 0.035 
149 0.733 0.644 0.023 
166 0.925 0.470 0.035 
180 0.496 0.300 0.022 
194 0.795 0.394 0.054 
208 0.514 0.340 0.041 
222 0.561 0.320 0.029 
236 0.478 0.380 0.012 
257 0.492 0.125 0.044 
271 0.416 0.218 0.046 
285 1.855 0.488 0.034 
299 0.492 0.318 0.022 
313 1.324 0.570 0.056 
327 3.053 0.341 0.226 
333 3.322 1.463  
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Ringlestown Flos aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
5 7.601 2.627 0.198 
9 41.294 9.649 0.383 
13 8.618 4.553 0.566 
16 2.756 0.347 1.137 
20 1.282 0.953 0.502 
23 1.270 0.825 0.867 
27 2.013 1.097 1.067 
30 2.362 0.605 0.984 
34 2.687 2.070 1.817 
37 1.614 0.733 1.298 
41 3.833 3.025 1.558 
44 3.308 0.421 1.025 
48 2.552 1.567 0.789 
51 2.218 1.058 0.415 
55 3.206 0.654 0.601 
58 1.117 0.449 0.159 
62 1.081 0.493 0.103 
65 2.062 0.966 0.093 
69 0.662 0.393 0.044 
72 0.506 0.208 0.044 
79 1.077 0.636 0.024 
86 5.064 2.664 0.037 
90 8.715 5.096 0.048 
100 0.622 0.524 0.009 
108 7.014 1.756 0.172 
110 2.333 1.465 0.033 
121 2.518 0.420 0.245 
128 7.190 3.427 0.019 
135 4.623 2.462 0.043 
149 7.942 4.389 0.034 
163 7.548 2.923 0.059 
170 8.627 4.318 0.058 
185 4.788 1.993 0.046 
213 3.512 2.553 0.095 
220 9.071 3.894 0.059 
227 10.896 6.040 0.033 
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GIVEHERTHEVOTE aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 5.904 5.332 0.079 
4 18.937 16.769 0.148 
7 2.528 1.693 0.125 
11 2.618 2.366 0.305 
14 2.759 2.092 0.692 
18 1.313 1.126 0.475 
21 1.964 1.450 0.515 
25 2.245 1.482 0.586 
28 2.482 1.791 0.629 
32 2.376 1.494 0.813 
35 2.842 1.526 0.563 
39 3.520 2.195 0.780 
42 1.643 1.221 0.509 
46 4.268 2.478 1.151 
49 2.649 1.671 0.490 
53 3.024 2.343 0.325 
56 3.618 2.018 0.280 
60 2.427 1.543 0.348 
63 2.261 1.736 0.140 
67 1.840 1.564 0.146 
70 2.557 1.447 0.141 
74 2.768 1.617 0.129 
77 2.218 1.109 0.070 
84 1.256 1.052 0.039 
88 2.450 1.585 0.022 
94 1.692 0.871 0.030 
101 1.449 0.883 0.024 
108 0.350 0.320 0.021 
115 0.666 0.537 0.012 
122 0.580 0.440 0.009 
129 0.708 0.619 0.008 
143 0.543 0.487 0.007 
157 1.369 0.910 0.015 
171 0.475 0.364 0.010 
185 2.951 1.667 0.025 
213 1.743 0.919 0.018 
227 4.760 3.252 0.014 
254 5.105 2.529 0.022 
269 3.296 1.519 0.020 
277 4.998 2.647 0.015 
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Wideopenspaces aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) 
Area 
Ratio 
0 5.825 3.593 0.027 
4 2.360 1.880 0.021 
8 4.285 3.925 0.098 
12 5.072 5.347 0.056 
17 0.636 0.540 0.140 
21 0.704 0.754 0.195 
25 0.263 0.494 0.195 
28 0.666 0.776 0.251 
32 1.501 3.373 0.195 
35 1.523 1.320 0.459 
39 1.017 0.871 0.414 
42 2.000 1.392 0.450 
46 1.468 1.530 0.348 
49 0.437 0.594 0.080 
53 2.287 2.276 0.433 
56 1.117 0.872 0.126 
60 3.845 2.496 0.171 
63 3.226 1.831 0.232 
67 1.054 0.730 0.118 
70 0.920 0.816 0.058 
74 0.609 0.525 0.048 
77 0.586 0.498 0.067 
81 0.186 0.234 0.041 
84 0.158 0.129 0.024 
88 0.113 0.036 0.022 
91 0.232 0.220 0.030 
95 1.927 1.097 0.010 
98 0.233 0.435 0.009 
102 0.725 0.498 0.021 
108 0.671 0.478 0.036 
112 1.297 0.875 0.047 
115 0.486 0.535 0.006 
119 0.045 0.093 0.011 
122 0.127 0.819 0.035 
129 0.470 0.377 0.015 
136 0.932 0.717 0.014 
143 0.461 0.319 0.017 
158 0.866 0.523 0.023 
164 0.722 0.438 0.048 
171 0.356 0.776 0.017 
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Marshal Promise aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 7.271 4.824 0.117 
4 3.525 1.927 0.081 
7 3.149 3.502 0.148 
14 0.876 0.389 0.941 
18 1.005 0.399 3.193 
22 0.754 0.369 1.251 
25 1.096 0.690 4.176 
29 1.038 0.491 2.626 
32 1.494 0.748 4.576 
36 1.660 0.935 5.783 
39 2.020 1.079 7.290 
43 2.072 1.217 5.132 
46 2.125 1.155 7.374 
50 0.741 0.412 0.792 
53 2.189 1.126 2.954 
57 2.122 1.371 1.634 
64 0.717 0.250 N/A 
71 1.821 0.872 N/A 
78 1.070 0.516 0.139 
85 0.916 0.201 0.150 
92 0.962 0.839 0.028 
99 1.347 0.614 0.085 
106 0.882 0.278 0.081 
120 0.328 0.146 0.041 
127 0.669 0.229 0.019 
140 1.745 0.961 0.061 
154 1.206 0.540 0.029 
182 1.167 0.561 0.044 
210 2.733 2.126 0.052 
224 0.950 0.295 0.046 
238 7.735 4.923 0.025 
251 1.601 0.812 0.042 
284 3.559 1.992 0.010 
294 3.468 2.117 0.018 
308 2.580 2.090 0.059 
322 0.980 0.291 0.025 
336 9.258 6.213 0.039 
350 4.802 3.423 0.014 
364 13.768 6.828 0.123 
 
  
 240 
 
Distant Pearl aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 6.823 4.012 0.105 
4 8.072 3.174 0.185 
7 6.833 2.613 0.124 
11 3.694 2.206 0.170 
14 1.538 0.537 1.563 
18 1.628 0.578 0.850 
21 1.655 0.488 1.546 
25 1.094 0.305 0.823 
28 1.515 0.401 1.074 
32 1.870 0.494 1.250 
35 2.205 0.926 1.724 
39 2.838 1.096 2.330 
42 2.207 0.875 1.385 
46 1.450 0.676 0.971 
49 1.809 0.446 0.712 
53 1.682 0.402 0.710 
60 2.999 1.084 1.008 
67 1.909 0.703 0.405 
74 1.447 0.548 0.101 
81 0.962 0.265 0.098 
88 1.277 0.451 0.023 
95 1.178 0.412 0.058 
102 0.887 0.271 0.091 
108 0.937 0.217 0.045 
115 0.712 0.135 0.093 
136 1.008 0.336 0.092 
164 1.271 0.470 0.012 
178 0.972 0.329  
206 7.823 4.482 0.091 
234 4.018 1.500 0.108 
262 2.210 0.668 0.033 
280 1.654 0.574 0.011 
304 5.091 2.043 0.016 
332 2.615 1.045 0.026 
360 0.849 0.130 0.027 
388 1.117 0.635 0.030 
416 0.860 0.180 0.021 
430 1.293 0.389 0.023 
444 0.724 0.208 0.088 
469 3.054 1.449 0.052 
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Drumpark Access aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 5.762 3.997 0.136 
14 1.381 1.236 0.854 
21 1.415 0.783 1.132 
42 4.076 1.633 1.093 
56 7.531 3.557 0.892 
63 2.768 1.255 0.182 
70 1.142 0.100 0.026 
77 0.897 0.439 0.016 
84 0.872 0.339 0.026 
91 0.434 0.090 0.061 
98 0.537 0.238 0.022 
105 1.040 0.560 0.012 
112 0.530 0.080 0.053 
119 0.548 0.204 0.005 
126 0.667 0.175 0.068 
133 1.212 0.424 0.055 
140 1.108 0.393 0.045 
147 0.992 0.354 0.003 
154 0.785 0.268 0.024 
168 0.987 0.424 0.070 
175 0.992 0.356 0.038 
182 0.951 0.423 0.049 
189 1.327 1.016 0.044 
196 1.366 0.609 0.096 
203 0.827 0.288 0.047 
210 0.620 0.286 0.021 
217 1.270 0.902 0.063 
224 1.875 0.761 0.085 
231 1.900 0.890 0.075 
238 2.498 1.428 0.025 
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Cannon Clover aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 5.160 7.679 0.118 
4 5.222 6.356 0.111 
7 5.711 4.412 0.205 
14 21.899 24.551 0.166 
18 8.834 7.653 0.708 
21 2.122 1.885 0.058 
25 1.306 1.441 0.070 
32 2.813 2.505 0.043 
35 1.453 1.438 0.046 
39 1.748 2.460 0.058 
42 2.461 2.451 0.070 
46 1.617 1.576 0.055 
49 1.819 1.985 0.044 
56 1.833 2.169 0.043 
60 3.498 2.937 0.040 
67 2.898 2.589 0.048 
70 1.662 1.338 0.038 
74 3.537 3.323 0.044 
77 2.476 3.009 0.035 
81 3.507 4.303 0.058 
84 8.088 8.399 0.038 
91 2.604 2.766 0.026 
98 3.525 3.450 0.041 
105 10.895 11.436 0.123 
116 3.520 3.490 1.656 
123 2.855 2.530 1.920 
137 1.087 1.958 1.063 
144 3.597 3.072 2.513 
151 3.163 4.167 2.754 
158 3.632 4.653 3.013 
171 4.271 4.581 3.122 
178 4.844 4.985 2.621 
185 4.126 4.444 0.808 
192 3.234 3.691 1.480 
206 4.076 4.342 0.963 
213 3.948 3.052 0.801 
228 5.215 4.890 0.346 
234 2.024 3.403 0.173 
247 2.197 1.739 0.080 
255 2.150 1.723 0.049 
263 1.786 1.925 0.036 
269 0.854 1.491 0.042 
276 1.077 1.018 0.026 
284 1.058 0.862 0.028 
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Miss Honcho aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
    
2 3.677 1.416 0.028 
4 4.914 1.789 0.021 
9 46.540 20.450 0.175 
12 3.846 1.464 0.076 
16 4.226 1.585 0.570 
18 5.129 1.878 0.653 
23 2.446 0.741 0.482 
27 1.605 0.451 0.444 
30 4.226 1.671 1.306 
32 1.762 0.658 0.905 
36 2.803 1.181 1.080 
40 4.155 2.288 1.757 
44 2.372 1.099 0.798 
46 2.697 1.350 0.919 
54 3.171 1.220 0.812 
61 2.134 1.065 0.327 
66 1.138 0.341 0.126 
72 2.751 1.198 0.181 
79 2.920 1.217 0.083 
88 1.198 0.175 0.012 
90 1.512 0.436 0.024 
94 1.292 0.292 0.023 
100 1.151 0.281 0.051 
108 1.418 0.646 0.026 
110 1.177 0.220 0.026 
115 1.412 0.426 0.016 
132 1.359 0.410 0.041 
152 0.882 1.831 0.026 
181 1.745 0.712 0.028 
187 1.335 0.574 0.014 
201 2.216 0.917 0.014 
215 2.820 1.409 0.015 
222 2.221 1.165 0.009 
237 1.898 1.255 0.012 
244 2.141 1.346 0.017 
250 1.685 0.878 0.020 
257 2.931 1.729 0.024 
264 3.575 2.198 0.014 
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Sparky Pacific aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 1.004 0.877 0.119 
4 3.093 2.549 0.405 
7 0.406 0.347 0.428 
11 0.603 0.397 0.978 
17 0.552 0.472 N/A 
21 1.276 1.561 2.267 
25 0.747 0.920 N/A 
28 0.477 0.374 1.090 
32 1.405 1.507 3.432 
35 1.340 1.325 1.837 
39 1.569 1.908 4.052 
42 0.816 1.006 1.082 
50 0.754 0.895 0.629 
52 0.612 0.786 N/A 
56 1.196 1.471 0.453 
60 0.826 0.429 0.344 
63 1.219 1.464 N/A 
67 2.011 0.802 N/A 
74 0.634 0.730 N/A 
80 0.377 0.247 0.114 
88 0.240 0.087 0.000 
95 0.324 0.057 0.000 
102 0.273 0.107 0.000 
105 0.180 0.026 0.000 
110 0.309 0.038 0.000 
115 0.345 0.193 0.000 
122 0.259 0.029 0.000 
126 0.284 0.010 N/A 
133 0.285 0.110 0.000 
136 0.450 0.182 0.000 
147 0.526 0.215 0.000 
154 0.456 0.025 0.000 
175 0.629 0.373 0.000 
189 1.318 0.861 0.000 
196 1.140 1.044 0.000 
202 0.811 0.549 0.000 
210 0.648 0.293 0.000 
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Queen Sally aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 13.238 10.015 0.098 
5 1.650 1.018 0.156 
7 3.597 0.688 0.144 
11 1.565 0.988 0.168 
13 1.194 0.872 0.333 
18 2.178 2.085 0.447 
22 2.157 1.576 0.716 
25 1.985 1.909 0.463 
29 0.493 0.513 0.324 
32 1.215 1.576 0.380 
36 0.388 0.580 0.246 
42 0.715 0.894 0.231 
46 0.689 0.873 0.243 
50 0.360 0.419 0.278 
53 0.650 0.871 0.111 
57 0.783 0.892 0.130 
60 0.157 0.275 0.095 
67 0.207 0.187 0.079 
75 1.732 1.768 0.083 
88 0.105 0.076 0.049 
95 0.510 0.502 0.005 
102 0.691 0.613 0.001 
123 0.671 0.654 0.011 
151 0.187 0.247 0.015 
180 0.206 0.213 0.011 
193 1.546 1.142 0.032 
221 0.111 0.024 0.025 
228 1.974 1.996 0.010 
242 3.863 3.064 0.054 
252 9.979 8.527 0.040 
266 10.206 8.266 0.039 
280 20.658 19.178 0.056 
295 7.886 6.183 0.017 
308 1.008 0.855 0.015 
322 1.726 1.066 0.031 
336 7.737 5.912 0.004 
350 1.426 1.286 0.012 
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BPXYP aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 1.116 0.723 0.083 
4 2.404 0.959 0.308 
8 3.681 1.445 0.455 
11 6.931 3.894 1.030 
18 8.485 5.742 2.601 
22 3.544 1.884 6.447 
25 5.407 3.523 11.127 
29 5.434 2.755 13.255 
32 4.900 2.643 11.373 
36 5.985 2.777 20.308 
39 1.851 1.270 15.989 
43 0.966 0.461 4.408 
46 0.642 0.152 5.198 
53 2.937 0.134 5.694 
57 0.804 0.362 4.287 
60 0.941 0.418 1.095 
64 0.623 0.107 0.410 
67 0.679 0.129 0.225 
71 0.764 0.321 0.053 
74 0.769 0.294 0.010 
78 0.589 0.140 0.141 
85 1.100 0.379 0.040 
91 0.968 0.359 0.039 
99 1.562 0.725 0.043 
106 0.295 0.042 0.011 
112 1.384 0.617 0.067 
123 0.433 0.069 0.083 
137 0.573 0.081 0.039 
151 0.467 0.118 0.034 
166 0.501 0.007 0.042 
180 0.468 0.027 0.043 
208 0.884 0.216 0.056 
222 1.426 0.504 0.048 
236 0.912 0.210 0.071 
250 1.320 0.490 0.058 
264 0.871 0.213 0.023 
278 0.702 0.208 0.042 
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Supreme Madonna aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 0.778 0.412 0.010 
1 3.562 0.508 0.015 
6 3.673 3.076 0.036 
10 1.173 0.651 0.068 
14 0.368 0.152 0.056 
18 0.368 0.125 0.138 
22 0.381 0.175 0.207 
26 0.358 0.104 0.095 
34 0.615 0.457 0.223 
38 0.501 0.372 0.257 
42 0.427 0.179 0.109 
46 0.508 0.264 0.249 
50 1.541 1.279 0.323 
54 0.657 0.504 0.211 
57 5.116 0.957 0.215 
61 0.683 0.570 0.055 
68 0.445 0.397 0.022 
75 0.250 0.147 0.025 
82 0.713 0.103 0.009 
89 0.388 0.027 0.011 
96 0.915 0.416 0.013 
110 0.664 0.075 0.013 
117 0.744 0.280 0.013 
138 0.443 0.093 0.012 
145 0.605 0.128 0.020 
152 0.446 0.073 0.022 
159 1.462 0.314 0.018 
166 2.142 1.655 0.012 
173 0.337 0.084 0.009 
180 0.272 0.006 0.006 
187 0.646 0.275 0.005 
194 0.273 0.004 0.004 
201 0.352 0.057 0.005 
215 1.118 0.859 0.007 
229 0.616 0.365 0.006 
236 0.686 0.335 0.006 
243 0.691 0.342 0.018 
246 0.687 0.314 0.022 
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Little Reaction aBB_Adiol epiandro 117 ion 
Days post season (ng/ml) (ng/ml) Area Ratio 
0 46.126 16.071 0.019 
1 19.951 8.817 0.010 
2 17.935 7.107 0.009 
6 5.869 2.236 0.014 
10 5.948 2.143 0.028 
14 6.892 2.655 0.039 
18 2.725 1.334 0.055 
22 1.703 0.908 0.103 
26 1.796 0.692 0.198 
30 2.105 0.874 0.190 
34 0.499 0.188 0.109 
38 1.103 0.462 0.097 
42 1.377 0.712 0.302 
46 3.833 1.170 0.410 
50 1.357 0.601 0.138 
54 1.293 0.491 0.174 
59 0.687 0.230 0.152 
61 2.192 0.687 0.383 
71 0.451 0.098 0.028 
106 0.178 0.009 0.008 
113 0.486 0.117 0.009 
127 0.307 0.028 0.006 
140 0.239 0.001 0.004 
155 0.252 0.001 0.008 
169 0.228 0.007 0.003 
183 0.289 0.046 0.003 
190 0.646 0.251 0.012 
215 0.602 0.350 0.006 
222 1.142 0.064 0.034 
229 0.866 0.442 0.011 
236 1.305 0.274 0.009 
243 0.812 0.248 0.016 
250 0.761 0.332 0.007 
260 0.767 0.235 0.009 
267 0.885 0.265 0.005 
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 Bolly for Molly aBB_Adiol epiandro 117 ion 
 Days post season (ng/ml) (ng/ml) Area Ratio 
 -9 0.997 0.596 0.138 
 -8 0.815 0.340 0.089 
 -7 1.403 0.757 0.149 
 -6 1.732 1.055 0.125 
 -5 1.819 1.004 0.138 
 -4 1.472 0.974 0.087 
 -3 2.369 1.546 0.080 
 -2 2.468 1.512 0.142 
 -1 2.246 1.496 0.167 
Day of Season 0 2.374 1.429 0.201 
 1 1.783 0.999 0.157 
 2 3.161 1.763 0.283 
 3 2.102 1.290 0.255 
 4 4.165 2.735 0.581 
 5 4.877 2.978 0.654 
 6 3.329 2.027 0.587 
 7 5.703 3.188 1.115 
 8 4.105 2.913 0.679 
 9 13.176 7.850 2.081 
Mated between Day 11 and 14  10 8.158 5.239 1.899 
 15 2.121 1.592 9.393 
 16 1.344 1.110 6.296 
 17 0.940 0.647 6.208 
 18 0.897 0.625 6.819 
 19 0.686 0.430 5.744 
 20 0.558 0.328 3.948 
 24 0.710 0.436 5.213 
 27 1.356 0.897 10.700 
 31 1.385 0.843 11.712 
 34 1.789 1.231 13.527 
 38 2.241 1.846 11.359 
 41 1.972 1.733 6.372 
 45 1.434 1.182 8.027 
 48 1.964 1.647 10.114 
 52 0.984 0.662 3.993 
 55 0.998 0.609 5.373 
 59 1.492 0.906 9.368 
 62 2.942 2.028 8.078 
 66 3.146 2.451 8.813 
 69 5.346 4.070 6.526 
Had pups Days 71/72 73 4.001 3.279 2.246 
 76 0.492 0.641 0.453 
 80 1.449 1.322 1.016 
 83 1.347 0.965 0.629 
 87 2.402 1.651 0.891 
 91 0.710 0.389 0.433 
 250 
 
 93 2.552 1.319 1.087 
 97 0.717 0.366 1.081 
 101 1.444 0.521 1.939 
In season Day 105 105 7.608 3.289 1.418 
 108 3.985 2.062 1.342 
 115 3.076 1.409 0.918 
Stopped bleeding Day 123 122 0.325 0.109 0.426 
 129 0.687 0.335 0.324 
 136 0.599 0.035 0.194 
 143 0.747 0.332 0.179 
 150 0.566 0.251 0.117 
 157 0.409 0.117 0.143 
 164 1.008 0.468 0.082 
 178 1.258 0.678 0.156 
 185 0.761 0.323 0.072 
 192 0.375 0.103 0.049 
 206 0.697 0.242 0.050 
 213 0.409 0.145 0.013 
 220 0.641 0.248 0.066 
 226 0.757 0.298 0.069 
 233 0.856 0.310 0.043 
Date of next season 240 2.662 1.197 0.255 
 
 
